{
    "testId": 373596629,
    "parentTestId": null,
    "userId": 4331736,
    "sequenceId": 13,
    "qbankId": 2,
    "isSim": 0,
    "testModeId": 0,
    "testModeName": "Timed",
    "questionModeId": 0,
    "questionModeName": "ALL",
    "testName": "",
    "totalQuestionCorrect": 20,
    "correctToIncorrect": 1,
    "incorrectToCorrect": 0,
    "incorrectToIncorrect": 5,
    "timeInSeconds": 2808,
    "averageTimeSpentInSeconds": 110,
    "otherAverageTimeSpentInSeconds": 60,
    "isStarted": true,
    "isEnded": true,
    "formId": 0,
    "bLockId": 0,
    "subscriptionId": 13863865,
    "lastQuestionVisited": 40,
    "containsMediaQuestion": false,
    "sectionId": 1010,
    "sectionName": "Step 2 Review",
    "difficultyLevelId": null,
    "difficultyLevelName": null,
    "testTypeId": null,
    "testTypeName": null,
    "allottedTime": null,
    "allottedTimeTypeId": null,
    "canResume": null,
    "assignmentId": null,
    "canViewAssignmentResult": null,
    "questionModeIds": "1",
    "testSource": 1,
    "testTypes": "",
    "questionList": [
        {
            "exhibits": null,
            "sequenceId": 1,
            "questionId": 2518,
            "questionIndex": 2518,
            "questionText": "<p>A 47-year-old man with a long history of schizoaffective disorder comes to the clinic with his wife.&nbsp; After a difficult course requiring several psychiatric hospitalizations and poor response to multiple antipsychotics and mood stabilizers, the patient&#39;s condition has been relatively stable for the past 3 years with high doses of lithium and risperidone.&nbsp; Lowering his dose of risperidone resulted in worsening psychotic symptoms, so the dose was subsequently increased.&nbsp; The patient&#39;s wife states that his psychiatric symptoms have improved with the current medications, but they are both concerned about new abnormal movements he has begun to make.&nbsp; He has no other medical conditions and takes no other medications.&nbsp; The patient does not use tobacco, alcohol, or illicit drugs.&nbsp; Blood pressure is 120/70 mm Hg, pulse is 72/min, and respirations are 12/min.&nbsp; Lithium level is 1.2 mEq/L (range: 0.8-1.2).&nbsp; During examination, the patient repeatedly taps his foot, protrudes his tongue, and smacks his lips.&nbsp; The rest of the examination shows no abnormalities.&nbsp; The patient is treated with sequential trials of valbenazine and deutetrabenazine but shows no significant improvement in abnormal movements at follow-up.&nbsp; Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t37658\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Tardive dyskinesia</strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Abnormal involuntary movements due to prolonged use of antipsychotics or metoclopramide</li><li>Orofacial dyskinesia (tongue protrusion, lip smacking, grimacing)</li><li>Limb dyskinesia (dystonic postures, foot tapping, chorea)</li><li>Trunk dyskinesia (rocking, thrusting, shoulder shrugging)</li><li>Greater risk with first-generation antipsychotics</li></ul></td></tr><tr><td><p align=\"center\"><strong>Management</strong></p></td><td><ul><li>Discontinue causative medication if feasible</li><li>Switch to second-generation antipsychotic (quetiapine, clozapine) if continued antipsychotic is required</li><li>Treat with valbenazine or deutetrabenazine&nbsp;</li></ul></td></tr></tbody></table></div><p>This patient&#39;s movements are most consistent with <strong>tardive dyskinesia (TD)</strong>, an <strong>involuntary hyperkinetic movement disorder</strong> resulting from prolonged exposure to dopamine receptor-blocking drugs, including <strong>antipsychotics</strong> (eg, risperidone)&nbsp;and metoclopramide.&nbsp; Management options for TD include:</p><ul><li><strong>Reducing </strong>the <strong>antipsychotic dose</strong>, which&nbsp;may not&nbsp;be possible as it can worsen psychosis (as in this patient).</li><li>Using<strong>&nbsp;</strong>valbenazine or deutetrabenazine, reversible inhibitors of the vesicular monoamine transporter 2 (VMAT2) recently approved by the FDA for use in&nbsp;TD.</li><li><strong>Switching</strong> (cross-tapering) to an antipsychotic with a lower tendency to cause TD, such as quetiapine or <strong>clozapine</strong>.&nbsp; In&nbsp;patients with a history of poor response to multiple antipsychotics, clozapine is the preferred option.</li></ul><p>In addition to TD, other side effects of first- and second-generation antipsychotics include&nbsp;extrapyramidal symptoms&nbsp;(dystonias, parkinsonism, akathisia), which can be treated with anticholinergics or, in the case of akathisia,&nbsp;beta blockers.&nbsp; Anticholinergics and beta blockers do not treat TD.</p><p><strong>(Choices A and B)</strong>&nbsp; Benztropine can treat drug-induced parkinsonism (eg, gradual-onset tremor, rigidity, bradykinesia) and acute dystonia (muscle spasms/stiffness, torticollis, opisthotonus, oculogyric crisis).&nbsp; Diphenhydramine (an antihistamine with strong anticholinergic properties) can also be used to treat&nbsp;dystonias.&nbsp; These medications have not been shown to improve the abnormal movements of TD (and&nbsp;anticholinergics may even worsen them).</p><p><strong>(Choice C)</strong>&nbsp; Propranolol, a beta blocker, is used to treat akathisia, a subjective feeling of restlessness that compels patients to move constantly (eg, repeated leg crossing, weight shifting, pacing) and that can occur at any time during treatment with antipsychotics.&nbsp; This patient&#39;s movements are not consistent with akathisia, and beta blockers do not treat TD.</p><p><strong>(Choice D)</strong>&nbsp; Although lithium can cause tremors, it does not cause other involuntary movements.&nbsp; It would be an unlikely explanation for the abnormal movements in this patient who has a normal lithium level and no other signs of lithium toxicity.</p><p><strong>Educational objective:</strong><br>Tardive dyskinesia occurs after prolonged exposure to antipsychotic drugs and is characterized by abnormal involuntary movements of the mouth, tongue, face, trunk, or extremities.&nbsp; When antipsychotic dose reduction or discontinuation is not feasible, using valbenazine or deutetrabenazine or switching to clozapine should be considered.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 456,
            "topic": "Tardive dyskinesia",
            "titleId": 456,
            "title": "Tardive dyskinesia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Add benztropine",
                    "choiceNumber": 1,
                    "correctTaken": 5428,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Add diphenhydramine",
                    "choiceNumber": 2,
                    "correctTaken": 1162,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Add propranolol",
                    "choiceNumber": 3,
                    "correctTaken": 739,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Decrease lithium",
                    "choiceNumber": 4,
                    "correctTaken": 522,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Switch from risperidone to clozapine",
                    "choiceNumber": 5,
                    "correctTaken": 9073,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2487,2568,true,-1,1*2168,2178,true,-1,1*2319,2378,true,-1,1*2262,2308,true,-1,1*1682,1730,true,-1,1*1785,1801,true,-1,1*713,845,true,-1,1*1235,1367,true,-1,1*997,1101,true,-1,1*140,154,true,-1,1*122,137,true,-1,1*337,386,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "699",
                    "mediaDataId": 0,
                    "title": "Extrapyramidal symptoms",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28638290",
                    "mediaDataId": 0,
                    "title": "Medication-induced tardive dyskinesia: a review and update.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28638290",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23858394",
                    "mediaDataId": 0,
                    "title": "An update on tardive dyskinesia: from phenomenology to treatment.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23858394",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 109,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 16924,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 54,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1342,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 2,
            "questionId": 4046,
            "questionIndex": 4046,
            "questionText": "<p>A 32-year-old man comes to the office for follow-up a month after being hospitalized for treatment of a manic episode related to schizoaffective disorder.&nbsp; His mania has resolved and he appears calm.&nbsp; Although he continues to hear a voice narrating his daily activities, the voice has diminished in frequency and intensity.&nbsp; The patient is less anxious and his sleep has improved.&nbsp; Medical history is otherwise noncontributory.&nbsp; Vitals signs are within normal limits.&nbsp; He is 175 cm (5 ft 9 in) tall and weighs 95.2 kg (210 lb); he has gained 4.5 kg (10 lb) since discharge.&nbsp; Physical examination shows no other abnormalities.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"padding-left: 2em;\">Hemoglobin</td><td>14.5 g/dL</td></tr><tr><td style=\"padding-left: 2em;\">Platelets</td><td>180,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"padding-left: 2em;\">Leukocytes</td><td>5,400/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"padding-left: 3em;\">Neutrophils</td><td>62%</td></tr><tr><td style=\"padding-left: 3em;\">Eosinophils</td><td>2%</td></tr><tr><td style=\"padding-left: 3em;\">Lymphocytes</td><td>29%</td></tr><tr><td style=\"padding-left: 3em;\">Monocytes</td><td>7%</td></tr><tr><td></td><td></td></tr><tr><td colspan=\"2\">Serum chemistry</td></tr><tr><td style=\"padding-left: 2em;\">Sodium</td><td>140 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Potassium</td><td>4.2 mEq/L</td></tr><tr><td style=\"padding-left: 2em;\">Creatinine</td><td>0.9 mg/dL</td></tr><tr><td style=\"padding-left: 2em;\">Fasting glucose</td><td 160=\"\" dl=\"\" mg=\"\">160 mg/dL</td></tr><tr><td></td><td></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Thyroid function tests</td></tr><tr><td style=\"padding-left: 2em;\">TSH</td><td>3.8 &micro;U/mL</td></tr></tbody></table><p>Which of the following medications is most likely to have caused this patient&#39;s physical examination and laboratory findings?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T35225\" style=\"overflow-x:auto;\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Metabolic effects of second-generation antipsychotics</strong></p></td></tr><tr><td><p align=\"center\"><strong>Metabolic syndrome</strong></p></td><td><ul><li>Weight gain</li><li>Dyslipidemia</li><li>Hyperglycemia (including new-onset diabetes mellitus)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Highest-risk drugs</strong></p></td><td><ul><li>Clozapine</li><li>Olanzapine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Monitoring guidelines</strong></p></td><td><p>Baseline &amp; regular follow-up</p><ul><li>BMI</li><li>Fasting glucose &amp; lipids</li><li>Blood pressure</li><li>Waist circumference</li></ul></td></tr></tbody></table></div><p>Patients with schizoaffective disorder are commonly managed with <strong>atypical (second-generation) antipsychotics</strong>.&nbsp; Although many psychotropic medications can cause weight gain, patients taking the second-generation antipsychotics <strong>olanzapine</strong> and clozapine are at increased risk for clinically significant <strong>weight gain</strong>, dyslipidemia, and <strong>hyperglycemia</strong>.&nbsp; Possible mechanisms of weight gain include blockade of histamine 1 receptors and pancreatic M3 muscarinic receptors, with the latter potentially contributing to insulin dysregulation.&nbsp; Given the risk of metabolic derangements, routine follow-up of patients taking olanzapine include monitoring BMI, fasting glucose and lipids levels, waist circumference, and blood pressure.</p><p><strong>(Choice A)</strong>&nbsp; The atypical antipsychotic aripiprazole is less commonly associated with weight gain.&nbsp; It is notably associated with risks for akathisia and impulse control problems (eg, pathological gambling) compared to other atypical antipsychotics.</p><p><strong>(Choice B)</strong>&nbsp; Lithium is a mood stabilizer that can be used to treat schizoaffective disorder and may cause weight gain; however, the concern is less than that of olanzapine.&nbsp; Patients taking lithium should be monitored for thyroid dysfunction; although metabolic laboratory testing is recommended when initiating lithium in overweight or obese patients and those gaining weight while taking the medication, it is less likely to cause hyperglycemia.</p><p><strong>(Choice C)</strong>&nbsp; Mirtazapine is an antidepressant that commonly causes weight gain and is sometimes used as a benefit in depressed patients with low appetite and weight loss; however, olanzapine carries the greater metabolic risk.</p><p><strong>(Choice E)</strong>&nbsp; As with all atypical antipsychotics, ziprasidone requires routine monitoring of BMI, waist circumference, fasting glucose and lipids, and blood pressure; however, it is not commonly associated with weight gain and has a lower risk of metabolic syndrome compared to olanzapine.&nbsp; Ziprasidone is notable for a greater risk of prolonging the QT interval compared to other atypical antipsychotics.</p><p><strong>Educational objective:</strong><br>Weight gain, dyslipidemia, and hyperglycemia are often encountered complications from treatment with psychotropic medications.&nbsp; Atypical antipsychotics require routine monitoring for metabolic derangements, with olanzapine and clozapine carrying the greatest risk.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Aripiprazole",
                    "choiceNumber": 1,
                    "correctTaken": 620,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lithium",
                    "choiceNumber": 2,
                    "correctTaken": 641,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Mirtazapine",
                    "choiceNumber": 3,
                    "correctTaken": 577,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Olanzapine",
                    "choiceNumber": 4,
                    "correctTaken": 10186,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ziprasidone",
                    "choiceNumber": 5,
                    "correctTaken": 373,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "302,336,true,-1,1*684,868,true,-1,1*1098,1110,true,-1,1*1164,1306,true,-1,1*1767,1834,true,-1,1*2272,2386,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21495734",
                    "mediaDataId": 0,
                    "title": "Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21495734",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28585153",
                    "mediaDataId": 0,
                    "title": "Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28585153",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 148,
            "othersAvgTimeSpent": 58,
            "notes": null,
            "peopleTaken": 12397,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 82,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 644,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 3,
            "questionId": 2505,
            "questionIndex": 2505,
            "questionText": "<p>A 57-year-old woman with ovarian cancer comes to the emergency department due to refractory nausea and vomiting due to chemotherapy.&nbsp; In the emergency department, the patient is treated with intravenous normal saline, ondansetron, and prochlorperazine.&nbsp; An hour later she experiences sudden-onset slurred speech, facial spasm, jaw clenching, and an inner feeling of restlessness.&nbsp; On examination, the patient is fully alert but anxious.&nbsp; Temperature is 37.3 C (99.1 F), blood pressure is 120/76 mm Hg, pulse is 92/min, and respirations are 20/min.&nbsp; Pulse oximetry shows an oxygen saturation of 98% on room air.&nbsp; There are no retractions or accessory muscle use.&nbsp; The mouth is open, and the tongue is protruding; there is no tongue swelling.&nbsp; The remainder of the examination shows no abnormalities.&nbsp; Which of the following is the most appropriate pharmacotherapy for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T92154\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Medication-induced dystonia</strong></p></td></tr><tr><td style=\"width: 30%;\"><p align=\"center\"><strong>Precipitating medications</strong><br>(dopamine antagonists)</p></td><td><ul><li>Antipsychotics (eg, haloperidol)</li><li>Antiemetics (eg, metoclopramide, prochlorperazine)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Onset minutes to 24 hours after starting medication</li><li>Sudden, sustained contraction of muscles, most often impacting the neck, mouth, tongue, &amp; extraocular muscles</li><li>Painful, distressing, often with tachycardia &amp;/or hypertension</li><li>Preserved mental status</li><li>&plusmn; Other extrapyramidal effects (eg, akathisia, parkinsonism, tardive dyskinesia)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Cessation (or &#8595; dose) of offending medication (if possible)</li><li>Anticholinergics (eg, diphenhydramine, benztropine)</li></ul></td></tr></tbody></table></div><p>This patient has facial spasms, tongue spasms, and jaw clenching following medication administration.&nbsp; Several features of her presentation are consistent with <strong>acute dystonic reaction</strong>, an <strong>extrapyramidal symptom (EPS)</strong> likely caused by <strong>prochlorperazine</strong>.</p><p><strong>Dopamine receptor antagonists</strong> that cross the blood-brain barrier, including antiemetics (eg, prochlorperazine, metoclopramide) and antipsychotics, can cause EPSs.&nbsp; The incidence may exceed 40% with high doses (eg, severe chemotherapy-induced nausea and vomiting).&nbsp; Symptoms usually occur within hours of therapy initiation.&nbsp; Dystonic reactions are characterized by sudden, sustained muscle contraction, most often impacting muscles in the head and neck (eg, <strong>facial spasms</strong>, jaw clenching, tongue protrusion) and extraocular muscles.&nbsp; They can be accompanied by other EPSs, including akathisia (inner <strong>restlessness</strong>) and parkinsonism.</p><p>Dopamine blockade causes an imbalance between acetylcholine and dopamine in the striatum/basal ganglia; therefore, anticholinergic agents (eg, <strong>diphenhydramine</strong>, <strong>benztropine</strong>), which help reverse this imbalance, are used for the immediate treatment of acute dystonia.&nbsp; Intravenous administration typically provides quick relief of symptoms (within minutes); diphenhydramine is sometimes administered with prochlorperazine to prevent acute dystonia.</p><p>Other, similar conditions that can develop following medication administration include angioedema/anaphylaxis and serotonin syndrome.&nbsp; Although anaphylaxis with angioedema (treated with epinephrine) can cause tongue protrusion, it is due to edema forcing the tongue out of the oral cavity (vs sustained contractions) and can lead to airway compromise (eg, accessory muscle use), findings not seen in this patient <strong>(Choice D)</strong>.&nbsp; Ondansetron can cause serotonin syndrome that is characterized by neuromuscular hyperactivity; however, manifestations are typically more pronounced in the extremities (eg, spontaneous clonus, hyperreflexia), with prominent autonomic hyperactivity (eg, hyperthermia, hypertension).</p><p><strong>(Choice A)</strong>&nbsp; Calcium gluconate is used to treat hypocalcemia, which can present with muscle spasms, including in the facial muscles.&nbsp; However, other manifestations of hypocalcemia (eg, paresthesia, hyperreflexia) and a predisposing cause (eg, neck surgery, liver disease) would be expected.</p><p><strong>(Choice B)</strong>&nbsp; Carbamazepine can be used to treat seizures.&nbsp; However, seizures that are widespread enough to lead to sustained muscle spasms would likely also be accompanied by changes in mental status.</p><p><strong>(Choice E)</strong>&nbsp; Haloperidol can be used to manage agitation in patients with delirium, but this patient is alert.&nbsp; In addition, the dopaminergic-blocking effects of haloperidol would likely worsen EPS.</p><p><strong>Educational objective:</strong><br>Acute dystonic reactions are extrapyramidal symptoms that can occur because of treatment with dopamine antagonists (eg, antipsychotics, prochlorperazine, metoclopramide).&nbsp; Anticholinergic medications such as intravenous diphenhydramine and benztropine are the drugs of choice for the immediate treatment of prochlorperazine-induced acute dystonia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Calcium gluconate",
                    "choiceNumber": 1,
                    "correctTaken": 3441,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Carbamazepine",
                    "choiceNumber": 2,
                    "correctTaken": 1635,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Diphenhydramine",
                    "choiceNumber": 3,
                    "correctTaken": 10726,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Epinephrine",
                    "choiceNumber": 4,
                    "correctTaken": 281,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Haloperidol",
                    "choiceNumber": 5,
                    "correctTaken": 855,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "126,139,true,-1,1*157,189,true,-1,1*209,235,true,-1,1*631,659,true,-1,1*371,457,true,-1,1*3616,3629,true,-1,1*2839,2987,true,-1,1*1544,1752,true,-1,1*2415,2697,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24116333",
                    "mediaDataId": 0,
                    "title": "Acute dystonic reaction as medical emergency: a report of two cases.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24116333",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26392457",
                    "mediaDataId": 0,
                    "title": "Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26392457",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 61,
            "othersAvgTimeSpent": 55,
            "notes": null,
            "peopleTaken": 16940,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 63,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 727,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 4,
            "questionId": 3380,
            "questionIndex": 3380,
            "questionText": "<p>A young mother brings her 5-year-old daughter to the office due to problems at school.&nbsp; The patient started kindergarten 2 months ago and appeared to be doing fine.&nbsp; Last week, the teacher called to say that the child has persistently refused to answer questions or speak to others in class since her arrival.&nbsp; The teacher did not report it earlier as she thought the child was undergoing an adjustment period.&nbsp; During playtime, she prefers to play by herself.&nbsp; In class she remains quiet while the other children sing songs or recite the alphabet.&nbsp; The mother finds this very surprising as the patient is talkative at home and plays with her siblings and neighborhood friends.&nbsp; In addition, the patient did not report any issues with school to her mother, saying it was &#x22;fine.&#x22;&nbsp; She is &#x22;a little shy&#x22; at social gatherings but interacts with other kids and adults when she gets to know them.&nbsp; The child is able to tie her shoelaces, jump rope, and dress and feed herself.&nbsp; She can copy a triangle and is able to count to 10.&nbsp; Physical examination shows no abnormalities.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s <strong>refusal to speak</strong> in a <strong>specific social situation</strong> (school), in contrast to her engagement in normal communication in situations in which she feels comfortable (eg, at home with siblings, friends), is consistent with <strong>selective mutism</strong>.&nbsp; This diagnosis requires consistent (&#8805;1 month) failure to talk in situations in which it is expected (eg, school) despite the patient&#39;s speaking in other situations.&nbsp; Refusal to speak at school can <strong>impair</strong> both <strong>academic</strong> and <strong>social development</strong> and should not be considered normal shyness <strong>(Choice B)</strong>.&nbsp; Evaluation should rule out the impaired communication that can occur in autism spectrum disorders, childhood-onset psychosis, or pervasive communication disorders (eg, language disorder, social [pragmatic] communication disorder).</p><p>Selective mutism is considered an anxiety disorder and is frequently comorbid with social anxiety disorder (SAD), in which social situations are avoided or endured with great distress due to fears of negative evaluation.</p><p>Treatment options for selective mutism include cognitive-behavioral therapy with graded exposure to social situations, family therapy, and selective serotonin reuptake inhibitors.</p><p><strong>(Choice A)</strong>&nbsp; Adjustment disorder is not diagnosed when the symptoms meet the criteria for a more specific psychiatric disorder.&nbsp; This patient&#39;s consistent refusal to speak in school for &#8805;1 month meets criteria for selective mutism.</p><p><strong>(Choice D)</strong>&nbsp; Separation anxiety disorder is characterized by extreme anxiety when separated from home or loved ones and excessive worry about losing major attachment figures.&nbsp; This patient neither refuses to go to school nor cries on separation, which would be expected with separation anxiety.</p><p><strong>(Choice E)</strong>&nbsp; Children with social (pragmatic) communication disorder have difficulties with social interaction involving both verbal and nonverbal communication (eg, eye contact, body language).&nbsp; Impairment in communication is evident in multiple settings.</p><p><strong>(Choice F)</strong>&nbsp; Stranger anxiety is a normal finding that usually begins in children age 6-9 months and generally subsides by age 3.&nbsp; It involves anxiety and distress when encountering unfamiliar people, even in the presence of a parent.</p><p><strong>Educational objective:</strong><br>Children with selective mutism are verbal at home but refuse to speak in specific social settings, commonly at school.&nbsp; It is considered an anxiety disorder and should be treated early to prevent long-term educational and social impairment.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 24020,
            "topic": "Selective mutism",
            "titleId": 24020,
            "title": "Selective mutism",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Adjustment disorder",
                    "choiceNumber": 1,
                    "correctTaken": 820,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Normal shyness",
                    "choiceNumber": 2,
                    "correctTaken": 2582,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Selective mutism",
                    "choiceNumber": 3,
                    "correctTaken": 12273,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Separation anxiety disorder",
                    "choiceNumber": 4,
                    "correctTaken": 288,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Social (pragmatic) communication disorder",
                    "choiceNumber": 5,
                    "correctTaken": 505,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Stranger anxiety",
                    "choiceNumber": 6,
                    "correctTaken": 535,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "277,442,true,-1,1*575,805,true,-1,1*807,921,true,-1,1*1075,1103,true,-1,1*1147,1161,true,-1,1*1167,1207,true,-1,1*2001,2116,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25724675",
                    "mediaDataId": 0,
                    "title": "Children who are anxious in silence:  a review on selective mutism, the new anxiety disorder in DSM-5.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25724675",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26709680",
                    "mediaDataId": 0,
                    "title": "Selective mutism.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26709680",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 91,
            "othersAvgTimeSpent": 52,
            "notes": null,
            "peopleTaken": 17005,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 72,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1578,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 5,
            "questionId": 3844,
            "questionIndex": 3844,
            "questionText": "<p>A 22-year-old woman is brought to the emergency department by her father due to &#x22;strange behavior.&#x22;&nbsp; Earlier that day, the patient insisted that a television newscaster was talking directly to her about the risks of &#x22;poison rays&#x22; from the moon.&nbsp; Her father says that she has &#x22;not been herself&#x22; for the past year.&nbsp; He is upset about her declining grades, along with increasing conflicts with her younger siblings and social isolation from her friends.&nbsp; A month ago, the patient abruptly quit the part-time job that she had previously enjoyed because she believed that her coworkers were spying on her.&nbsp; In the emergency department, she is agitated and the decision is made to admit her to the psychiatric unit.&nbsp; After a comprehensive evaluation, the patient is diagnosed with schizophrenia.&nbsp; She is stabilized on risperidone over a period of 3 weeks, and discharge plans to return home are discussed.&nbsp; Her father asks what can be done to decrease the likelihood of rehospitalization.&nbsp; In addition to maintaining risperidone, which of the following measures would be most helpful for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>Although antipsychotic medication is the primary treatment for <strong>schizophrenia</strong>, integrating psychosocial interventions into a broader treatment program can improve outcomes.&nbsp; <strong>Family interventions</strong>, including psychoeducation and family therapy, have proved to be high-yield interventions in schizophrenia that <strong>reduce</strong> the <strong>risk of rehospitalization</strong>.</p><p>Family intervention consists of a collaborative process that educates the patient and family about the symptoms and course of schizophrenia with the goal of reducing family stress and conflict (eg, educating the family that the patient&#39;s social isolation and declining grades are not &#x22;laziness&#x22;; they are negative symptoms of schizophrenia).&nbsp; Patients with schizophrenia who have <strong>critical</strong>, hostile, or <strong>overinvolved family</strong> members have a <strong>higher risk of relapse</strong>; patients in a home atmosphere that is stable and supportive, with family stressors kept to a minimum, have a decreased risk of relapse.</p><p><strong>(Choice A)</strong>&nbsp; Employment can help provide a sense of purpose and worth; however, asking this patient to resume employment shortly after a psychotic episode in which she felt paranoid about her coworkers would be unnecessarily stressful and could increase the risk of relapse.&nbsp; Structured employment programs that provide on-the-job support can be helpful for patients with serious mental illness.</p><p><strong>(Choice B)</strong>&nbsp; Although returning to school would provide structure and goals for this patient, she is unlikely to be successful immediately after a psychotic episode.&nbsp; A gradual return with a reduced schedule would be a more appropriate recommendation.</p><p><strong>(Choice C)</strong>&nbsp; Having family members supervise the patient at all times is likely to be experienced as intrusive and stressful.&nbsp; Overinvolved family-patient interactions are associated with worse outcomes.</p><p><strong>(Choice E)</strong>&nbsp; Insight-oriented psychotherapy focuses on uncovering unconscious patterns originating in childhood experiences; it is not indicated for patients with schizophrenia because it may initially cause increased anxiety that can destabilize those recovering from an acute psychotic episode.&nbsp; In contrast, cognitive-behavioral therapy, which combines cognitive approaches and social skills training, is a helpful adjunct to medication in the treatment of schizophrenia.</p><p><strong>Educational objective:</strong><br>Family psychosocial interventions are indicated for patients with a recent psychotic episode who have significant ongoing contact with family members.&nbsp; Minimizing conflict and stress in the home decreases the risk of relapse in patients with schizophrenia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Encourage the patient to resume employment",
                    "choiceNumber": 1,
                    "correctTaken": 815,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Encourage the patient to return to school immediately",
                    "choiceNumber": 2,
                    "correctTaken": 144,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend close supervision of the patient at all times",
                    "choiceNumber": 3,
                    "correctTaken": 325,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend family therapy",
                    "choiceNumber": 4,
                    "correctTaken": 9969,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Recommend insight-oriented psychotherapy",
                    "choiceNumber": 5,
                    "correctTaken": 5801,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "717,970,true,-1,1*1743,1819,true,-1,1*1831,2293,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22437626",
                    "mediaDataId": 0,
                    "title": "Family interventions in schizophrenia: promise and pitfalls over 30 years.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22437626",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29537779",
                    "mediaDataId": 0,
                    "title": "Treatments for schizophrenia in adults: a systematic review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29537779",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 170,
            "othersAvgTimeSpent": 48,
            "notes": null,
            "peopleTaken": 17054,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 544,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 6,
            "questionId": 1349,
            "questionIndex": 7957,
            "questionText": "<p>A 21-year-old man with a history of schizophrenia is brought to the emergency department by his parents for agitation.&nbsp; Over the last month, the patient has exhibited increasingly odd behavior at home, such as accusing the FBI of sending him threatening messages through the radio.&nbsp; Earlier today, he threatened to kill himself and barricaded his bedroom door so that FBI agents would not find him.&nbsp; The patient has been taking olanzapine daily for the past 3 months under the supervision of his parents.&nbsp; Despite treatment, he has been unable to return to school or work and has persistent delusions of reference as well as recurrent episodes of paranoia, self-isolation, and poor hygiene.&nbsp; The patient has had multiple hospitalizations for similar behavior.&nbsp; He was initially treated with haloperidol, which resulted in muscle spasms and an inability to sit still; the patient was then switched to risperidone with minimal improvement of psychotic symptoms.&nbsp; Physical examination and laboratory evaluation are unremarkable.&nbsp; On mental status examination, he appears restless and makes minimal eye contact.&nbsp; Olanzapine is stopped and a new pharmacotherapy is planned.&nbsp; Which of the following is the most appropriate treatment for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t39827\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Clozapine treatment guidelines</strong></p></td></tr><tr><td><p align=\"center\"><strong>Indications</strong></p></td><td><ul><li>Treatment-resistant schizophrenia</li><li>Schizophrenia associated with suicidality</li></ul></td></tr><tr><td><p align=\"center\"><strong>Adverse effects</strong></p></td><td><ul><li>Agranulocytosis</li><li>Seizures</li><li>Myocarditis</li><li>Metabolic syndrome</li></ul></td></tr></tbody></table></div><p>Switching antipsychotic medication requires a careful review of the patient&#39;s medication history.&nbsp; This patient is treatment-resistant (poor response to &#8805;2 antipsychotic trials) because he has failed 3 trials, including the first-generation antipsychotic haloperidol and 2 second-generation antipsychotics (risperidone, olanzapine).&nbsp; With the exception of clozapine, there is no evidence that any antipsychotic is more effective than another.&nbsp; <strong>Clozapine</strong> is unique because it has shown <strong>superiority</strong> in <strong>treatment-resistant schizophrenia</strong> and schizophrenia associated with persistent suicidality.</p><p>Due to the risk of <strong>agranulocytosis</strong>, clozapine is reserved for patients with treatment-resistant schizophrenia.&nbsp; Other serious adverse effects include seizures, myocarditis, and metabolic syndrome.&nbsp; Despite these concerns, clozapine is recommended by multiple evidence-based guidelines as the treatment of choice for treatment-resistant schizophrenia due to the severe disability associated with this illness.</p><p><strong>(Choices A, E, and G)</strong>&nbsp; Aripiprazole, quetiapine, and ziprasidone are second-generation antipsychotics used in schizophrenia, but they are not as effective as clozapine in treatment-resistant cases.</p><p><strong>(Choice C)</strong>&nbsp; Fluphenazine is a high-potency, first-generation antipsychotic (similar to haloperidol).&nbsp; It is unlikely to be effective in treatment-resistant schizophrenia and has a high risk of extrapyramidal adverse effects (eg, acute dystonic reactions, akathisia).</p><p><strong>(Choice D)</strong>&nbsp; Phenelzine is a monoamine oxidase inhibitor used in treatment-resistant depression.</p><p><strong>(Choice F)</strong>&nbsp; Long-acting, injectable antipsychotics are used in patients who have shown a good response to the oral formulations and are a useful strategy in those who are chronically nonadherent.&nbsp; However, this patient has had a poor response to risperidone.</p><p><strong>Educational objective:</strong><br>Clozapine is the medication of choice for treatment-resistant schizophrenia and should be considered in patients who have failed &#8805;2 antipsychotic drug trials.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Aripiprazole",
                    "choiceNumber": 1,
                    "correctTaken": 975,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 2,
                    "correctTaken": 13679,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Fluphenazine long-acting injectable",
                    "choiceNumber": 3,
                    "correctTaken": 359,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Phenelzine",
                    "choiceNumber": 4,
                    "correctTaken": 100,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Quetiapine",
                    "choiceNumber": 5,
                    "correctTaken": 1166,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Risperidone long-acting injectable",
                    "choiceNumber": 6,
                    "correctTaken": 480,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ziprasidone",
                    "choiceNumber": 7,
                    "correctTaken": 244,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "73,106,true,-1,1*107,148,true,-1,1*181,201,true,-1,1*663,812,true,-1,1*1698,1781,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23006238",
                    "mediaDataId": 0,
                    "title": "Clozapine: balancing safety with superior antipsychotic efficacy.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23006238",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24708834",
                    "mediaDataId": 0,
                    "title": "Clozapine: a review of clinical practice guidelines and prescribing trends.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24708834",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 98,
            "othersAvgTimeSpent": 56,
            "notes": null,
            "peopleTaken": 17003,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 80,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 449,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 7,
            "questionId": 2507,
            "questionIndex": 2507,
            "questionText": "<p>A 33-year-old woman is brought to the office by her husband due to bizarre and isolative behavior over the past 8 months.&nbsp; He often finds his wife whispering to the television, even when it is turned off.&nbsp; The patient says she communicates with dead people and hears the devil telling her that she should be dead.&nbsp; She has a history of schizoaffective disorder and has failed to respond to multiple antipsychotic medications, some of which caused severe muscle stiffness.&nbsp; To target psychotic symptoms, the patient is started on a new medication that requires frequent and regular blood draws.&nbsp; Over the next few weeks, she begins to show gradual improvement.&nbsp; This patient is likely being monitored for which of the following adverse reactions?</p>",
            "questionHeader": "",
            "explanationText": "<p><strong>Clozapine</strong> is a second-generation antipsychotic used in <strong>treatment-resistant schizophrenia</strong> and schizoaffective disorder (ie, patients who have failed &#8805;2 antipsychotic trials).&nbsp; It is associated with risk of <strong>neutropenia</strong>.&nbsp; Life-threatening <strong>agranulocytosis</strong> (ie, complete absence of neutrophils) has been reported in approximately 1% of patients treated, but this rate has been reduced with regular blood monitoring.&nbsp; Patients must participate in a computer-based registry that requires <strong>regular monitoring</strong> of the <strong>absolute neutrophil counts</strong> (ANCs) before dispensing of the drug.&nbsp; Prescribing guidelines dictate ANC cutoffs for continued prescription and provide guidance on how to manage low ANCs.</p><p>Other adverse effects of clozapine include weight gain, metabolic syndrome, seizures, ileus, myocarditis, and hypotension.&nbsp; Compared to other antipsychotics, clozapine is the least likely to cause extrapyramidal symptoms and has not been shown to cause tardive dyskinesia.&nbsp; Clozapine is also indicated in schizophrenic and schizoaffective patients with recurrent suicidality.</p><p><strong>(Choices B, D, E, F, and G)</strong>&nbsp; Lymphocytopenia, neutrophilia, pancytopenia, thrombocytopenia, and thrombocytosis are not commonly associated with clozapine use.</p><p><strong>(Choice A)</strong>&nbsp; Eosinophilia may occur with clozapine treatment, but this is not the rationale for the frequent blood draws.</p><p><strong>Educational objective:</strong><br>Clozapine is indicated for the treatment of psychotic patients who do not respond to other antipsychotics.&nbsp; Patients must undergo regular monitoring of absolute neutrophil counts due to the risk of neutropenia and agranulocytosis.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 25402,
            "topic": "Neutropenia",
            "titleId": 25402,
            "title": "Neutropenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Eosinophilia",
                    "choiceNumber": 1,
                    "correctTaken": 124,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lymphocytopenia",
                    "choiceNumber": 2,
                    "correctTaken": 707,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Neutropenia",
                    "choiceNumber": 3,
                    "correctTaken": 12403,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Neutrophilia",
                    "choiceNumber": 4,
                    "correctTaken": 322,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Pancytopenia",
                    "choiceNumber": 5,
                    "correctTaken": 2618,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thrombocytopenia",
                    "choiceNumber": 6,
                    "correctTaken": 611,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thrombocytosis",
                    "choiceNumber": 7,
                    "correctTaken": 170,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1598,1629,true,-1,1*123,147,true,-1,1*442,497,true,-1,1*807,812,true,-1,1*831,844,true,-1,1*878,994,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27207070",
                    "mediaDataId": 0,
                    "title": "Clozapine&#39;s critical role in treatment resistant schizophrenia: ensuring both safety and use.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27207070",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23006238",
                    "mediaDataId": 0,
                    "title": "Clozapine: balancing safety with superior antipsychotic efficacy.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23006238",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 90,
            "othersAvgTimeSpent": 38,
            "notes": null,
            "peopleTaken": 16955,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 73,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 295,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 8,
            "questionId": 4896,
            "questionIndex": 4896,
            "questionText": "<p>A 23-year-old man comes to the emergency department declaring that police helicopters have followed him for the past year.&nbsp; The patient is convinced that their surveillance lasers are damaging his sperm.&nbsp; He says that the lasers have caused burns on his stomach and a low sperm count.&nbsp; As evidence, the patient points to an area of slight discoloration that looks like a birthmark on his lower abdomen.&nbsp; He has contacted an officer in charge of internal affairs who is investigating his charge of police brutality.&nbsp; The patient has a history of 2 prior psychiatric hospitalizations.&nbsp; His psychosis rapidly improves during hospitalization, but following discharge he stops taking his medication.&nbsp; The patient says, &#x22;I used to have schizophrenia, but now I&#39;m cured.&#x22;&nbsp; He is highly anxious and frequently gets up to pace and look out the window.&nbsp; After describing his fears, he asks if the physician believes him.&nbsp; Which of the following is the best response to the patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>Effective <strong>communication</strong> with <strong>psychotic patients</strong> requires <strong>assessment</strong> of their <strong>level of insight</strong>.&nbsp; This patient is acutely psychotic, does not believe he has a psychiatric illness, and has no insight that his fears are delusional.&nbsp; Although a clinician should never lie or make statements affirming a delusion, the outright rebuttal of the patient&#39;s beliefs or labeling them as symptoms of an illness is likely to damage the physician-patient relationship and jeopardize adherence to treatment.</p><p>The best approach to the <strong>psychotic patient with no insight</strong> is a nonjudgmental stance that <strong>acknowledges</strong> the <strong>patient&#39;s experience</strong> and perspective without endorsing specific delusions or hallucinations.&nbsp; After a physician-patient relationship is established and the patient&#39;s psychosis begins to improve, it may be appropriate to assist the patient in distinguishing delusional thoughts from reality.</p><p><strong>(Choice B)</strong>&nbsp; This response suggests that the patient&#39;s concerns are reasonable.&nbsp; Physicians should avoid reinforcing psychotic beliefs while working to establish rapport and open communication.</p><p><strong>(Choices C, D, E, and F)</strong>&nbsp; These statements fail to acknowledge the patient&#39;s total lack of insight.&nbsp; Disputing the patient&#39;s paranoid delusions or labeling his experiences as symptoms of an illness is unlikely to be effective in his acutely psychotic state and may lead to further agitation.&nbsp; The priority is to acknowledge the patient&#39;s distress and establish rapport so he is more likely to be receptive to treatment.</p><p><strong>Educational objective:</strong><br>Acutely psychotic patients with no insight are unable to determine that their psychotic experiences are not real.&nbsp; To build rapport, it is important to acknowledge the patient&#39;s experience and distress without endorsing specific delusions or hallucinations.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 24827,
            "topic": "Physician patient communication",
            "titleId": 24827,
            "title": "Physician patient communication",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "1",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "I believe that these experiences have been very frightening for you.",
                    "choiceNumber": 1,
                    "correctTaken": 14516,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "I can assure you that in the hospital you are safe from any further attacks.",
                    "choiceNumber": 2,
                    "correctTaken": 692,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "I can see that you are frightened but can assure you that the police are not following you.",
                    "choiceNumber": 3,
                    "correctTaken": 379,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "I understand that you are frightened, but your concerns are more likely symptoms of your illness.",
                    "choiceNumber": 4,
                    "correctTaken": 1051,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Let me assure you that we are here to help you and that the discoloration is only a birthmark.",
                    "choiceNumber": 5,
                    "correctTaken": 208,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia is a chronic illness; you have previously experienced similar fears that respond well to medication.",
                    "choiceNumber": 6,
                    "correctTaken": 1011,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": null,
            "questionMedia": null,
            "timeSpent": 82,
            "othersAvgTimeSpent": 55,
            "notes": null,
            "peopleTaken": 17857,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 81,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 285,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 9,
            "questionId": 14698,
            "questionIndex": 16115,
            "questionText": "<p>A 53-year-old man is brought to the emergency department after a witnessed seizure 1 hour prior.&nbsp; The patient lives in a group home and was observed by the staff to suddenly become stiff and unresponsive during lunch.&nbsp; He was then noted to have brief jerking movements of his arms and was lowered to the floor.&nbsp; The patient regained consciousness after 1-2 minutes.&nbsp; Medical history includes schizoaffective disorder with multiple hospitalizations for psychotic and mood episodes beginning at age 22.&nbsp; Vital signs are within normal limits.&nbsp; On physical examination, the patient is awake and alert.&nbsp; A 1-cm laceration is noted on the right side of the tongue.&nbsp; Musculoskeletal, cardiopulmonary, and neurologic examinations show no abnormalities.&nbsp; Serum chemistry is normal.&nbsp; A CT scan of the head reveals no abnormalities.&nbsp; Which of the following medications most likely contributed to this patient&#39;s presentation?</p>",
            "questionHeader": "",
            "explanationText": "<p>Of the medications listed, the second-generation antipsychotic <strong>clozapine</strong> has the greatest risk of causing <strong>seizures</strong>.&nbsp; Clozapine is indicated for treatment-resistant psychosis, and this patient&#39;s long history of schizoaffective disorder with multiple hospitalizations and limited functional independence (ie, living in a group home) make it likely that he was prescribed clozapine.</p><p>Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia and schizoaffective disorder, but its use is limited by several serious adverse effects, including <strong>neutropenia/agranulocytosis</strong>, seizures, and <strong>myocarditis</strong>.&nbsp; Compared with other antipsychotics, clozapine carries the greatest risk of seizure.&nbsp; The risk is dose-dependent, although clozapine-induced seizures may occur at any dose level.&nbsp; Tonic-clonic seizures are the most common seizure type observed.</p><p><strong>(Choice A)</strong>&nbsp; Buspirone, a partial serotonin agonist used in the treatment of generalized anxiety disorder, is not associated with an increased risk of seizures.&nbsp; It can cause dizziness and orthostatic hypotension.</p><p><strong>(Choice B)</strong>&nbsp; Carbamazepine, an anticonvulsant that is also used as a mood stabilizer, would not cause seizures.&nbsp; It is associated with&nbsp;gastrointestinal (eg, nausea, vomiting), dermatologic (eg, rash, pruritus), and neurologic (eg, drowsiness, blurred vision) side effects.&nbsp; Toxicity can manifest with cerebellar findings and anticholinergic symptoms.</p><p><strong>(Choice C)</strong>&nbsp; The selective serotonin reuptake inhibitor citalopram is much less likely to cause seizures compared with clozapine.&nbsp; Citalopram is associated with dose-dependent QT prolongation.</p><p><strong>(Choice E)</strong>&nbsp; Phenelzine is a monoamine oxidase inhibitor used in treatment-resistant depression.&nbsp; It has the potential to cause hypertensive crisis and serotonin syndrome due to food and drug interactions but is not associated with a high risk of seizures.</p><p><strong>Educational objective:</strong><br>The antipsychotic clozapine is associated with an increased risk of seizure.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 10805,
            "topic": "Clozapine",
            "titleId": 10805,
            "title": "Clozapine",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Buspirone",
                    "choiceNumber": 1,
                    "correctTaken": 2862,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Carbamazepine",
                    "choiceNumber": 2,
                    "correctTaken": 2385,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Citalopram",
                    "choiceNumber": 3,
                    "correctTaken": 1041,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 4,
                    "correctTaken": 8467,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Phenelzine",
                    "choiceNumber": 5,
                    "correctTaken": 2113,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1660,1744,true,-1,1*1775,1818,true,-1,1*1586,1648,true,-1,1*1068,1106,true,-1,1*1174,1191,true,-1,1*1241,1456,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "610",
                    "mediaDataId": 0,
                    "title": "Antipsychotics",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25537107",
                    "mediaDataId": 0,
                    "title": "Seizure associated with clozapine: incidence, etiology, and management.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25537107",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23996793",
                    "mediaDataId": 0,
                    "title": "Use of anticonvulsants as prophylaxis for seizures in patients on clozapine.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23996793",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 178,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 16868,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 50,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 525,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 10,
            "questionId": 13647,
            "questionIndex": 15037,
            "questionText": "<p>A 27-year-old woman is brought to the office by her husband due to anxiety.&nbsp; The patient had an uncomplicated vaginal delivery a week ago and was discharged on postpartum day 2.&nbsp; Her husband notes that she was &#x22;really nervous&#x22; after returning home.&nbsp; The patient would watch the infant overnight to check for respirations and followed a strict feeding regimen.&nbsp; At the first well-child visit, she expressed concerns about the newborn&#39;s weight but was told he had surpassed his birth weight and was healthy and doing well.&nbsp; Despite this reassurance, the patient has continued to worry.&nbsp; For the past 2 days, she has been pacing around the house, sleeping poorly, and eating minimally.&nbsp; This morning, the husband found the patient mixing protein powder with formula due to concern that the infant was &#x22;shrinking.&#x22;&nbsp; The patient says, &#x22;I know my baby is sick, but the doctors won&#39;t tell me the truth.&nbsp; They&#39;re trying to hurt my baby.&#x22;&nbsp; She has no psychiatric history.&nbsp; Vital signs and physical examination are within normal limits.&nbsp; The patient appears tearful and exhausted.&nbsp; Which of the following is the most likely diagnosis?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s acute onset of agitation, mood symptoms, and delusions shortly after giving birth is consistent with <strong>postpartum psychosis</strong>, a relatively rare condition (1-2 of every 1,000 births) that generally occurs within the <strong>first 2 weeks</strong> after delivery.&nbsp; Clinical features include depressed and/or manic moods, severe insomnia, agitation, disorganized behavior, and <strong>delusions</strong> and/or <strong>hallucinations</strong>, with content frequently related to the infant (eg, this patient&#39;s delusions that the infant is &#x22;shrinking&#x22; and that doctors are trying to hurt her baby).&nbsp; Postpartum psychosis is a medical emergency because affected patients, under the influence of delusions, may harm the child and are also at high risk for suicide.&nbsp; Hospitalization to ensure safety and rapid intervention with antipsychotic medication are often necessary.</p><p>Postpartum psychosis is most often seen in patients who have a history of <strong>bipolar disorder</strong> or who are later diagnosed with bipolar disorder based on mood episodes occurring outside the postpartum period.&nbsp; These patients are at especially high risk for recurrent episodes in subsequent pregnancies.</p><p><strong>(Choice A)</strong>&nbsp; Acute stress disorder involves nonpsychotic symptoms (eg, intrusion, negative mood, avoidance, hyperarousal, dissociation) that develop within a month of exposure to a traumatic event.</p><p><strong>(Choice B)</strong>&nbsp; Adjustment disorder is diagnosed when nonpsychotic symptoms (eg, depressed, anxious mood) develop within 3 months of a stressor.&nbsp; Although this patient has severe anxiety related to her newborn&#39;s health, adjustment disorder would not explain her psychosis.</p><p><strong>(Choice C)</strong>&nbsp; A diagnosis of delusional disorder requires delusions lasting &#8805;1 month in the absence of other psychotic or mood symptoms.&nbsp; It is not consistent with this patient&#39;s 1-week history of symptoms characterized by delusions and prominent mood symptoms.</p><p><strong>(Choice D)</strong>&nbsp; Although high levels of anxiety are seen in obsessive-compulsive disorder (OCD), this patient&#39;s 1-week history of mood symptoms and delusions about the infant is not consistent with this disorder.&nbsp; OCD is characterized by prominent obsessions and compulsions and would not explain this patient&#39;s paranoid delusions that doctors are trying to harm her infant.</p><p><strong>(Choice E)</strong>&nbsp; Postpartum blues is a common, self-limited condition of mild depressive symptoms, tearfulness, and irritability.&nbsp; It typically peaks at day 5 postpartum and resolves within 14 days.&nbsp; It does not include psychotic symptoms.</p><p><strong>Educational objective:</strong><br>Postpartum psychosis is characterized by an acute onset of delusions, hallucinations, and disorganized behavior within the first 2 weeks postpartum.&nbsp; It is typically accompanied by mood symptoms, agitation, and severe insomnia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 103,
            "subject": "Obstetrics & Gynecology",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 10428,
            "topic": "Postpartum psychosis",
            "titleId": 10428,
            "title": "Postpartum psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "6",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Acute stress disorder",
                    "choiceNumber": 1,
                    "correctTaken": 590,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Adjustment disorder with anxiety",
                    "choiceNumber": 2,
                    "correctTaken": 1211,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 3,
                    "correctTaken": 1240,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obsessive-compulsive disorder",
                    "choiceNumber": 4,
                    "correctTaken": 496,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Postpartum blues",
                    "choiceNumber": 5,
                    "correctTaken": 1301,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Postpartum psychosis",
                    "choiceNumber": 6,
                    "correctTaken": 15899,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1295,1352,true,-1,1*1454,1493,true,-1,1*858,1062,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27609245",
                    "mediaDataId": 0,
                    "title": "Postpartum psychosis: madness, mania, and melancholia in motherhood.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27609245",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25640930",
                    "mediaDataId": 0,
                    "title": "Treatment of psychosis and mania in the postpartum period.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25640930",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26514657",
                    "mediaDataId": 0,
                    "title": "Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26514657",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 81,
            "othersAvgTimeSpent": 50,
            "notes": null,
            "peopleTaken": 20753,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 77,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 486,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 11,
            "questionId": 14447,
            "questionIndex": 15856,
            "questionText": "<p>A 29-year-old man is brought to the emergency department by police after he broke into a radio station and started yelling about being a &#x22;child of nature destined to reverse global warming and save the planet.&#x22;&nbsp; He is initially cooperative with the nurse taking his vital signs but then starts pacing around the room and raising his arms with clenched fists, motioning toward the hospital staff.&nbsp; His speech is rapid, loud, and difficult to interrupt.&nbsp; Medical records indicate a history of depression treated with antidepressants and a hospitalization 2 years ago following a suicide attempt.&nbsp; Temperature is 37 C (98.6 F), blood pressure is 142/85 mm Hg, pulse is 96/min, and respirations are 20/min.&nbsp; Administering which of the following medications is the most appropriate initial step in pharmacological management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient shows <strong>acutely agitated behavior</strong> that poses a <strong>safety risk</strong> to the emergency department staff.&nbsp; Diagnostic possibilities include a manic episode with psychotic features (eg, grandiose delusions, hyperactivity, pressured speech), substance-induced psychosis, psychosis due to another medical condition, and other psychotic disorders.</p><p>If verbal deescalation is unsuccessful, administering a <strong>benzodiazepine</strong> (eg, lorazepam) would be the most appropriate pharmacotherapy to manage this patient&#39;s escalating agitation and can be administered intramuscularly for a more rapid effect.&nbsp; Administration of a first- or second-generation <strong>antipsychotic</strong> (eg, haloperidol, olanzapine, risperidone, ziprasidone) is another option for management of acute agitation.&nbsp; The first-generation antipsychotic haloperidol is often coadministered with lorazepam to achieve more rapid sedation in severely agitated, combative patients.</p><p>When the patient is calmer and cooperative, further workup (eg, urine drug screen, chemistries, complete blood count, thyroid function tests) would be indicated to rule out substance-related and medical causes of psychosis.</p><p><strong>(Choices A, C, and F)</strong>&nbsp; Carbamazepine, lithium, and valproate are mood stabilizers used in bipolar disorder.&nbsp; Although a manic episode of bipolar disorder is a diagnostic possibility in this patient with a history of severe depressive episodes, these medications would be ineffective in managing acute agitation.&nbsp; They must be taken orally and are typically titrated over several days to achieve a therapeutic blood level.</p><p><strong>(Choice B)</strong>&nbsp; The second-generation antipsychotic clozapine is not used to manage acute agitation.&nbsp; It is typically reserved for treatment-resistant psychosis due to the risk of neutropenia/agranulocytosis.</p><p><strong>(Choice E)</strong>&nbsp; Mirtazapine, an antidepressant that has sedating properties, would be ineffective in managing this patient&#39;s acute agitation and could worsen symptoms in a patient presenting with mania.</p><p><strong>Educational objective:</strong><br>Options for pharmacological management of an acutely agitated patient include the administration of a benzodiazepine and/or an antipsychotic agent.&nbsp; The benzodiazepine lorazepam is often used due to its rapid onset of action and intramuscular formulation.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 9838,
            "topic": "Psychosis",
            "titleId": 9838,
            "title": "Psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Carbamazepine",
                    "choiceNumber": 1,
                    "correctTaken": 186,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 2,
                    "correctTaken": 1121,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lithium",
                    "choiceNumber": 3,
                    "correctTaken": 2270,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lorazepam",
                    "choiceNumber": 4,
                    "correctTaken": 7829,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Mirtazapine",
                    "choiceNumber": 5,
                    "correctTaken": 144,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Valproate",
                    "choiceNumber": 6,
                    "correctTaken": 567,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "135,372,true,-1,1*790,948,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29395692",
                    "mediaDataId": 0,
                    "title": "Approach to the agitated emergency department patient.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29395692",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 152,
            "othersAvgTimeSpent": 41,
            "notes": null,
            "peopleTaken": 12117,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 65,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 450,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 12,
            "questionId": 14648,
            "questionIndex": 16063,
            "questionText": "<p>A 76-year-old man comes to the office for follow-up of hypertension.&nbsp; He says, &#x22;I wouldn&#39;t be surprised if my blood pressure is up with all the stress I am under.&nbsp; My wife has been having an ongoing affair with our accountant.&nbsp; I&#39;ve known about this for years, and she continues to deny it.&nbsp; Even my children are in on it.&nbsp; They tell me that I&#39;m imagining things.&#x22;&nbsp; The patient reports that he monitors his wife closely and calls her multiple times a day to check on her whereabouts but admits that he has not found any evidence of the affair.&nbsp; He reports intermittent insomnia but no change in appetite.&nbsp; The patient occasionally forgets names and has word-finding difficulty.&nbsp; He continues to perform household chores and handle finances.&nbsp; Blood pressure is 132/85 mm Hg, pulse is 82/min, and respirations are 16/min.&nbsp; Physical examination, including neurologic examination, is unremarkable.&nbsp; The patient is alert and oriented, and his mood is irritable.&nbsp; Which of the following is the most likely diagnosis for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38406\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Delusional disorder</strong></p></td></tr><tr><td><p style=\"text-align: center;\"><strong>Clinical features</strong></p></td><td><ul><li>&ge;1 delusions for &ge;1 months</li><li>Other psychotic symptoms absent or not prominent</li><li>Behavior not obviously odd/bizarre; ability to function apart from delusion&#39;s impact</li><li>Subtypes: erotomanic, grandiose, jealous, persecutory &amp; somatic</li></ul></td></tr><tr><td><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td><ul><li>Antipsychotics</li><li>Cognitive-behavioral therapy</li></ul></td></tr></tbody></table></div><p>This patient&#39;s persistent belief that his wife is unfaithful in the absence of any real evidence is most consistent with <strong>delusional disorder</strong>, jealous type.&nbsp; Delusional disorder is characterized by delusions in the <strong>absence of other prominent psychotic symptoms</strong> (eg, hallucinations, disorganization), with subtypes based on the delusional theme:</p><ul><li>Persecutory (eg, being poisoned, harassed, plotted against)</li><li>Erotomanic (eg, false belief that someone of higher status is in love with the person)</li><li>Grandiose (eg, great talent, insights, achievements)</li><li>Jealous (eg, unfaithful partners)</li><li>Somatic (eg, bodily functions, sensations)</li></ul><p>In the <strong>jealous type</strong>, the patient typically searches for evidence to support the delusion that the partner is unfaithful, which in severe cases can lead to threatening and violent behavior toward the suspected individuals.</p><p>As in this patient, individuals with delusional disorder do not appear to be obviously bizarre or odd and are still <strong>able to function</strong> in areas apart from their delusion (eg, this patient manages household chores and finances).</p><p><strong>(Choice A)</strong>&nbsp; Patients with Alzheimer disease may develop psychosis, including delusions of jealousy.&nbsp; However, this would typically occur in the middle to late course of the disease.&nbsp; Occasional forgetting of names and word-finding difficulty are relatively age normative, and the patient does not have evidence of the severity of cognitive impairment necessary to affect activities of daily living (eg, managing finances) and thereby fulfill a diagnosis of dementia (eg, Alzheimer disease).</p><p><strong>(Choices C and F)</strong>&nbsp; Delusional disorder must be differentiated from other disorders presenting with psychotic symptoms.&nbsp; The diagnosis of major depressive disorder (which can be associated with psychotic features) requires depressed mood or anhedonia (not seen in this patient) and would cause daily insomnia and difficulty concentrating (rather than intermittent insomnia and occasional word-finding difficulty).&nbsp; Patients with schizophrenia have additional psychotic symptoms (eg, hallucinations, disorganization, negative symptoms) and greater functional impairment.</p><p><strong>(Choice D)</strong>&nbsp; Paranoid personality disorder involves a lifelong pattern of distrust and suspicion of others, beginning in early adulthood.&nbsp; The paranoid beliefs are generally pervasive (not simply directly at one person) and not of delusional intensity, unlike what is evident in this patient.</p><p><strong>(Choice E)</strong>&nbsp; The chronic course of this patient&#39;s delusional thinking and unremarkable physical examination (including neurologic examination) make psychotic disorder due to another medical condition unlikely.</p><p><strong>Educational objective:</strong><br>Delusional disorder is characterized by one or more delusions.&nbsp; Other prominent psychotic symptoms are absent, and the individual is still able to function in areas unrelated to the delusion.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 9838,
            "topic": "Psychosis",
            "titleId": 9838,
            "title": "Psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "6",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Alzheimer disease",
                    "choiceNumber": 1,
                    "correctTaken": 880,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 2,
                    "correctTaken": 12528,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Major depressive disorder with psychotic features",
                    "choiceNumber": 3,
                    "correctTaken": 103,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Paranoid personality disorder",
                    "choiceNumber": 4,
                    "correctTaken": 2566,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Psychotic disorder due to another medical condition",
                    "choiceNumber": 5,
                    "correctTaken": 645,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 6,
                    "correctTaken": 101,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "144,228,true,-1,1*751,837,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28595494",
                    "mediaDataId": 0,
                    "title": "A psychopathological comparison between delusional disorder and schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28595494",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27468631",
                    "mediaDataId": 0,
                    "title": "Delusional disorder and schizophrenia: a comparative study across multiple domains.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27468631",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 98,
            "othersAvgTimeSpent": 56,
            "notes": null,
            "peopleTaken": 16823,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 74,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 556,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 13,
            "questionId": 4895,
            "questionIndex": 4895,
            "questionText": "<p>A 37-year-old woman is brought to the hospital by the police after she was found wandering in the street.&nbsp; The patient is unable to provide a coherent history of recent events but mentions that she had a psychiatric hospitalization in her 20s.&nbsp; She has no medical history.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 110/70 mm Hg, pulse is 88/min, and respirations are 16/min.&nbsp; The patient is disheveled and malodorous, but physical examination is otherwise unremarkable.&nbsp; On mental status examination, she is alert and smiles pleasantly, but it is difficult to hold her attention.&nbsp; The patient gets up from her chair several times to stare at the air conditioning vent and put her ear against the wall as if listening for something.&nbsp; When asked about her behavior, she says, &#x22;Jingle jangle, doctor.&nbsp; Jingle jangle.&#x22;&nbsp; A decision is made to admit her to the psychiatric unit.&nbsp; Which of the following medications is the most appropriate initial treatment for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t50257\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Pharmacotherapy of psychosis</strong></p></td></tr><tr><td style=\"width: 25%;\"><p align=\"center\"><strong>Medications</strong></p></td><td style=\"width: 75%;\"><ul><li>Second-generation antipsychotics (eg, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone)</li><li>First-generation antipsychotics (eg, haloperidol)</li><li>Adjunctive benzodiazepines for agitation</li></ul></td></tr><tr><td style=\"width: 25%;\"><p align=\"center\"><strong>Special populations</strong></p></td><td style=\"width: 75%;\"><ul><li>Chronic nonadherence: consider long-acting injectable</li><li>Treatment resistance (2 failed trials): consider clozapine</li></ul></td></tr></tbody></table></div><p>This patient exhibits symptoms of acute psychosis (eg, grossly disorganized speech and behavior, probable hallucinations) that are most likely due to <strong>schizophrenia</strong>.&nbsp; Definitive diagnosis of schizophrenia requires ruling out other psychotic disorders, mood disorders with psychotic features, substance-induced psychosis, and psychosis secondary to a general medical condition.</p><p>Because the patient is cooperative, <strong>initial treatment</strong> with an <strong>oral antipsychotic medication</strong> is appropriate.&nbsp; Medication selection depends on a patient&#39;s history of response as well as the medication side effect profile.&nbsp; <strong>Second-generation</strong> antipsychotics, such as <strong>aripiprazole</strong>, are often chosen due to their lower risk of extrapyramidal side effects and tardive dyskinesia compared with first-generation antipsychotics.&nbsp; With the exception of clozapine, there is no evidence that one antipsychotic is more effective than another.</p><p>If further evaluation indicates a pattern of repeated <strong>medication nonadherence</strong>, switching to a <strong>long-acting injectable</strong> antipsychotic could be considered.&nbsp; However, this should be done only after the patient&#39;s ability to tolerate the oral formulation and therapeutic dosage is established, making long-acting injectable antipsychotics inappropriate choices as initial agents <strong>(Choices C and F)</strong>.&nbsp; If this patient tolerates and responds well to oral aripiprazole then subsequently switching to a long-acting formulation of aripiprazole could be considered.</p><p><strong>(Choice B)</strong>&nbsp; Clozapine is a second-generation antipsychotic that is considered the gold standard for treatment-resistant schizophrenia.&nbsp; However, due to the risk of agranulocytosis, it is reserved for patients who have failed to respond to at least 2 antipsychotic trials.</p><p><strong>(Choice D)</strong>&nbsp; Lithium is a mood stabilizer used primarily in bipolar disorder.&nbsp; It requires gradual up-titration and is unlikely to facilitate rapid improvement in an acutely psychotic patient.&nbsp; Although manic episodes can present with psychotic features, there is no clear evidence of a distinct mood component to this patient&#39;s illness.</p><p><strong>(Choice E)</strong>&nbsp; Lorazepam is a benzodiazepine that can be used as an adjunct for agitation associated with psychosis.&nbsp; However, lorazepam alone is not sufficient to treat this patient&#39;s psychosis.</p><p><strong>Educational objective:</strong><br>Antipsychotic medications are the first-line treatment for psychosis.&nbsp; Long-acting injectables should be considered for nonadherence after tolerability and dosage parameters are established on oral medications.&nbsp; Clozapine should be considered for patients who have failed at least 2 antipsychotic trials.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "1",
            "userAnswer": "6",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Aripiprazole",
                    "choiceNumber": 1,
                    "correctTaken": 8680,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 2,
                    "correctTaken": 853,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Haloperidol long-acting injectable",
                    "choiceNumber": 3,
                    "correctTaken": 2592,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lithium",
                    "choiceNumber": 4,
                    "correctTaken": 594,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lorazepam",
                    "choiceNumber": 5,
                    "correctTaken": 1403,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Risperidone long-acting injectable",
                    "choiceNumber": 6,
                    "correctTaken": 2894,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "223,263,true,-1,1*563,772,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27229275",
                    "mediaDataId": 0,
                    "title": "Assessing and treating the patient with acute&#160;psychotic disorders.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27229275",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19320529",
                    "mediaDataId": 0,
                    "title": "Management of patients presenting with acute psychotic episodes of schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19320529",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 96,
            "othersAvgTimeSpent": 58,
            "notes": null,
            "peopleTaken": 17017,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 51,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 468,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 14,
            "questionId": 2501,
            "questionIndex": 2501,
            "questionText": "<p>A 44-year-old man is brought to the emergency department after he was found talking to himself in a park.&nbsp; When authorities asked him to leave, he became agitated and combative, saying he was &#x22;destined to lead&#x22; and has to &#x22;wait in the park for the sign.&#x22;&nbsp; The patient admits to not sleeping for the past week.&nbsp; His thoughts jump from topic to topic, and he appears distractible, disorganized, and unable to care for himself.&nbsp; The patient is admitted to the hospital and prescribed daily haloperidol and valproate.&nbsp; Over the next week, he becomes significantly calmer.&nbsp; Although he continues to believe that he will &#x22;lead a spiritual revolution,&#x22; he sleeps 6 hours a night and is better able to focus.&nbsp; Ten days after admission, nursing staff members find him lying in bed, confused, sweating, and stiff.&nbsp; Temperature is 39.2 C (102.6 F), blood pressure is 164/98 mm Hg, pulse is 122/min, and respirations are 28/min.&nbsp; As a precaution, all medications are stopped.&nbsp; If the patient&#39;s condition fails to improve with supportive measures, which of the following medications would be most appropriate to administer at this time?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t64797\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Neuroleptic malignant syndrome</strong></p></td></tr><tr><td><p align=\"center\"><strong>Causative<br />agents</strong></p></td><td><ul><li>Antipsychotic medication (eg,&nbsp;haloperidol)</li><li>Antiemetic medications (eg,&nbsp;promethazine)</li><li>Withdrawal of Parkinson medications</li></ul></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Central dopaminergic receptor blockade (hyperthermia, dysautonomia)</li><li>Disruption of nigrostriatal dopamine pathways (rigidity)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Signs/symptoms</strong></p></td><td><ul><li>Fever</li><li>Altered mental status</li><li>Generalized muscle rigidity (lead-pipe rigidity)</li><li>Autonomic instability (abnormal vital signs, diaphoresis)</li><li>Elevated creatine kinase &plusmn; renal failure</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Stop antipsychotics or restart dopamine agents</li><li>Supportive care (hydration, cooling), intensive care unit</li><li>Benzodiazepines</li><li>Bromocriptine or dantrolene if refractory</li></ul></td></tr></tbody></table></div><p>This patient has <strong>neuroleptic malignant syndrome (NMS)</strong>, a rare but potentially lethal adverse reaction to antipsychotic medications (neuroleptics).&nbsp; Its cardinal features include <strong>severe hyperthermia, autonomic dysregulation, lead-pipe rigidity, and altered mental status</strong>.</p><p><strong>Treatment of NMS</strong> includes the following:</p><ul><li><p>Prompt <strong>discontinuation of the offending agent</strong> (the antipsychotic).&nbsp; Both first-generation (eg, haloperidol) and second-generation <strong>antipsychotics</strong> can cause NMS.&nbsp; It may occur at any time but usually develops within the first 2 weeks of treatment.</p></li><li><p><strong>Supportive care</strong> (ie, aggressive cooling, intravenous fluids, and electrolyte repletion).</p></li><li><p><strong>Benzodiazepines</strong>, which can improve agitation and decrease muscle contraction</p></li><li><p><strong>Bromocriptine</strong> or <strong>amantadine</strong>, dopaminergic medications that can be considered in a patient whose condition does not respond to supportive care and withdrawal of medication.</p></li><li><p><strong>Dantrolene</strong>, a direct-acting muscle relaxant with a rapid onset of action that can reduce heat production and muscle rigidity.</p></li></ul><p><strong>(Choice A)</strong>&nbsp; The anticholinergic medication benztropine can be used to treat antipsychotic-induced extrapyramidal symptoms (eg, dystonia).&nbsp; Although extrapyramidal symptoms can present as stiffness in a patient taking antipsychotics, they would not be expected to cause hyperthermia, hypertension, altered mental status, and tachycardia.</p><p><strong>(Choice C)</strong>&nbsp; Cyproheptadine, a serotonin antagonist, is used to treat severe cases of serotonin syndrome (SS).&nbsp; Although this patient has symptoms that overlap with SS (eg, autonomic instability, altered mental status), his exposure to an antipsychotic rather than a serotonergic medication and his lead-pipe rigidity, as opposed to hyperreflexia, are consistent with NMS.</p><p><strong>(Choice D)</strong>&nbsp; Physostigmine is a cholinesterase inhibitor used to reverse the toxic CNS effects caused by anticholinergic drugs.&nbsp; Patients with anticholinergic toxicity would have dry skin, not diaphoresis.</p><p><strong>(Choice E)</strong>&nbsp; The beta blocker propranolol can be used to control hypertension and tachycardia associated with NMS, but it would not address the underlying cause of these symptoms.</p><p><strong>(Choice F)</strong>&nbsp; Succinylcholine is a very short-acting, depolarizing muscle relaxant used to induce brief paralysis during anesthesia.&nbsp; It can cause malignant hyperthermia, a clinical syndrome similar to NMS known to occur immediately following exposure to halogenated inhalational anesthetic agents.&nbsp; Succinylcholine is not a treatment for NMS.</p><p><strong>Educational objective:</strong><br>Neuroleptic malignant syndrome is a rare but potentially life-threatening emergency associated with the use of antipsychotics (neuroleptics).&nbsp; A patient whose condition does not improve with cessation of the antipsychotic and intensive supportive care can be treated with benzodiazepines, dopamine agonists, and/or dantrolene.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 7877,
            "topic": "Neuroleptic malignant syndrome",
            "titleId": 7877,
            "title": "Neuroleptic malignant syndrome",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Benztropine",
                    "choiceNumber": 1,
                    "correctTaken": 4803,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Bromocriptine",
                    "choiceNumber": 2,
                    "correctTaken": 8313,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Cyproheptadine",
                    "choiceNumber": 3,
                    "correctTaken": 1889,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Physostigmine",
                    "choiceNumber": 4,
                    "correctTaken": 605,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Propranolol",
                    "choiceNumber": 5,
                    "correctTaken": 669,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Succinylcholine",
                    "choiceNumber": 6,
                    "correctTaken": 659,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "121,198,true,-1,1*215,339,true,-1,1*411,431,true,-1,1*490,530,true,-1,1*1177,1262,true,-1,1*1432,1461,true,-1,1*2366,2439,true,-1,1*3448,3515,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27469512",
                    "mediaDataId": 0,
                    "title": "Management of serotonin syndrome and neuroleptic malignant syndrome.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27469512",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27423483",
                    "mediaDataId": 0,
                    "title": "Neuroleptic malignant syndrome.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27423483",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26411967",
                    "mediaDataId": 0,
                    "title": "Neuroleptic malignant syndrome: a review from a clinically oriented perspective.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26411967",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 97,
            "othersAvgTimeSpent": 62,
            "notes": null,
            "peopleTaken": 16938,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 49,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 790,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 15,
            "questionId": 13656,
            "questionIndex": 15046,
            "questionText": "<p>A 15-year-old, previously healthy boy is brought to the clinic by his mother due to declining academic performance and change in behavior.&nbsp; The mother says that the patient used to be a straight A student but has been struggling to keep up in class for the last 3 months.&nbsp; He has also been uncharacteristically moody and irritable.&nbsp; She says, &#x22;I recently saw him talking to a wall, but when I asked him about it, he told me to mind my own business.&#x22;&nbsp; When interviewed privately, the patient says he has been hearing voices at times but is unable to understand what they are saying.&nbsp; Vital signs are within normal limits.&nbsp; Growth tracks above the 60th percentile.&nbsp; Facial expressivity is diminished.&nbsp; The patient&#39;s voice is soft, and he has excess saliva.&nbsp; Motor examination shows increased tone in the arms and a mild tremor.&nbsp; Mental status examination is significant for an irritable affect and minimal eye contact.&nbsp; The most likely cause of this patient&#39;s underlying condition is an abnormality in which of the following physiologic processes?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t32077\"><table class=\"table-default-style\" style=\"width:540px\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Wilson disease</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis</strong></p></td><td><ul><li>Autosomal recessive mutation of <em>ATP7B</em>&nbsp;&rarr; hepatic copper accumulation&nbsp;&rarr; leak from damaged hepatocytes&nbsp;&rarr; deposits in tissues (eg,&nbsp;basal ganglia, cornea)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical<br />findings</strong></p></td><td><ul><li>Hepatic (acute liver failure, chronic hepatitis, cirrhosis)</li><li>Neurologic (parkinsonism, gait disturbance, dysarthria)</li><li>Psychiatric (depression, personality changes, psychosis)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Diagnosis</strong></p></td><td><ul><li>&darr;&nbsp;Ceruloplasmin&nbsp;&amp; &uarr;&nbsp;urinary copper excretion</li><li>Kayser-Fleischer rings on slit-lamp examination</li><li>&uarr;&nbsp;Copper content on liver biopsy</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Chelators (eg,&nbsp;D-penicillamine, trientine)</li><li>Zinc (interferes with copper absorption)</li></ul></td></tr></tbody></table></div><p>This <strong>adolescent</strong> has new-onset <strong>psychosis</strong>, as evidenced by impaired reality through auditory hallucinations.&nbsp; With an <strong>abnormal neurologic examination</strong> (eg, tremor, hypertonia, facial stiffness), these findings are concerning for <strong>parkinsonism</strong> due to <strong>Wilson disease</strong>.</p><p>Wilson disease is an autosomal recessive disorder characterized by <a href=\"35425\">defective hepatic copper transport</a>, resulting in <strong>copper accumulation</strong> throughout the body.&nbsp; Initial copper buildup occurs within the liver, leading to hepatocellular apoptosis and release of free copper into the bloodstream.&nbsp; Extrahepatic copper is then deposited in various tissues, including the CNS, kidney, and cornea.&nbsp; The <strong>basal ganglia</strong> is the primary site of deposition in the CNS and accounts for the movement abnormalities seen in Wilson disease.&nbsp; Because the basal ganglia, frontal cortex, and limbic system communicate, copper buildup also affects mood and cognition.</p><p>Neuropsychiatric symptoms often precede hepatic symptoms, such as hepatomegaly or jaundice, in teenagers and may be mistakenly attributed to normal adolescence or primary psychiatric illness.&nbsp; Symptoms may be subtle (eg, personality change, academic decline, irritability) or more severe, as in this patient.&nbsp; Neurologic findings can also include dysarthria, dystonia, and <strong>tremor</strong>.&nbsp; This patient&#39;s diminished expressivity, soft voice, and pooled saliva are consistent with <strong>parkinsonism</strong> seen in Wilson disease.</p><p><strong>(Choice A)</strong>&nbsp; Very-long-chain fatty acid accumulation occurs in X-linked adrenoleukodystrophy, which can present with academic difficulties and behavioral abnormalities in early childhood or adolescence.&nbsp; Weakness, ataxia, and paralysis can occur, but tremor and parkinsonism would not be seen.</p><p><strong>(Choice C)</strong>&nbsp; Hereditary hemochromatosis is an autosomal recessive disorder characterized by increased absorption of iron.&nbsp; Symptoms include fatigue and hepatic dysfunction, but neuropsychiatric symptoms would not be seen.</p><p><strong>(Choice D)</strong>&nbsp; Fanconi syndrome, characterized by proximal tubular dysfunction, occurs in Wilson disease due to renal copper deposition.&nbsp; This complication is a result and not the cause of impaired cellular copper transport.</p><p><strong>(Choice E)</strong>&nbsp; Thyrotoxicosis due to hyperthyroidism can cause tremor and altered mental status (eg, agitation, delirium) or frank psychosis.&nbsp; However, these patients typically have tachycardia, high fever, and goiter, none of which are present in this case.</p><p><strong>Educational objective:</strong><br>New-onset psychosis in an adolescent with neurologic dysfunction (eg, tremor, parkinsonism) raises concern for Wilson disease.&nbsp; Pathogenesis involves defective hepatocellular copper transport, leading to copper accumulation in the liver and basal ganglia.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 104,
            "subject": "Pediatrics",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 19953,
            "topic": "Wilson disease",
            "titleId": 19953,
            "title": "Wilson disease",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Fatty acid metabolism",
                    "choiceNumber": 1,
                    "correctTaken": 3769,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hepatocellular transport",
                    "choiceNumber": 2,
                    "correctTaken": 10537,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Intestinal absorption",
                    "choiceNumber": 3,
                    "correctTaken": 2173,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Renal tubular function",
                    "choiceNumber": 4,
                    "correctTaken": 923,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thyroid hormone regulation",
                    "choiceNumber": 5,
                    "correctTaken": 3274,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2570,2779,true,-1,1*2055,2336,true,-1,1*1844,2043,true,-1,1*1280,1534,true,-1,1*1254,1279,true,-1,1*312,340,true,-1,1*355,365,true,-1,1*386,397,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29200569",
                    "mediaDataId": 0,
                    "title": "Misidentification of Wilson disease as schizophrenia (1998-2013): case report and review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29200569",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28723019",
                    "mediaDataId": 0,
                    "title": "Wilson disease.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28723019",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24120023",
                    "mediaDataId": 0,
                    "title": "Psychiatric aspects of Wilson disease: a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24120023",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 245,
            "othersAvgTimeSpent": 71,
            "notes": null,
            "peopleTaken": 20676,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 51,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1458,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 16,
            "questionId": 4887,
            "questionIndex": 4887,
            "questionText": "<p>A 32-year-old man is admitted to the hospital after being found standing on the edge of a bridge.&nbsp; He appears severely depressed and says that his life is over.&nbsp; The patient is in financial ruin, and his wife recently left him and took their children.&nbsp; He is crying, is unable to sleep, has no appetite, and continues to express hopelessness and suicidal thoughts.&nbsp; He was taking phenelzine for depression but stopped the medication a month ago due to adverse effects.&nbsp; In the hospital, the patient is given sertraline.&nbsp; The next day, after calling his wife, he becomes agitated and starts to blame himself for destroying his life and family.&nbsp; The patient is given olanzapine for worsening agitation during the first 3 days, after which he is noticeably calmer but unable to get out of bed.&nbsp; He appears confused and does not respond to questions appropriately.&nbsp; The patient is diaphoretic.&nbsp; Temperature is 40.1 C (104.2 F), blood pressure is 167/97 mm Hg, and pulse is 112/min.&nbsp; As staff members attempt to get him out of bed, they notice that his arms and legs are stiff and difficult to bend.&nbsp; Which of the following is the most likely cause of this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t64737\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Neuroleptic malignant syndrome vs serotonin toxicity</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>Neuroleptic malignant syndrome</strong></p></td><td><p align=\"center\"><strong>Serotonin toxicity</strong></p></td></tr><tr><td><p align=\"center\"><strong>Causative agent</strong></p></td><td><ul><li>Dopamine antagonist</li></ul></td><td><ul><li>Serotonergic agent</li></ul></td></tr><tr><td><p align=\"center\"><strong>Course</strong></p></td><td><ul><li>Slow onset/offset (days to weeks)</li><li>Not dose dependent, can occur anytime</li></ul></td><td><ul><li>Rapid onset/offset (&lt;24 hr)</li><li>Often associated with dose increase or additional serotonergic agent</li></ul></td></tr><tr><td><p align=\"center\"><strong>Overlapping features</strong></p></td><td><ul><li>Autonomic dysregulation</li><li>Altered mental status</li><li>Hyperthermia</li></ul></td><td><ul><li>Autonomic dysregulation</li><li>Altered mental status</li><li>Hyperthermia</li></ul></td></tr><tr><td><p align=\"center\"><strong>Distinct features</strong></p></td><td><ul><li>Severe, diffuse muscle rigidity</li></ul></td><td><ul><li>Hyperreflexia</li><li>Clonus</li><li>Nausea, vomiting common</li></ul></td></tr></tbody></table></div><p>This patient&#39;s presentation is consistent with <strong>neuroleptic malignant syndrome</strong> (NMS).&nbsp; NMS is a rare, idiosyncratic, and potentially life-threatening complication of treatment with antipsychotics.&nbsp; Although it is more commonly associated with the use of high-potency, first-generation antipsychotics (eg, haloperidol), NMS can occur with <strong>every class of antipsychotics</strong>, including second-generation drugs (eg, olanzapine).</p><p>Physical examination findings of <a href=\"3377\">NMS</a> include <strong>hyperthermia, lead-pipe rigidity</strong> (eg, stiff arms and legs), <strong>mental status changes</strong> (eg, agitation), and <strong>autonomic instability</strong> (eg, hyperthermia, hypertension, tachycardia, diaphoresis).&nbsp; Overlapping symptoms with serotonin syndrome (SS) are common (eg, hypertension, tachycardia, hyperthermia, altered mental status); NMS can be differentiated from SS as follows:</p><ul><li>NMS is caused by dopamine antagonists, not serotonergic agents (eg, sertraline) <strong>(Choice E)</strong>.&nbsp; SS is typically due to a combination of serotonergic agents or a drug interaction between these medications and a monoamine oxidase inhibitor (eg, phenelzine) <strong>(Choice B)</strong>.&nbsp; This patient has had a sufficient 2-week washout period from phenelzine, and sertraline alone (or in combination with olanzapine) is unlikely to cause SS.</li></ul><ul><li>The onset of NMS is gradual, as seen in this patient.&nbsp; In contrast, SS is characterized by abrupt onset (usually &lt;24 hr).</li></ul><ul><li>Severe, generalized <strong>lead-pipe rigidity</strong> is the hallmark of NMS.&nbsp; Neuromuscular excitability (eg, clonus, hyperreflexia) distinguishes SS.</li></ul><ul><li>Gastrointestinal symptoms (eg, vomiting, diarrhea) are usually absent in NMS but present in SS.</li></ul><p><strong>(Choice A)</strong>&nbsp; Catatonia is a syndrome that occurs in severely ill psychiatric and medical patients, characterized by decreased motor activity, lack of responsiveness during interview, and posturing.&nbsp; It is not to be confused with malignant catatonia, a specific disorder with autonomic instability (similar to NMS) but with motor symptoms that include posturing and waxy flexibility.&nbsp; Catatonia would not explain this patient&#39;s hyperthermia and autonomic dysregulation.</p><p><strong>(Choice C)</strong>&nbsp; Malignant hyperthermia is a specific disorder characterized by symptoms similar to those of NMS, but it presents with the use of volatile anesthetics or succinylcholine.&nbsp; Symptoms occur during or immediately after anesthetic use (not present in this patient).</p><p><strong>Educational objective:</strong><br>Neuroleptic malignant syndrome (NMS) is a potentially life-threatening condition that can occur after administration of antipsychotic medications.&nbsp; Symptoms include hyperthermia, autonomic dysregulation, altered mental status, and generalized muscle rigidity.&nbsp; Lead-pipe rigidity and absence of hyperreflexia can distinguish NMS from serotonin syndrome.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Catatonia",
                    "choiceNumber": 1,
                    "correctTaken": 777,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Drug-drug interaction",
                    "choiceNumber": 2,
                    "correctTaken": 3179,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Malignant hyperthermia",
                    "choiceNumber": 3,
                    "correctTaken": 2344,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Olanzapine",
                    "choiceNumber": 4,
                    "correctTaken": 9713,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Sertraline",
                    "choiceNumber": 5,
                    "correctTaken": 935,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "3226,3318,true,-1,1*2399,2584,true,-1,1*196,229,true,-1,1*268,295,true,-1,1*230,267,true,-1,1*1633,1678,true,-1,1*1692,1846,true,-1,1*2106,2200,true,-1,1*575,598,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22563571",
                    "mediaDataId": 0,
                    "title": "Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22563571",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26411967",
                    "mediaDataId": 0,
                    "title": "Neuroleptic malignant syndrome: a review from a clinically oriented perspective.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26411967",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27469512",
                    "mediaDataId": 0,
                    "title": "Management of serotonin syndrome and neuroleptic malignant syndrome.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27469512",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 115,
            "othersAvgTimeSpent": 59,
            "notes": null,
            "peopleTaken": 16948,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 57,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 583,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 17,
            "questionId": 4885,
            "questionIndex": 4885,
            "questionText": "<p>A 28-year-old woman is evaluated for the recent onset of paranoid thinking.&nbsp; For the past 4 months, she has thought that coworkers have been spying on her and talking behind her back.&nbsp; She is afraid to go to work and worries that she might lose her job.&nbsp; She has no hallucinations or depression and no significant medical history.&nbsp; Her father has coronary artery disease and hypertension, and her mother has a history of depression and hypothyroidism.&nbsp; The patient has a 9-pack-year smoking history and drinks alcohol socially.&nbsp; Physical examination is unremarkable.&nbsp; ECG, complete blood count, comprehensive metabolic panel, and urine toxicology screen are normal.&nbsp; The patient is started on olanzapine.&nbsp; Which of the following tests would be most important to obtain at the patient&#39;s 3-month follow-up visit?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t35225\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Metabolic effects of second-generation antipsychotics</strong></p></td></tr><tr><td><p align=\"center\"><strong>Metabolic syndrome</strong></p></td><td><ul><li>Weight gain</li><li>Dyslipidemia</li><li>Hyperglycemia (including new-onset diabetes mellitus)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Highest-risk drugs</strong></p></td><td><ul><li>Clozapine</li><li>Olanzapine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Monitoring guidelines</strong></p></td><td><p>Baseline &amp; regular follow-up</p><ul><li>BMI</li><li>Fasting glucose &amp; lipids</li><li>Blood pressure</li><li>Waist circumference</li></ul></td></tr></tbody></table></div><p>Olanzapine is a <strong>second-generation antipsychotic</strong> medication used to treat schizophrenia, bipolar disorder, and other psychotic disorders.&nbsp; Although second-generation antipsychotics have a lower risk of extrapyramidal side effects, they are all associated with <strong>metabolic adverse effects</strong> (eg, weight gain, dyslipidemia, hyperglycemia, increased risk of diabetes) to varying degrees.&nbsp; <strong>Olanzapine</strong> and <strong>clozapine</strong> appear to pose the <strong>greatest risk</strong>.&nbsp; Due to these potential side effects, body mass index should be measured monthly, and fasting plasma glucose and lipids, blood pressure, and waist circumference should be assessed at baseline, 3 months, and then annually.&nbsp; Earlier and more frequent monitoring is recommended for patients with diabetes or those who have gained &gt;5% of initial weight.</p><p><strong>(Choices A and G)</strong>&nbsp; Kidney and thyroid function tests should be monitored in patients taking lithium, not olanzapine.&nbsp; Lithium is associated with nephrogenic diabetes insipidus, chronic interstitial nephritis, and hypothyroidism.&nbsp; Lithium also accumulates in patients with renal insufficiency, and dose adjustment is needed.</p><p><strong>(Choice B)</strong>&nbsp; Reports of olanzapine causing neutropenia or agranulocytosis are rare, and complete blood counts are not routinely checked.&nbsp; The risk for agranulocytosis is higher with clozapine, which requires weekly blood counts during the first 6 months of treatment.</p><p><strong>(Choice C)</strong>&nbsp; ECG is not routinely required in patients on olanzapine.&nbsp; However, ECG monitoring is advised for those with a history of cardiac disease.&nbsp; The second-generation antipsychotic ziprasidone has been associated with QT prolongation at higher doses.</p><p><strong>(Choice E)</strong>&nbsp; Antipsychotic drugs can cause asymptomatic increases in liver enzymes, but significant liver enzyme elevations are rare.&nbsp; In asymptomatic patients, it is reasonable to obtain liver function tests at baseline and then yearly.</p><p><strong>(Choice F)</strong>&nbsp; Hyperprolactinemia (galactorrhea, menstrual disturbances, sexual dysfunction, gynecomastia) can occur with first-generation antipsychotics and the second-generation antipsychotic risperidone.&nbsp; Olanzapine, however, does not commonly increase prolactin levels.</p><p><strong>Educational objective:</strong><br>Second-generation antipsychotics cause metabolic side effects (eg, weight gain, hyperglycemia, dyslipidemia) to varying degrees.&nbsp; Routine monitoring for the development of these side effects is recommended in patients taking second-generation antipsychotics.&nbsp; Olanzapine and clozapine are associated with the greatest risk.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Blood urea nitrogen and creatinine",
                    "choiceNumber": 1,
                    "correctTaken": 118,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Complete blood count",
                    "choiceNumber": 2,
                    "correctTaken": 1409,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "ECG",
                    "choiceNumber": 3,
                    "correctTaken": 577,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Fasting glucose and lipids",
                    "choiceNumber": 4,
                    "correctTaken": 13895,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Liver function tests",
                    "choiceNumber": 5,
                    "correctTaken": 436,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prolactin level",
                    "choiceNumber": 6,
                    "correctTaken": 401,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Thyroid function tests",
                    "choiceNumber": 7,
                    "correctTaken": 137,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "778,1126,true,-1,1*1303,1334,true,-1,1*1463,1717,true,-1,1*1868,1974,true,-1,1*2223,2242,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28585153",
                    "mediaDataId": 0,
                    "title": "Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28585153",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "19083283",
                    "mediaDataId": 0,
                    "title": "Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/19083283",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 68,
            "othersAvgTimeSpent": 37,
            "notes": null,
            "peopleTaken": 16973,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 82,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 970,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 18,
            "questionId": 10828,
            "questionIndex": 11958,
            "questionText": "<p>A 31-year-old man is brought to the office by his father due to behaving bizarrely and hearing voices.&nbsp; Over the past month, the patient has locked his bedroom door at night and has refused to drink the tea that his mother prepared.&nbsp; He believes that she has been replaced by an imposter and is trying to poison him.&nbsp; When interviewed alone, the patient says, &#x22;People are trying to control me through a chip that was implanted in my brain.&#x22;&nbsp; The patient was hospitalized for an acute psychotic episode at age 27.&nbsp; He was successfully treated with haloperidol, but he discontinued the medication after experiencing muscle spasms in his neck, restlessness, and difficulty sitting still.&nbsp; Medical issues include type 2 diabetes mellitus and seasonal allergies.&nbsp; Physical examination is unremarkable and urine drug screening is negative.&nbsp; Which of the following is the most appropriate pharmacotherapy for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient is acutely psychotic and requires prompt treatment with antipsychotic medication.&nbsp; Although he responded to haloperidol during his previous episode, he experienced major tolerability issues due to <strong>extrapyramidal symptoms</strong> (EPS) (eg, acute dystonic reaction, akathisia), which likely contributed to his subsequent nonadherence.&nbsp; EPS are <strong>more common</strong> with high-potency, <strong>first-generation antipsychotics</strong> such as haloperidol due to their potent dopamine D2 antagonism in the nigrostriatal pathway.</p><p>The best approach in this patient would be to treat with a <strong>second-generation antipsychotic</strong> (eg, ziprasidone) as it reduces the risk of EPS.&nbsp; Among the second-generation antipsychotics, <strong>ziprasidone</strong> has a low <a href=\"11398\">metabolic risk profile</a>, whereas <strong>olanzapine</strong> is associated with the highest risk of <strong>weight gain and metabolic side effects</strong> (eg, insulin resistance, hyperlipidemia) and should be avoided in this patient due to his history of type 2 diabetes <strong>(Choice D)</strong>.&nbsp; Other second-generation antipsychotics with lower metabolic risk include aripiprazole and lurasidone.</p><p><strong>(Choice A)</strong>&nbsp; Although clozapine causes virtually no EPS, it is reserved for patients who have failed at least 2 antipsychotic trials due to the risk of agranulocytosis.&nbsp; It is also associated with significant risk of weight gain and metabolic side effects.</p><p><strong>(Choice B)</strong>&nbsp; Switching to another high-potency, first-generation antipsychotic such as fluphenazine may result in similar side effects (ie, EPS) and again lead to nonadherence.</p><p><strong>(Choice C)</strong>&nbsp; Switching to the long-acting injectable form of haloperidol would be indicated if the patient were nonadherent and had no tolerability issues on oral haloperidol.</p><p><strong>Educational objective:</strong><br>Compared with first-generation antipsychotics, second-generation antipsychotics cause fewer extrapyramidal symptoms but are associated with metabolic effects to varying degrees.&nbsp; Clozapine and olanzapine carry a high risk of metabolic side effects, whereas ziprasidone, aripiprazole, and lurasidone are associated with the lowest risk.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 1,
                    "correctTaken": 2177,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Fluphenazine",
                    "choiceNumber": 2,
                    "correctTaken": 816,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Haloperidol long-acting injectable",
                    "choiceNumber": 3,
                    "correctTaken": 698,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Olanzapine",
                    "choiceNumber": 4,
                    "correctTaken": 4750,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ziprasidone",
                    "choiceNumber": 5,
                    "correctTaken": 8477,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1902,2059,true,-1,1*369,533,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29162032",
                    "mediaDataId": 0,
                    "title": "The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose:  a network meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29162032",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "20187598",
                    "mediaDataId": 0,
                    "title": "Adverse effects of antipsychotic medications.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/20187598",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 62,
            "othersAvgTimeSpent": 53,
            "notes": null,
            "peopleTaken": 16918,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 50,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 474,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 19,
            "questionId": 11062,
            "questionIndex": 12203,
            "questionText": "<p>A 75-year-old hospitalized woman with a history of Alzheimer dementia is evaluated due to labile blood pressure and worsening agitation.&nbsp; The patient was admitted 4 days ago for right hip replacement after a traumatic fall and hip fracture.&nbsp; Her immediate postoperative course was complicated by agitation, and she was treated with haloperidol.&nbsp; Despite treatment, the patient continues to be agitated and confused.&nbsp; Today, her systolic blood pressure has measured between 120 and 170 mm Hg.&nbsp; Temperature is 38.7 C (101.6 F), pulse is 120/min, and respirations are 22/min.&nbsp; Pulse oximetry is 97% on room air.&nbsp; On mental status examination, the patient is not oriented to place or person.&nbsp; She is drooling and diaphoretic.&nbsp; Heart and lungs are normal.&nbsp; The abdomen is soft and nontender.&nbsp; The operative site is clean and dry.&nbsp; Muscle tone is increased in both the upper and the lower extremities.&nbsp; Tremor is present.&nbsp; Deep tendon reflexes are 2+.&nbsp; Babinski sign is absent.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td style=\"padding-left:2em\">Leukocytes</td><td>15,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"padding-left:4em\">Neutrophils</td><td>80%</td></tr><tr><td style=\"padding-left:4em\">Lymphocytes</td><td>15%</td></tr><tr><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">Urinalysis</td></tr><tr><td style=\"padding-left:2em\">Blood</td><td>moderate</td></tr><tr><td style=\"padding-left:2em\">Nitrites</td><td>negative</td></tr><tr><td style=\"padding-left:2em\">Bacteria</td><td>none</td></tr><tr><td style=\"padding-left:2em\">White blood cells</td><td>1-2/hpf</td></tr><tr><td style=\"padding-left:2em\">Red blood cells</td><td>1-2/hpf</td></tr></tbody></table><p>Which of the following is the most likely explanation for this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t64797\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Neuroleptic malignant syndrome</strong></p></td></tr><tr><td><p align=\"center\"><strong>Causative<br />agents</strong></p></td><td><ul><li>Antipsychotic medication (eg,&nbsp;haloperidol)</li><li>Antiemetic medications (eg,&nbsp;promethazine)</li><li>Withdrawal of Parkinson medications</li></ul></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Central dopaminergic receptor blockade (hyperthermia, dysautonomia)</li><li>Disruption of nigrostriatal dopamine pathways (rigidity)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Signs/symptoms</strong></p></td><td><ul><li>Fever</li><li>Altered mental status</li><li>Generalized muscle rigidity (lead-pipe rigidity)</li><li>Autonomic instability (abnormal vital signs, diaphoresis)</li><li>Elevated creatine kinase &plusmn; renal failure</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Stop antipsychotics or restart dopamine agents</li><li>Supportive care (hydration, cooling), intensive care unit</li><li>Benzodiazepines</li><li>Bromocriptine or dantrolene if refractory</li></ul></td></tr></tbody></table></div><p>This patient initially had postoperative delirium, which is common in elderly patients with dementia, and received treatment with an <strong>antipsychotic</strong> (haloperidol).&nbsp; She subsequently developed <strong>muscular rigidity</strong>, <strong>altered mental status</strong>, <strong>autonomic dysregulation</strong> (eg, labile blood pressure, tachycardia, diaphoresis), and <strong>fever</strong>, findings concerning for <strong>neuroleptic malignant syndrome (NMS)</strong>, an uncommon but life-threatening idiosyncratic complication of antipsychotics.</p><p>Because dopamine antagonism is the mechanism of action of all first-generation and most second-generation <strong>antipsychotics</strong>, NMS is likely due to dopamine dysregulation:</p><ul><li><strong>Central dopamine receptor blockade</strong> in the hypothalamus may cause autonomic dysregulation and hyperthermia.</li></ul><ul><li><strong>Dopamine antagonism</strong> in the nigrostriatal pathway may lead to tremor and diffuse <strong>lead-pipe rigidity</strong> (stiffness maintained equally through the entire range of motion).</li></ul><p>Sustained muscle contraction can lead to muscle breakdown, leading to laboratory abnormalities, including elevated creatine kinase and myoglobinuria (urinalysis positive for blood but few red blood cells).&nbsp; Leukocytosis with left shift is also common.</p><p><strong>(Choice A)</strong>&nbsp; In malignant hyperthermia (MH), exposure to certain anesthetic agents (eg, succinylcholine, inhalational gasses) causes a hypermetabolic crisis with sustained muscle contraction that leads to tachypnea, tachycardia, hyperthermia, and myoglobinuria.&nbsp; However, most cases arise during or shortly after induction of anesthesia and are associated with high mortality within 24 hours if untreated (eg, with dantrolene); this makes MH an unlikely explanation for this patient&#39;s symptoms persisting 4 days postoperatively.</p><p><strong>(Choice B)</strong>&nbsp; Excessive catecholamine-producing tumors (eg, pheochromocytomas) can cause resistant hypertension with tachycardia.&nbsp; Surgical removal can precipitate catecholamine surges and result in labile blood pressures, high fever, and fatal arrhythmias.&nbsp; However, muscle rigidity and altered mental status would not be expected.</p><p><strong>(Choice D)</strong>&nbsp; Although infection should be considered in this postoperative patient with fever and leukocytosis, her labile hypertension (vs hypotension more commonly seen in sepsis), increased muscle tone, and tremor make NMS more likely.&nbsp; In addition, her urinalysis shows no evidence of infection (negative nitrites, 1-2 white blood cells/hpf), and deep joint infections without overlying skin breakdown are unlikely in the first few postoperative days.</p><p><strong>(Choice E)</strong>&nbsp; Cerebellar infarctions classically present with vertigo, nystagmus, and ataxia.&nbsp; Although infarction can be accompanied by autonomic dysregulation if the lateral medulla is also affected, increased muscle tone, fever, and altered mental status would not be expected.</p><p><strong>Educational objective:</strong><br>Neuroleptic malignant syndrome (NMS) is characterized by severe muscular rigidity, mental status changes, autonomic dysregulation, and fever.&nbsp; Dopamine antagonism, which occurs with the use of most antipsychotics, has been implicated as a primary cause of NMS.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Anesthetic-triggered hypermetabolic crisis",
                    "choiceNumber": 1,
                    "correctTaken": 6158,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Excessive catecholamine production by a tumor",
                    "choiceNumber": 2,
                    "correctTaken": 807,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Decreased central dopaminergic activity",
                    "choiceNumber": 3,
                    "correctTaken": 8061,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Infection-induced hyperarousal",
                    "choiceNumber": 4,
                    "correctTaken": 5927,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ischemic infarction of the cerebellum",
                    "choiceNumber": 5,
                    "correctTaken": 288,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2120,2386,true,-1,1*3265,3371,true,-1,1*2516,2641,true,-1,1*1607,1857,true,-1,1*1120,1166,true,-1,1*1368,1388,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26411967",
                    "mediaDataId": 0,
                    "title": "Neuroleptic malignant syndrome: a review from a clinically oriented perspective.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26411967",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 112,
            "othersAvgTimeSpent": 90,
            "notes": null,
            "peopleTaken": 21241,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 38,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 595,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 20,
            "questionId": 14650,
            "questionIndex": 16065,
            "questionText": "<p>A 26-year-old woman is brought to the hospital by her family due to increasingly bizarre behavior.&nbsp; The patient abruptly quit her sales job 8 months ago because she believed that her coworkers and boss were poisoning her coffee and trying to kill her.&nbsp; Shortly thereafter, she stopped going outside the house because she was convinced that black cars were following her.&nbsp; The patient has been hearing multiple voices over the past month and says, &#x22;Mostly they mumble and I can&#39;t make out what they&#39;re saying, but sometimes they tell me I&#39;m stupid and should kill myself.&#x22;&nbsp; A comprehensive medical evaluation, including drug screen testing, is unrevealing.&nbsp; She is admitted, and aripiprazole is initiated with improvement in her condition.&nbsp; The patient is discharged 1 week later.&nbsp; At her 1-month follow-up, she is no longer hearing voices, is much less paranoid, and is able to go outside the house; however, she still has periods of anxiety and has been reluctant to look for work.&nbsp; She continues to take the medication as prescribed.&nbsp; Which of the following is the most appropriate treatment recommendation for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t41553\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Schizophrenia</strong></p></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Diagnosis</strong></p></td><td style=\"width: 85%;\"><ul><li>&ge;2 of the following (at least 1 symptom from 1-3)<ol><li>Delusions</li><li>Hallucinations</li><li>Disorganized speech</li><li>Disorganized or catatonic behavior</li><li>Negative symptoms (eg, apathy, flat affect)</li></ol></li><li>Continuous impairment &ge;6 months</li><li>Significant functional decline</li></ul></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td style=\"width: 85%;\"><ul><li>Antipsychotic medication</li><li>Adjunctive psychosocial interventions (eg, social skills training,<br />cognitive-behavioral therapy, family intervention)</li></ul></td></tr></tbody></table></div><p>This patient&#39;s history of paranoid delusions, auditory hallucinations, significant functional decline, and continuous impairment for &#8805;6 months is consistent with <strong>schizophrenia</strong>.&nbsp; Although her psychotic symptoms are much improved at her 1-month follow-up, evidenced-based guidelines consistently recommend that <strong>antipsychotic medication</strong> be <strong>continued indefinitely</strong> to reduce the risk of relapse.</p><p>This recommendation applies to <strong>all patients</strong> with schizophrenia, including those experiencing a first psychotic episode, as in this case.&nbsp; In addition, many patients who show initial rapid improvement with antipsychotic medication experience further symptomatic and functional improvement on maintenance medication over the course of many months.</p><p>Patients with schizophrenia who discontinue medication have significantly higher rates of relapse, which often leads to rehospitalization and an overall poor outcome <strong>(Choices B and E)</strong>.&nbsp; Cognitive-behavioral therapy is an effective adjunct treatment intervention for schizophrenia but should be used in combination with maintenance pharmacotherapy <strong>(Choice D)</strong>.</p><p><strong>(Choice A)</strong>&nbsp; Patients with schizophrenia frequently have anxiety, especially during and immediately following an acute psychotic episode.&nbsp; Psychosocial approaches (eg, reassurance, psychoeducation, social skills training, family therapy, cognitive-behavioral therapy) are preferred initial interventions due to the risk of abuse and dependence associated with benzodiazepines.</p><p><strong>Educational objective:</strong><br>Antipsychotic medication should be maintained indefinitely in patients with schizophrenia, including those with a first episode of psychosis.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Add short-acting benzodiazepine as needed for anxiety",
                    "choiceNumber": 1,
                    "correctTaken": 3903,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Continue medication for 6 months then gradually taper off",
                    "choiceNumber": 2,
                    "correctTaken": 2344,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Continue medication indefinitely with regular follow-up",
                    "choiceNumber": 3,
                    "correctTaken": 10333,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue medication now and begin cognitive-behavioral therapy",
                    "choiceNumber": 4,
                    "correctTaken": 175,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Gradually taper and discontinue medication over 1 month",
                    "choiceNumber": 5,
                    "correctTaken": 356,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1551,1915,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "103",
                    "mediaDataId": 0,
                    "title": "Schizophrenia",
                    "referenceTypeId": 18,
                    "referenceLink": null,
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22592725",
                    "mediaDataId": 0,
                    "title": "Maintenance treatment with antipsychotic drugs for schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22592725",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26759992",
                    "mediaDataId": 0,
                    "title": "Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26759992",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26967313",
                    "mediaDataId": 0,
                    "title": "How long should antipsychotic treatment be continued after a single episode of schizophrenia?",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26967313",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 146,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 17111,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 60,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 427,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 21,
            "questionId": 14711,
            "questionIndex": 16128,
            "questionText": "<p>A 15-year-old boy is brought to the office by his mother due to &#x22;odd behavior.&#x22;&nbsp; The mother says, &#x22;Since moving to a new school 8 months ago, he has started talking to his imaginary friend Henry again.&nbsp; He hasn&#39;t done this since kindergarten&mdash;he used to cry a lot when I dropped him off, but Henry was a big comfort to him.&#x22;&nbsp; She adds that the patient can get easily overwhelmed by social situations and has always had a hard time making friends.&nbsp; The mother also notes that her son has been spending more time alone, and when passing by his bedroom she can sometimes hear him laughing and talking to Henry.&nbsp; His teachers have said that the patient has not been paying attention in class or completing homework.&nbsp; He no longer spends time with his siblings and says he &#x22;would rather play videogames with Henry.&#x22;&nbsp; The patient states, &#x22;Henry is always with me and likes to comment on what I am doing.&#x22;&nbsp; The patient reports no depressed mood; sleep and appetite are normal.&nbsp; He has tried marijuana in the past but does not drink alcohol or use other drugs.&nbsp; Medical history is not significant.&nbsp; Vital signs and physical examination are normal.&nbsp; On mental status examination, the patient avoids eye contact and has a flat affect.&nbsp; Which of the following is the most likely explanation for the patient&#39;s behavior?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t41553\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Schizophrenia</strong></p></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Diagnosis</strong></p></td><td style=\"width: 85%;\"><ul><li>&#8805;2 of the following (at least 1 symptom from 1-3)<ol><li>Delusions</li><li>Hallucinations</li><li>Disorganized speech</li><li>Disorganized or catatonic behavior</li><li>Negative symptoms (eg, apathy, flat affect)</li></ol></li><li>Continuous impairment &#8805;6 months</li><li>Significant functional decline</li></ul></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td style=\"width: 85%;\"><ul><li>Antipsychotic medication</li><li>Adjunctive psychosocial interventions (eg, social skills training, cognitive-behavioral therapy, family intervention)</li></ul></td></tr></tbody></table></div><p>This boy&#39;s 8-month history of auditory hallucinations and negative symptoms (social withdrawal, flat affect) resulting in significant functional decline from baseline is consistent with schizophrenia.&nbsp; Onset of psychotic symptoms prior to age 18 is referred to as <strong>early-onset schizophrenia</strong> and is associated with a <strong>more severe</strong> course of illness.&nbsp; Adolescents commonly have a <strong>prodromal</strong> phase marked by <strong>social withdrawal</strong> and academic decline, which can last for weeks to years prior to the onset of active psychotic symptoms.</p><p><strong>Hallucinations</strong> are more frequent than delusions in pediatric schizophrenia.&nbsp; Auditory hallucinations may consist of comments about what the patient is doing, as in this case, or commands.&nbsp; Visual and tactile hallucinations as well as multisensory hallucinations may also occur.&nbsp; Youth with schizophrenia frequently name their hallucinations, which need to be differentiated from imaginary friends.&nbsp; Imaginary friends typically decline in prevalence around age 6 and are not associated with functional decline, as in this patient&#39;s case.</p><p><strong>(Choice A)</strong>&nbsp; Although this patient has a history of feeling overwhelmed in social situations and difficulty making friends, he was interacting with his siblings and family prior to his decline, and he does not have a history of repetitive behaviors or the restricted interests that characterize autism spectrum disorder (ASD).&nbsp; ASD would not explain this patient&#39;s hallucinations or functional decline from baseline.</p><p><strong>(Choice B)</strong>&nbsp; Patients with dissociative identity disorder have &#8805;2 distinct personality states, which are associated with memory lapses and a disruption in self-continuity.</p><p><strong>(Choices C and E)</strong>&nbsp; Schizoid personality disorder is characterized by social detachment and decreased range of emotion and affect.&nbsp; In schizotypal personality disorder, patients have deficits in social interaction together with eccentric behaviors, odd beliefs, and idiosyncratic thought and speech patterns (eg, using metaphorical or over-elaborative language).&nbsp; Neither disorder would explain this patient&#39;s hallucinations.&nbsp; In addition, personality disorders are not typically diagnosed in youth, during which personalities are still developing.</p><p><strong>(Choice F)</strong>&nbsp; Heavy marijuana use has been associated with the onset of psychotic disorders.&nbsp; However, this patient reports only sporadic use in the past, with ongoing symptoms of schizophrenia for the last 8 months, making substance-induced psychosis unlikely.</p><p><strong>Educational objective:</strong><br>Early-onset schizophrenia (onset age &lt;18) is associated with a more severe and impairing course.&nbsp; Youth commonly have a prodromal phase marked by social withdrawal and academic decline prior to the onset of active psychotic symptoms.&nbsp; Hallucinations are common and need to be differentiated from imaginary friends.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Autism spectrum disorder",
                    "choiceNumber": 1,
                    "correctTaken": 2484,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Dissociative identity disorder",
                    "choiceNumber": 2,
                    "correctTaken": 438,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizoid personality disorder",
                    "choiceNumber": 3,
                    "correctTaken": 1938,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 4,
                    "correctTaken": 9696,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizotypal personality disorder",
                    "choiceNumber": 5,
                    "correctTaken": 2047,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Substance-induced psychotic disorder",
                    "choiceNumber": 6,
                    "correctTaken": 397,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1246,1366,true,-1,1*1367,1504,true,-1,1*1702,1920,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24012072",
                    "mediaDataId": 0,
                    "title": "Childhood&#160;onset&#160;schizophrenia&#160;and&#160;early&#160;onset&#160;schizophrenia&#160;spectrum disorders.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24012072",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28701088",
                    "mediaDataId": 0,
                    "title": "Early-onset&#160;schizophrenia: symptoms and social class of origin.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28701088",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 111,
            "othersAvgTimeSpent": 66,
            "notes": null,
            "peopleTaken": 17000,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 57,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 638,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 22,
            "questionId": 3638,
            "questionIndex": 3638,
            "questionText": "<p>A 22-year-old woman is brought to the emergency department by her husband for right-sided abdominal pain and vaginal bleeding.&nbsp; A urine pregnancy test is positive.&nbsp; Serial hCG levels and a transvaginal ultrasound confirm an ectopic pregnancy.&nbsp; The patient&#39;s vital signs are stable with a blood pressure of 106/68 mm Hg and pulse of 92/min.&nbsp; She is responsive, participates in her care, and reports that her pain is improving with oxycodone.&nbsp; When the patient is informed of the diagnosis, she begins to cry saying, &#x22;My husband and I have been trying to get pregnant for so long.&#x22;&nbsp; The physician discusses treatment options, including medical versus surgical management, with her.&nbsp; The patient tearfully reports that she would like to have the surgery done &#x22;to get it over with as quickly as possible.&#x22;&nbsp; Her medical history is unremarkable except for a psychiatric diagnosis of schizophrenia.&nbsp; On arrival a few hours ago, the patient said she had no psychiatric symptoms, including hallucinations.&nbsp; At that time, she also reported being adherent with her medications, aripiprazole and sertraline, which her husband confirms.&nbsp; Which of the following is the most appropriate course of action for obtaining informed consent for the patient&#39;s procedure?</p>",
            "questionHeader": "",
            "explanationText": "<p>Although this woman has a diagnosis of schizophrenia, it is well controlled and there is no indication that her decision-making ability is impaired due to psychosis or other factors.&nbsp; She is conscious, is able to participate in her own care, and can give consent for the procedure.</p><p><strong>Capacity</strong> is a patient&#39;s ability to <strong>understand the illness, treatment options</strong>, and consequences and to <strong>express a choice</strong> <a href=\"3445\">reflecting a preference</a>.&nbsp; It is used in medical situations to determine if someone has the ability to <strong>give informed consent</strong> to receive or refuse a specific intervention.&nbsp; Assessing capacity is especially important when someone&#39;s cognition may be impaired, such as in neurological conditions (eg, dementia) or severe psychiatric illness.&nbsp; However, the presence of a psychiatric diagnosis does not render a person incapable of making decisions.</p><p><strong>(Choice A)</strong>&nbsp; A patient&#39;s consent should be &#x22;presumed,&#x22; rather than obtained, in an emergency.&nbsp; This includes situations in which the patient is unconscious or incapacitated or when no surrogate decision maker is available.&nbsp; Had the patient been unconscious or unstable with rapid deterioration, the physician may have considered the situation to be an emergency and proceeded with presumed consent.</p><p><strong>(Choice B)</strong>&nbsp; If there is evidence that the patient lacks capacity to make treatment decisions (eg, delirious, psychotic symptoms interfering with rational thought process), then a surrogate decision maker, usually the spouse or next of kin (commonly a parent or adult child) can be approached for consent.</p><p><strong>(Choice D)</strong>&nbsp; It is also important to note the difference between competency and capacity.&nbsp; In contrast to medical capacity, which can be assessed by a physician, competency is a legal definition determined by the courts.</p><p><strong>(Choice E)</strong>&nbsp; Although pain medications can alter mental status, there is no evidence that this patient is overly sedated or incapable of making decisions.</p><p><strong>Educational objective:</strong><br>Patients with psychiatric diagnoses can give informed consent as long as they have capacity, meaning that their judgment and decision-making abilities are determined to be intact at the time of treatment.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 14800,
            "topic": "Informed consent",
            "titleId": 14800,
            "title": "Informed consent",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Consent is not necessary as this situation is emergent; the patient can be taken directly to the operating room.",
                    "choiceNumber": 1,
                    "correctTaken": 1062,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "The patient has a psychiatric condition that affects her decision-making capacity; her husband should be approached for consent.",
                    "choiceNumber": 2,
                    "correctTaken": 356,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "The patient should be approached to provide consent before proceeding with the surgery.",
                    "choiceNumber": 3,
                    "correctTaken": 26457,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "The patient should be assessed as incompetent, making her husband the medical guardian.",
                    "choiceNumber": 4,
                    "correctTaken": 97,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "The patient&#39;s husband should be approached for consent as opioid medication can alter her decision-making capacity.",
                    "choiceNumber": 5,
                    "correctTaken": 247,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1666,1796,true,-1,1*767,873,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26407382",
                    "mediaDataId": 0,
                    "title": "Systematic review on the prevalence of lack of capacity in medical and psychiatric settings.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26407382",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25782767",
                    "mediaDataId": 0,
                    "title": "Challenges of the capacity evaluation for the consultation-liaison psychiatrist.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25782767",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 87,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 28219,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 94,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 472,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 23,
            "questionId": 2508,
            "questionIndex": 2508,
            "questionText": "<p>A 15-year-old boy is brought to the office due to unusual behavior.&nbsp; The patient&#39;s mother reports that his behavior began to change 2 months ago, when he started withdrawing from his friends and losing interest in his classes and school activities.&nbsp; During this time, his grades declined, and he spent hours each day developing a code in which certain colors had specific, personal meanings.&nbsp; His mother says, &#x22;He insists on wearing the same blue shirt every day.&nbsp; He doesn&#39;t even wash it anymore.&#x22;&nbsp; The patient refuses to ride in the family&#39;s gray car because &#x22;only primary colors are good.&#x22;&nbsp; His mother has heard him talking to himself late at night and worries that he is not getting enough sleep.&nbsp; The patient does not use alcohol or illicit drugs.&nbsp; Medical and family history are unremarkable.&nbsp; Vital signs are within normal limits.&nbsp; The patient is tracking appropriately on growth curves.&nbsp; On physical examination, the patient is wearing a stained blue shirt and jeans.&nbsp; Cardiopulmonary examination is normal, and the abdomen is soft and nontender with no hepatosplenomegaly.&nbsp; Neurologic examination is unremarkable.&nbsp; The patient makes minimal eye contact and is slow to respond, but he becomes eager to describe his color system when asked about it.&nbsp; Which of the following is the most likely diagnosis for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38889\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Differential diagnosis of DSM-5 psychotic disorders</strong></p></td></tr><tr><td><p align=\"center\"><strong>Brief psychotic disorder</strong></p></td><td><p>&ge;1 days &amp; &lt;1 month, sudden onset, full return to function</p></td></tr><tr><td><p align=\"center\"><strong>Schizophreniform disorder</strong></p></td><td><p>&ge;1 months &amp; &lt;6 months, same symptoms as schizophrenia, functional decline not required</p></td></tr><tr><td><p align=\"center\"><strong>Schizophrenia</strong></p></td><td><p>&ge;6 months (includes &ge;1 months of active symptoms, can include prodromal &amp; residual periods), requires functional decline</p></td></tr><tr><td><p align=\"center\"><strong>Schizoaffective disorder</strong></p></td><td><p>Mood episode with concurrent active-phase symptoms of schizophrenia + &ge;2 weeks of delusions or hallucinations in the absence of prominent mood symptoms</p></td></tr><tr><td><p align=\"center\"><strong>Delusional disorder</strong></p></td><td><p>&ge;1 delusions &amp; &ge;1 months, no other psychotic symptoms, normal functioning apart from direct impact of delusions</p></td></tr></tbody></table></div><p>This patient&#39;s 2-month history of behavioral change, which is characterized by delusional thinking and behavior, possible hallucinations (ie, talking to himself), and negative symptoms (eg, social withdrawal, poor eye contact, neglect of personal hygiene), is consistent with <strong>schizophreniform disorder</strong>.&nbsp; Schizophreniform disorder is diagnosed when the symptoms of schizophrenia are present for <strong>&#8805;1 month but &lt;6 months</strong>.&nbsp; These symptoms include &#8805;2 of the following: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms.&nbsp; Impairment in functioning may be present but is not required for the diagnosis.</p><p>The diagnosis of schizophreniform disorder is made provisionally; if symptoms persist &#8805;6 months, the diagnosis is changed to schizophrenia.&nbsp; The psychotic features of schizophrenia typically emerge between the late teens and the mid-30s; childhood onset is rare and is associated with a poorer prognosis.</p><p><strong>(Choice A)</strong>&nbsp; Although this patient has fixated interests characteristic of an autism spectrum disorder, symptoms of autism are usually recognized by age 2 and include chronic deficits in social communication and repetitive behaviors.&nbsp; It would not explain this patient&#39;s recent social withdrawal and development of psychosis.</p><p><strong>(Choice B)</strong>&nbsp; Brief psychotic disorder is diagnosed when positive psychotic symptoms last &#8805;1 day and &lt;1 month.&nbsp; It is characterized by a sudden onset and a full return to premorbid level of functioning.</p><p><strong>(Choice C)</strong>&nbsp; Delusional disorder is characterized by &#8805;1 delusion in the absence of other psychotic symptoms.&nbsp; Functioning may be normal apart from the direct impact of the delusion.</p><p><strong>(Choice D)</strong>&nbsp; Although obsessive-compulsive disorder can present with obsessions related to color coding, these obsessions do not appear to be associated with a feared event or anxiety in this patient (who is eager to discuss his color system).&nbsp; In addition, his negative symptoms, possible hallucinations, and progressive functional impairment are more consistent with schizophreniform disorder.</p><p><strong>(Choice F)</strong>&nbsp; Schizotypal personality disorder is characterized by a pervasive pattern of social deficits, cognitive or perceptual distortions, and eccentric behavior with no clear delusions or hallucinations.&nbsp; In this patient, the abrupt onset and short-lived timeline of symptoms make a personality disorder unlikely and are more consistent with schizophreniform disorder.</p><p><strong>Educational objective:</strong><br>Schizophreniform disorder is differentiated from schizophrenia by the duration of symptoms.&nbsp; In schizophreniform disorder, symptoms must last for &#8805;1 month but &lt;6 months.&nbsp; The diagnosis of schizophrenia requires symptoms to persist for &#8805;6 months.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 9838,
            "topic": "Psychosis",
            "titleId": 9838,
            "title": "Psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Autism spectrum disorder",
                    "choiceNumber": 1,
                    "correctTaken": 2400,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Brief psychotic disorder",
                    "choiceNumber": 2,
                    "correctTaken": 372,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 3,
                    "correctTaken": 582,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obsessive-compulsive disorder",
                    "choiceNumber": 4,
                    "correctTaken": 1371,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophreniform disorder",
                    "choiceNumber": 5,
                    "correctTaken": 10027,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizotypal personality disorder",
                    "choiceNumber": 6,
                    "correctTaken": 2299,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "508,589,true,-1,1*665,721,true,-1,1*1301,1380,true,-1,1*1521,1685,true,-1,1*1698,2010,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27102425",
                    "mediaDataId": 0,
                    "title": "Adolescent vs. adult onset of a first episode psychosis:  impact on remission of positive and negative symptoms.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27102425",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23538289",
                    "mediaDataId": 0,
                    "title": "Schizophrenia and other psychotic disorders in DSM-5.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23538289",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 160,
            "othersAvgTimeSpent": 65,
            "notes": null,
            "peopleTaken": 17051,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 59,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 608,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 24,
            "questionId": 13605,
            "questionIndex": 14991,
            "questionText": "<p>A 76-year-old man is brought to the office by his daughter due to increasing confusion and falls.&nbsp; The patient was diagnosed with dementia with Lewy bodies 2 weeks ago and started on carbidopa-levodopa, risperidone, and rivastigmine for symptomatic management.&nbsp; Temperature is 37.2 C (99 F) and respirations are 14/min.&nbsp; Supine blood pressure and pulse are 129/82 mm Hg and 75/min, respectively; standing blood pressure and pulse are 101/74 mm Hg and 97/min, respectively.&nbsp; The patient is not oriented to place or time.&nbsp; Cranial nerves are intact and upper and lower limb deep tendon reflexes are 2+.&nbsp; Rigidity is present in both the upper and the lower extremities on passive movement and is notably worse compared with the previous examination.&nbsp; Which of the following is the most likely explanation for this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<p><strong>Dementia with Lewy bodies</strong> (DLB) presents with dementia plus &#8805;2 of the following features:&nbsp; Visual hallucinations, parkinsonism, fluctuating cognition, and REM sleep behavior disorder.&nbsp; Treatments for DLB include carbidopa-levodopa for parkinsonism, cholinesterase inhibitors (eg, rivastigmine) for cognitive impairment, and melatonin for REM sleep behavior disorder.&nbsp; A trial of an antipsychotic medication (eg, risperidone) may be indicated in patients with functionally impairing visual hallucinations or delusions, but it must be prescribed with caution due to the <strong>extreme antipsychotic hypersensitivity</strong> of patients with DLB.&nbsp; Antipsychotics may be associated with worsening <strong>confusion</strong>, <strong>parkinsonism</strong>, and <strong>autonomic dysfunction</strong> when used in such patients.</p><p>This patient&#39;s sudden increase in falls, confusion, orthostatic hypotension, and rigidity is most likely due to the recent prescription of <strong>risperidone</strong>, an antipsychotic known for stronger dopamine receptor antagonism relative to other second-generation antipsychotics.&nbsp; When antipsychotics are indicated in the treatment of DLB, evidence favors low-potency second-generation antipsychotics (eg, quetiapine).&nbsp; First-generation antipsychotics (eg, haloperidol) should be avoided entirely.</p><p><strong>(Choice A)</strong>&nbsp; Although carbidopa-levodopa may produce orthostatic hypotension and confusion, it would not explain this patient&#39;s increased rigidity.&nbsp; Carbidopa-levodopa and other anti-Parkinson drugs may worsen psychotic symptoms in DLB, but this risk can be minimized by cautious dose titration and as-needed use of low-potency antipsychotics.</p><p><strong>(Choice B)</strong>&nbsp; Postural tachycardia syndrome generally affects young women and typically causes excessive tachycardia without associated hypotension on standing.&nbsp; This patient&#39;s autonomic dysfunction and overall clinical picture are better explained by DLB.</p><p><strong>(Choice C)</strong>&nbsp; Although cognitive impairment, parkinsonism, and other symptoms may worsen over the course of DLB, the acute nature of this patient&#39;s symptom exacerbation in the context of a recent prescription of antipsychotic medication makes risperidone a better explanation for his presentation.</p><p><strong>(Choice E)</strong>&nbsp; Cholinesterase inhibitors (eg, rivastigmine) may be associated with diarrhea, vomiting, and bradycardia.&nbsp; This patient&#39;s presentation is better explained by the prescription of the antipsychotic risperidone.</p><p><strong>Educational objective:</strong><br>Patients with dementia with Lewy bodies (DLB) are extremely sensitive to antipsychotics, and use of this class of medication may be associated with worsening confusion, parkinsonism, and autonomic dysfunction.&nbsp; If DLB-associated psychotic symptoms are functionally impairing, a trial of a low-potency second-generation antipsychotic (eg, quetiapine) may be cautiously undertaken.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 17990,
            "topic": "Dementia with lewy bodies",
            "titleId": 17990,
            "title": "Dementia with lewy bodies",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "4",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Carbidopa-levodopa",
                    "choiceNumber": 1,
                    "correctTaken": 3000,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Postural tachycardia syndrome",
                    "choiceNumber": 2,
                    "correctTaken": 474,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Progression of disease",
                    "choiceNumber": 3,
                    "correctTaken": 1636,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Risperidone",
                    "choiceNumber": 4,
                    "correctTaken": 11561,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Rivastigmine",
                    "choiceNumber": 5,
                    "correctTaken": 2002,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "30,213,true,-1,1*278,348,true,-1,1*353,395,true,-1,1*598,786,true,-1,1*1056,1194,true,-1,1*1285,1420,true,-1,1*1628,1776,true,-1,1*2179,2285,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28592453",
                    "mediaDataId": 0,
                    "title": "Diagnosis and management of dementia with Lewy bodies:  fourth consensus report of the DLB Consortium.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28592453",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28990131",
                    "mediaDataId": 0,
                    "title": "Diagnosis and management of cognitive and behavioral changes in dementia with Lewy bodies.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28990131",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 75,
            "othersAvgTimeSpent": 61,
            "notes": null,
            "peopleTaken": 18673,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 62,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1161,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 25,
            "questionId": 4886,
            "questionIndex": 4886,
            "questionText": "<p>A 52-year-old woman with a history of schizoaffective disorder, depressive type, is brought to the office by her husband for follow-up.&nbsp; The patient was hospitalized last month due to worsening auditory hallucinations that were telling her to kill herself.&nbsp; She responded to an increased dose of risperidone and was discharged a week later.&nbsp; The patient reports feeling relieved that the voices telling her to kill herself have gone away since her antipsychotic dose was increased.&nbsp; Her husband also reports that she is much less agitated since the voices have subsided, but he is concerned that she smiles less and seems slowed down.&nbsp; He is worried that she is becoming depressed.&nbsp; On examination the patient is alert, calm, and cooperative.&nbsp; She has a mild tremor and does not swing her arms when she walks.&nbsp; Her affect appears sad.&nbsp; She denies any auditory hallucinations or thoughts of wanting to die.&nbsp; Which of the following is the most appropriate pharmacological management for this patient&#39;s condition?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t39773\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\" style=\"width: 60%;\"><p align=\"center\"><strong>Antipsychotic extrapyramidal effects</strong></p></td><td style=\"width: 40%;\"><p align=\"center\"><strong>Pharmacotherapy<sup>*</sup></strong></p></td></tr><tr><td style=\"width: 20%;\"><p align=\"center\"><strong>Acute<br>dystonia</strong></p></td><td style=\"width: 40%;\"><ul><li>Sudden, sustained contraction of the neck, mouth, tongue &amp; eye muscles</li></ul></td><td style=\"width: 40%;\"><ul><li>Benztropine</li><li>Diphenhydramine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Akathisia</strong></p></td><td style=\"width: 40%;\"><ul><li>Subjective restlessness, inability to sit still</li></ul></td><td style=\"width: 40%;\"><ul><li>Beta blocker (propranolol)</li><li>Benzodiazepine (lorazepam)</li><li>Benztropine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Parkinsonism</strong></p></td><td><ul><li>Gradual-onset tremor, rigidity &amp; bradykinesia</li></ul></td><td><ul><li>Benztropine</li><li>Amantadine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Tardive<br>dyskinesia</strong></p></td><td><ul><li>Gradual onset after prolonged therapy (&gt;6 months): dyskinesia of the mouth, face, trunk &amp; extremities</li></ul></td><td><ul><li>Valbenazine</li><li>Deutetrabenazine</li></ul></td></tr><tr><td colspan=\"3\"><p><sup>*</sup>Management may include reducing the dose or switching to another antipsychotic, depending on the clinical scenario.</p></td></tr></tbody></table></div><p>This patient&#39;s development of <strong>tremor</strong>, psychomotor retardation (<strong>bradykinesia</strong>), and decreased arm swing shortly after an increase in risperidone dose is suggestive of <strong>antipsychotic-induced parkinsonism</strong>.&nbsp; <strong>Cogwheel rigidity, shuffling gait</strong>, and <strong>masklike facies</strong> (which can be difficult to differentiate from depressed affect) are also characteristic.</p><p>Risperidone is a second-generation antipsychotic (SGA) with dopamine receptor antagonist activity.&nbsp; It is less likely to cause extrapyramidal symptoms (EPS) compared to a first-generation antipsychotic (FGA).&nbsp; However, among SGAs, risperidone is the most likely to cause EPS, especially at higher doses.&nbsp; Options to manage antipsychotic-induced parkinsonism include:</p><ul><li>Reducing the dose of the antipsychotic.</li><li>Switching to an antipsychotic with less potential to cause EPS if feasible.&nbsp;</li><li>Adding an anticholinergic antiparkinsonian medication&nbsp;when the antipsychotic is working well and there is concern for destabilizing the patient with a dosage reduction or switching to a new antipsychotic (as in this patient).&nbsp;</li></ul><p>The anticholinergic antiparkinsonian medication <strong>benztropine</strong> is commonly used.&nbsp; <strong>Amantadine</strong>, a dopaminergic medication (that usually does not worsen psychosis), can also be used.</p><p><strong>(Choice B)</strong>&nbsp; Propranolol, a beta blocker, has been used to treat akathisia, another type of EPS characterized by an inability to sit still.</p><p><strong>(Choice C)</strong>&nbsp; The patient has EPS, not current symptoms of a major depressive episode.&nbsp; By definition, patients with schizoaffective disorder may have periods with psychotic symptoms in the absence of mood episodes.&nbsp; Adding an antidepressant (eg, sertraline) may be needed during the course of the patient&#39;s illness, but this will not improve her current presenting symptoms and is not the most appropriate treatment at this time.</p><p><strong>(Choice D)</strong>&nbsp; Due to the risk of agranulocytosis, clozapine is generally reserved for psychotic patients who do not respond to &#8805;2 other antipsychotics.&nbsp; Switching to clozapine is not necessary because drug-induced parkinsonism is reversible and will likely improve with the addition of benztropine to risperidone.&nbsp; In cases of tardive dyskinesia, which is a potentially progressive, debilitating, and irreversible form of EPS classically characterized by orobuccolingual and facial dyskinesia (eg, tongue protrusion, lip smacking), switching to clozapine would be an option.</p><p><strong>(Choice E)</strong>&nbsp; Switching to haloperidol (a high-potency FGA) would be incorrect because it carries a higher risk of parkinsonian side effects compared to risperidone.</p><p><strong>Educational objective:</strong><br>Antipsychotics may cause drug-induced parkinsonism, a type of extrapyramidal symptom (EPS).&nbsp; Treatment options include antipsychotic dose reduction, treatment with benztropine or amantadine, or switching to another antipsychotic with a lower potential to cause EPS, if feasible.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "1",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Continue risperidone and add benztropine",
                    "choiceNumber": 1,
                    "correctTaken": 9824,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Continue risperidone and add propranolol",
                    "choiceNumber": 2,
                    "correctTaken": 750,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Continue risperidone and add sertraline",
                    "choiceNumber": 3,
                    "correctTaken": 3646,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone and start clozapine",
                    "choiceNumber": 4,
                    "correctTaken": 2436,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone and start haloperidol",
                    "choiceNumber": 5,
                    "correctTaken": 336,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "182,197,true,-1,1*423,472,true,-1,1*872,1016,true,-1,1*1226,1320,true,-1,1*1728,1904,true,-1,1*2786,3045,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28721057",
                    "mediaDataId": 0,
                    "title": "Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28721057",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27514296",
                    "mediaDataId": 0,
                    "title": "Drug-induced extrapyramidal syndromes: implications for contemporary practice.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27514296",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23887211",
                    "mediaDataId": 0,
                    "title": "Drug-induced Parkinson&#39;s disease.  a clinical review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23887211",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 76,
            "othersAvgTimeSpent": 62,
            "notes": null,
            "peopleTaken": 16992,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 558,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 26,
            "questionId": 3376,
            "questionIndex": 3376,
            "questionText": "<p>A 32-year-old man is brought to the emergency department by his mother.&nbsp; She says that he has stayed up late every night for the past week, praying and shouting that he is &#x22;the Messiah.&#x22;&nbsp; The patient speaks rapidly without interruption and believes that he has special powers to end all wars and save humankind.&nbsp; He shakes his head in response to voices, saying that there is a fight between good and evil and that he must &#x22;drown out the devil.&#x22;&nbsp; The patient has had a history of psychiatric illness since his early 20s, when he was discharged from the military due to severe depression and suicidal ideation.&nbsp; At that time, he heard voices blaming him for all the suffering in war.&nbsp; He has been hospitalized for several depressive episodes over the past 10 years.&nbsp; Between hospitalizations, he has had periods lasting for several months during which his mood is stable, but he has continued to hear the voices of God and the devil.&nbsp; The patient lives with his mother and is able to work stocking groceries, but he spends most of his time at home alone.&nbsp; He has been prescribed risperidone, but his mother is unsure if he takes it regularly.&nbsp; Which of the following is the most likely diagnosis?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t37651\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Schizoaffective disorder</strong></p></td></tr><tr><td><p align=\"center\"><strong>DSM-5 criteria</strong></p></td><td><ul><li>Major depressive or manic episode concurrent with symptoms of schizophrenia</li><li>Lifetime history of delusions or hallucinations for &ge;2 weeks in the absence of major depressive or manic episode</li><li>Mood episodes are prominent &amp; recur throughout illness</li><li>Not due to substances or another medical condition</li></ul></td></tr><tr><td><p align=\"center\"><strong>Differential diagnosis</strong></p></td><td><ul><li>Major depressive or bipolar disorder with psychotic features: &nbsp;Psychotic symptoms occur exclusively during mood episodes</li><li>Schizophrenia:<strong>&nbsp; </strong>Mood symptoms may be present for relatively brief periods</li></ul></td></tr></tbody></table></div><p>This patient&#39;s clinical presentation and history are consistent with a diagnosis of <strong>schizoaffective disorder</strong>, bipolar type.&nbsp; He currently exhibits symptoms of a <strong>manic episode</strong> (decreased need for sleep; grandiose delusions; loud, pressured speech).&nbsp; He also meets DSM-5 <strong>criterion A for schizophrenia</strong> (&#8805;2 of the following:&nbsp; delusions, hallucinations, disorganized speech, grossly disorganized behavior, negative symptoms).&nbsp; His history indicates periods of <strong>persistent hallucinations for &#8805;2 weeks in the absence of a major depressive or manic episode</strong> (ie, when his mood is stable).</p><p>Schizoaffective disorder can be differentiated from schizophrenia and bipolar disorder by assessing the relationship of mood and psychotic symptoms over the course of the illness.&nbsp; If mood symptoms occur in schizophrenia, they are typically present for a small portion of the illness.&nbsp; In contrast, this patient&#39;s mood symptoms appear to be present for a significant portion of his illness, making schizophrenia less likely <strong>(Choice F).</strong>&nbsp; In bipolar I disorder, psychotic symptoms occur exclusively during manic or depressive episodes.&nbsp; The persistence of hallucinations when this patient&#39;s mood is stable rules out a bipolar I diagnosis <strong>(Choice A)</strong>.</p><p><strong>(Choice B)</strong>&nbsp; Brief psychotic disorder is characterized by sudden onset of &#8805;1 psychotic symptom with full remission within a month.&nbsp; It would not explain this patient&#39;s longstanding illness with prominent mood episodes.</p><p><strong>(Choice C)</strong>&nbsp; In delusional disorder, other symptoms of psychosis (eg, hallucinations, disorganized speech or behavior) are not present.&nbsp; In addition, delusional disorder would not explain this patient&#39;s current manic symptoms and history of depressive episodes.</p><p><strong>(Choice D)</strong>&nbsp; This patient&#39;s current mood episode is consistent with a manic episode, thereby ruling out major depression with psychotic features.</p><p><strong>Educational objective</strong>:<br>The diagnosis of schizoaffective disorder requires assessing the longitudinal course of the illness and determining if the patient has had at least 2 weeks of psychotic symptoms in the absence of a mood episode.&nbsp; Schizoaffective disorder is distinguished from schizophrenia by the presence of mood symptoms for a significant portion of the illness.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15461,
            "topic": "Schizoaffective disorder",
            "titleId": 15461,
            "title": "Schizoaffective disorder",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "6",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Bipolar I disorder with psychotic features",
                    "choiceNumber": 1,
                    "correctTaken": 1231,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Brief psychotic disorder",
                    "choiceNumber": 2,
                    "correctTaken": 28,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder, grandiose type",
                    "choiceNumber": 3,
                    "correctTaken": 30,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Major depression with psychotic features",
                    "choiceNumber": 4,
                    "correctTaken": 183,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizoaffective disorder",
                    "choiceNumber": 5,
                    "correctTaken": 2812,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 6,
                    "correctTaken": 692,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2571,2805,true,-1,1*1162,1798,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23707642",
                    "mediaDataId": 0,
                    "title": "Schizoaffective disorder in the DSM-5.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23707642",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 150,
            "othersAvgTimeSpent": 80,
            "notes": null,
            "peopleTaken": 5057,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 56,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 573,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 27,
            "questionId": 14649,
            "questionIndex": 16064,
            "questionText": "<p>A 22-year-old man is brought to the emergency department by the police due to agitated behavior and hearing voices.&nbsp; The patient&#39;s mother called the police after he locked himself in his bedroom while shouting, &#x22;The voices won&#39;t leave me alone.&nbsp; They have taken over my brain.&#x22;&nbsp; The patient had a previous psychotic episode a year ago while attending college out-of-state and was treated in a psychiatric hospital.&nbsp; After being discharged, he moved in with his parents and younger sister but did not take any medications or attend follow-up appointments.&nbsp; His mother says the patient is unemployed, and she must frequently remind him to tend to personal hygiene.&nbsp; She has also noticed him laughing to himself on several occasions.&nbsp; A comprehensive medical evaluation is within normal limits.&nbsp; The patient is treated with quetiapine in the hospital and is discharged 5 days later.&nbsp; At his 1-week outpatient follow-up, the patient feels &#x22;okay&#x22; and notes that the voices are quieter since starting medication.&nbsp; His mother says, &#x22;He is much calmer, but I&#39;m worried because he just stays in his room and seems unmotivated to do anything.&#x22;&nbsp; In addition to continuing pharmacotherapy, which of the following would be most effective in reducing this patient&#39;s risk of relapse?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s &#8805;1 year history of illness, characterized by episodes of acute psychosis (auditory hallucinations; delusions; disorganized and agitated behavior) and negative symptoms (lack of motivation, poor personal hygiene), is consistent with <strong>schizophrenia</strong>, a psychotic disorder with onset typically in young adulthood.&nbsp; In addition to pharmacotherapy with antipsychotic medication, <strong>family therapy</strong> involving psychoeducation is an important treatment intervention that has demonstrated efficacy in reducing the risk of relapse.&nbsp; Family intervention is particularly helpful for patients who have had a recent psychotic relapse and who live with or have frequent contact with family members.</p><p>In family therapy, the patient and family are <strong>educated</strong> about the symptoms, course, and treatment of schizophrenia.&nbsp; Topics addressed include the importance of adhering to medication, developing realistic expectations for improvement, and recognizing early signs of relapse.&nbsp; Explaining that the patient&#39;s lack of motivation, social withdrawal, and difficulty maintaining personal hygiene are negative symptoms rather than willful laziness can promote family support and help minimize critical comments that result in a stressful environment, which increases the patient&#39;s <strong>risk of relapse</strong>.</p><p>Other psychosocial interventions that are beneficial include cognitive-behavioral therapy, social skills training, assertive community treatment, and supported employment.</p><p><strong>(Choice A)</strong>&nbsp; Dialectical behavior therapy is a type of psychotherapy that specifically targets severe emotional dysregulation.&nbsp; It is most commonly used in the treatment of borderline personality disorder.</p><p><strong>(Choice B)</strong>&nbsp; Exposure therapy is a type of behavioral psychotherapy whose goal is to decrease the patient&#39;s reactivity through repetitive exposures to a stimulus.&nbsp; It typically requires a highly motivated patient and is commonly used in the treatment of phobic and other anxiety disorders.</p><p><strong>(Choice D)</strong>&nbsp; Motivational enhancement therapy is a structured type of motivational interviewing that is primarily used in the treatment of substance use disorders to encourage patients to change maladaptive behaviors.</p><p><strong>(Choice E)</strong>&nbsp; Psychodynamic psychotherapy involves developing insight into unconscious conflicts originating in childhood experiences.&nbsp; It is not recommended in schizophrenia because individuals must be able to tolerate an initial increase in anxiety, which can be overly stressful and destabilizing for patients with psychotic illness.</p><p><strong>Educational objective:</strong><br>Family therapy is an effective adjunct to antipsychotic medication in patients with schizophrenia and has been shown to reduce the risk of relapse.&nbsp; It focuses on educating the family about the symptoms, course, and treatment of the disorder, and it helps to promote a supportive family environment.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Dialectical behavior therapy",
                    "choiceNumber": 1,
                    "correctTaken": 858,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Exposure therapy",
                    "choiceNumber": 2,
                    "correctTaken": 50,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Family therapy",
                    "choiceNumber": 3,
                    "correctTaken": 9240,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Motivational enhancement therapy",
                    "choiceNumber": 4,
                    "correctTaken": 3052,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Psychodynamic psychotherapy",
                    "choiceNumber": 5,
                    "correctTaken": 3937,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1928,1977,true,-1,1*723,1483,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27896805",
                    "mediaDataId": 0,
                    "title": "Key elements of a family intervention for schizophrenia: a qualitative analysis of an RCT.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27896805",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27411376",
                    "mediaDataId": 0,
                    "title": "Family interventions for schizophrenia and the psychoses: a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27411376",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 186,
            "othersAvgTimeSpent": 54,
            "notes": null,
            "peopleTaken": 17137,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 54,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 416,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 28,
            "questionId": 13645,
            "questionIndex": 15035,
            "questionText": "<p>A 56-year-old man is brought to the emergency department by police after being found walking down the middle of a busy highway saying he is &#x22;blessed with the power to save all souls.&#x22;&nbsp; The patient believes he is &#x22;the reincarnation of the Savior&#x22; and was sent to &#x22;spread peace on Earth.&#x22;&nbsp; He recently moved to the city and is renting a room at a boarding house where he says he has been &#x22;turning water into wine.&#x22;&nbsp; The patient has been unable to hold down a steady job for most of his adult life but works intermittently in construction.&nbsp; Blood pressure is 168/94 mm Hg and pulse is 90/min.&nbsp; The patient appears thin and has stained clothing and unwashed hair.&nbsp; He avoids direct eye contact, mostly looking at the ceiling and smiling intermittently for no apparent reason.&nbsp; His speech is difficult to follow, and he repeatedly says in a monotone voice, &#x22;I am blessed.&#x22;&nbsp; Neurological examination is otherwise unremarkable.&nbsp; Routine laboratory studies are within normal range, and blood alcohol level is undetectable.&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t41553\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Schizophrenia</strong></p></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Diagnosis</strong></p></td><td style=\"width: 85%;\"><ul><li>&ge;2 of the following (at least 1 symptom from 1-3)<ol><li>Delusions</li><li>Hallucinations</li><li>Disorganized speech</li><li>Disorganized or catatonic behavior</li><li>Negative symptoms (eg, apathy, flat affect)</li></ol></li><li>Continuous impairment &ge;6 months</li><li>Significant functional decline</li></ul></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td style=\"width: 85%;\"><ul><li>Antipsychotic medication</li><li>Adjunctive psychosocial interventions (eg, social skills training,<br />cognitive-behavioral therapy, family intervention)</li></ul></td></tr></tbody></table></div><p>This patient&#39;s multiple <strong>delusions</strong>, <strong>disorganized speech and behavior</strong>, and history suggestive of <strong>impaired functioning</strong> for &#8805;6 months (eg, his inability to hold down a steady job for most of his adult life)&nbsp;are most consistent with <strong>schizophrenia</strong>.&nbsp; His poor hygiene, negative symptoms (eg, flat affect, poor eye contact, monotonous voice), and probable response to internal stimuli (eg, smiling out of context) are further clues.&nbsp; Patients with schizophrenia can have grandiose delusions that they possess special powers or are related to or have become someone famous.&nbsp; Other common types of delusions include paranoid delusions and delusions of reference (eg, receiving special messages from electronic media).</p><p><strong>(Choice A)</strong>&nbsp; Alcoholic hallucinosis is an alcohol withdrawal syndrome characterized by hallucinations in patients with stable vital signs.&nbsp; Patients are generally aware of their hallucinations and maintain insight. This patient&#39;s prominent delusions as well as disorganized speech and behavior are more consistent with schizophrenia.</p><p><strong>(Choice B)</strong>&nbsp; Patients experiencing a manic episode in bipolar disorder can also have grandiose delusions.&nbsp; However, these patients typically have associated symptoms of elated mood, increased energy, hyperactivity, and decreased need for sleep, which are not present in this patient.&nbsp; Patients with mania have an intense, elated, or irritable affect consistent with their mood, whereas this patient has an inappropriate or flat affect.&nbsp; In addition, patients with mania typically have pressured speech that is difficult to interrupt; this patient&#39;s speech is disorganized.</p><p><strong>(Choice C)</strong>&nbsp; Patients with delusional disorder do not have the other psychotic symptoms characteristic of schizophrenia (eg, disorganization, negative symptoms).&nbsp; In contrast to this patient, they may function normally apart from the impact of the delusion.</p><p><strong>(Choices&nbsp;D and F)</strong>&nbsp; Although psychosis may be associated with these medical conditions, they are much less likely causes of this patient&#39;s clinical presentation.&nbsp; Lead toxicity typically presents with abdominal and joint/muscle pain, headache, cognitive impairment, and irritability&mdash;symptoms notably absent in this patient.&nbsp; Wernicke-Korsakoff syndrome develops in the context of thiamine (vitamin B<font size=\"2\"><sub>1</sub></font>) deficiency and presents with the triad of oculomotor impairment (eg, lateral rectus palsy), ataxia, and encephalopathy.</p><p><strong>Educational objective:</strong><br>Schizophrenia is characterized by delusions, hallucinations, disorganized speech and behavior, and negative symptoms of &#8805;6 months duration.&nbsp; The differential diagnosis includes mood disorders with psychotic features, other primary psychotic disorders, and substance and medical causes of psychosis.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 9838,
            "topic": "Psychosis",
            "titleId": 9838,
            "title": "Psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Alcoholic hallucinosis<span style=\"display: none;\">&nbsp;</span>",
                    "choiceNumber": 1,
                    "correctTaken": 488,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Bipolar disorder",
                    "choiceNumber": 2,
                    "correctTaken": 1294,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 3,
                    "correctTaken": 1560,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lead toxicity",
                    "choiceNumber": 4,
                    "correctTaken": 270,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 5,
                    "correctTaken": 13234,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Wernicke-Korsakoff syndrome",
                    "choiceNumber": 6,
                    "correctTaken": 246,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1163,1290,true,-1,1*1497,2056,true,-1,1*2637,2834,true,-1,1*2475,2595,true,-1,1*869,1151,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26777917",
                    "mediaDataId": 0,
                    "title": "Schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26777917",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23800613",
                    "mediaDataId": 0,
                    "title": "Definition and description of schizophrenia in the DSM-5.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23800613",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21482326",
                    "mediaDataId": 0,
                    "title": "Grandiose delusions: a review and theoretical integration of cognitive and affective perspectives.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21482326",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 117,
            "othersAvgTimeSpent": 65,
            "notes": null,
            "peopleTaken": 17092,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 77,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 791,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 29,
            "questionId": 2499,
            "questionIndex": 2499,
            "questionText": "<p>A 32-year-old man is brought to the office by his mother for a follow-up visit for depressive disorder.&nbsp; The mother is very concerned because the patient has become increasingly withdrawn and has behaved strangely for the past 2 weeks.&nbsp; She reports that he expresses fears that his body is decomposing and hears the voice of his long-deceased father telling him, &#x22;Come to me.&#x22;&nbsp; Current medications include venlafaxine and lorazepam as needed for anxiety.&nbsp; Vital signs are normal and physical examination is unremarkable.&nbsp; On mental status examination, the patient appears depressed and makes poor eye contact.&nbsp; At times, he does not answer and mumbles to himself.&nbsp; The decision is made to add quetiapine to treat psychosis.&nbsp; Which of the following is the primary mechanism of action of this medication?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient has developed psychotic symptoms (ie, delusions that his body is decomposing, auditory hallucinations) requiring the addition of an antipsychotic to his antidepressant, venlafaxine.&nbsp; Quetiapine is a commonly used <strong>second-generation antipsychotic</strong> (SGA) whose primary mechanism of action is mixed <strong>serotonin-dopamine antagonist</strong> activity with binding at both <strong>serotonin 2A</strong> and <strong>dopamine D2 receptors</strong>.&nbsp; The addition of serotonin antagonism, together with lower dopamine binding affinity when compared with first-generation antipsychotics, is believed to contribute to the decreased risk of extrapyramidal side effects seen with SGAs.</p><p>SGAs also have affinities for other receptors (eg, alpha adrenergic, muscarinic, histaminic) to varying degrees, resulting in different adverse effect profiles.&nbsp; Alpha-1 adrenergic blockade may cause orthostatic hypotension, and muscarinic receptor antagonism may result in anticholinergic adverse effects.&nbsp; Histaminic antagonism contributes to weight gain and sedation.</p><p><strong>(Choice A)</strong>&nbsp; Although antipsychotics block alpha-1 adrenergic receptors and may block other dopamine receptors, including dopamine D1 receptors, it is dopamine D2 blockade that is thought to be responsible for their antipsychotic effect.</p><p><strong>(Choice B)</strong>&nbsp; Dopamine reuptake inhibition and stimulation of dopamine release are the mechanisms of action of stimulants commonly used in the treatment of attention deficit hyperactivity disorder.</p><p><strong>(Choice C)</strong>&nbsp; Norepinephrine and dopamine reuptake inhibition is the mechanism of action of the antidepressant bupropion.</p><p><strong>(Choice D)</strong>&nbsp; Serotonin and norepinephrine reuptake inhibition is the primary mechanism of action of venlafaxine, as well as other serotonin and norepinephrine reuptake inhibitors and tricyclic antidepressants.</p><p><strong>Educational objective:</strong><br>Second-generation antipsychotics (SGAs) are serotonin 2A and dopamine D2 antagonists.&nbsp; The added serotonin receptor binding and lower dopamine binding affinity of SGAs reduce the likelihood of extrapyramidal adverse effects.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15858,
            "topic": "Antipsychotics",
            "titleId": 15858,
            "title": "Antipsychotics",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "5",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Alpha-1 adrenergic and dopamine D1 receptor blockade",
                    "choiceNumber": 1,
                    "correctTaken": 1994,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Dopamine reuptake inhibition and stimulation of dopamine release",
                    "choiceNumber": 2,
                    "correctTaken": 850,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Norepinephrine and dopamine reuptake inhibition",
                    "choiceNumber": 3,
                    "correctTaken": 563,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serotonin and norepinephrine reuptake inhibition",
                    "choiceNumber": 4,
                    "correctTaken": 265,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serotonin 2A and dopamine D2 receptor blockade",
                    "choiceNumber": 5,
                    "correctTaken": 13275,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "669,1038,true,-1,1*1692,1801,true,-1,1*1485,1592,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "24995318",
                    "mediaDataId": 0,
                    "title": "Second-generation antipsychotics and extrapyramidal adverse effects.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/24995318",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27291902",
                    "mediaDataId": 0,
                    "title": "Dopamine targeting drugs for the treatment of schizophrenia: past,&#160;present and future.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27291902",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 74,
            "othersAvgTimeSpent": 46,
            "notes": null,
            "peopleTaken": 16947,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 78,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 712,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 30,
            "questionId": 4195,
            "questionIndex": 4195,
            "questionText": "<p>A 27-year-old woman is brought to the emergency department by police after she was found trespassing on a local newscaster&#39;s property.&nbsp; The patient informed police that she has been dating the newscaster for a few months and was surprising him for his birthday.&nbsp; She reports their relationship started after she met him briefly when they were both eating at the same restaurant.&nbsp; The patient says, &#x22;We&#39;ve been so busy we haven&#39;t met up since then.&nbsp; But every night, he makes sure to send me a special message when he&#39;s presenting the evening news.&nbsp; I know he is in love with me because he always wears my favorite color.&nbsp; He&#39;s the most amazing man I&#39;ve ever known.&#x22;&nbsp; The patient is completing her final year of graduate school and lives alone.&nbsp; Medical and psychiatric history are noncontributory.&nbsp; Family history is significant for schizophrenia in her father.&nbsp; The patient&#39;s thoughts are linear, and she has no hallucinations.&nbsp; She is irritated that the police spoiled the surprise she had planned and repeatedly asks the staff to call her boyfriend so that he can &#x22;clear everything up.&#x22;&nbsp; Which of the following is the most likely diagnosis in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38406\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Delusional disorder</strong></p></td></tr><tr><td><p style=\"text-align: center;\"><strong>Clinical features</strong></p></td><td><ul><li>&ge;1 delusions for &ge;1 months</li><li>Other psychotic symptoms absent or not prominent</li><li>Behavior not obviously odd/bizarre; ability to function apart from delusion&#39;s impact</li><li>Subtypes: erotomanic, grandiose, jealous, persecutory &amp; somatic</li></ul></td></tr><tr><td><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td><ul><li>Antipsychotics</li><li>Cognitive-behavioral therapy</li></ul></td></tr></tbody></table></div><p>This patient&#39;s belief that a newscaster is in love with her, combined with the absence of other prominent psychotic symptoms or significant mood disturbance, is most consistent with <strong>delusional disorder</strong>, <strong>erotomanic subtype</strong>.&nbsp; Delusions are fixed beliefs that are firmly held despite conflicting evidence.&nbsp; Delusional disorder is subtyped based on the delusional theme (ie, erotomanic, grandiose, jealous, persecutory, somatic).&nbsp; In the erotomanic type, efforts to contact the object of the delusion are common and may result in legal difficulties.</p><p>In comparison with patients with schizophrenia, individuals with delusional disorder <strong>lack other prominent psychotic symptoms</strong>; they do not have prominent hallucinations or grossly disorganized behavior.&nbsp; They are typically <strong>higher functioning</strong>, and their behavior unrelated to their delusional concern is often normal.</p><p><strong>(Choice A)</strong>&nbsp; Although erotomanic delusions could be seen in a manic episode of bipolar I disorder with psychotic features, this patient lacks other symptoms (eg, increased energy, pressured speech, decreased need for sleep) required for this diagnosis.</p><p><strong>(Choices B, D, and F)</strong>&nbsp; Personality disorders are characterized by long-standing patterns of interpersonal issues but no persistent delusions or other psychotic symptoms.&nbsp; This patient lacks key features of borderline personality disorder (eg, abandonment fears, feelings of emptiness, identity disturbance, recurrent suicidal behavior).&nbsp; She does not have the pervasive emotionality or the need to be the center of attention seen in histrionic personality disorder.&nbsp; Individuals with schizotypal personality disorder exhibit eccentric behavior and odd beliefs or magical thinking (eg, superstitions, clairvoyance), but their beliefs are not held with delusional conviction as in delusional disorder.</p><p><strong>(Choice E)</strong>&nbsp; Schizophreniform disorder is diagnosed when the symptoms of schizophrenia are present for &#8805;1 month but &lt;6 months.&nbsp; These symptoms include &#8805;2 of the following: delusions, hallucinations, disorganized speech (eg, frequent derailment, incoherence), grossly disorganized or catatonic behavior, and negative symptoms (eg, flat affect, social withdrawal).&nbsp; The lack of other psychotic symptoms in this patient makes delusional disorder more likely.</p><p><strong>Educational objective:</strong><br>Delusional disorder is characterized by at least 1 persistent delusion and no other prominent psychotic symptoms.&nbsp; Apart from the impact of the delusion or delusions, functioning is not markedly impaired.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 17983,
            "topic": "Delusional disorder",
            "titleId": 17983,
            "title": "Delusional disorder",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Bipolar I disorder with psychotic features",
                    "choiceNumber": 1,
                    "correctTaken": 159,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Borderline personality disorder",
                    "choiceNumber": 2,
                    "correctTaken": 186,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 3,
                    "correctTaken": 15211,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Histrionic personality disorder",
                    "choiceNumber": 4,
                    "correctTaken": 394,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophreniform disorder",
                    "choiceNumber": 5,
                    "correctTaken": 777,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizotypal personality disorder",
                    "choiceNumber": 6,
                    "correctTaken": 208,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1096,1208,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27468631",
                    "mediaDataId": 0,
                    "title": "Delusional disorder and schizophrenia: a comparative study across multiple domains.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27468631",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28595494",
                    "mediaDataId": 0,
                    "title": "A psychopathological comparison between delusional disorder and schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28595494",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 75,
            "othersAvgTimeSpent": 49,
            "notes": null,
            "peopleTaken": 16935,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 90,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 950,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 31,
            "questionId": 10837,
            "questionIndex": 11967,
            "questionText": "<p>A 14-year-old girl is brought to the emergency department after throwing a notebook at her teacher, rambling about &#x22;bats on the ceiling,&#x22; and trying to run out of school.&nbsp; Medical history is significant for asthma, for which she uses albuterol as needed, and attention-deficit hyperactivity disorder, for which she takes extended-release mixed amphetamine salts on school days.&nbsp; There has been no recent change in the patient&#39;s medications.&nbsp; Family history is significant for Graves disease in her mother and schizophrenia in her maternal aunt.&nbsp; The patient says, &#x22;There are bats everywhere.&nbsp; They can hurt me now that all sorts are involved.&#x22;&nbsp; She is alert but appears fearful and distracted and makes poor eye contact.&nbsp; Her father says that this behavior is uncharacteristic but that she has been behaving &#x22;oddly&#x22; for a few days, sleeping poorly, appearing anxious, and staring at her bedroom walls.&nbsp; Several weeks ago, the patient started missing multiple days of school and did not want to go out with friends, saying that her joints hurt too much.&nbsp; She has also recently experienced headaches and poor concentration.&nbsp; Temperature is 37.2 C (99 F), blood pressure is 110/70 mm Hg, pulse is 98/min, and respirations are 18/min.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Complete blood count</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td style=\"vertical-align:middle;\">13 g/dL</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Mean corpuscular volume</td><td style=\"vertical-align:middle;\">90 &micro;m<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td style=\"vertical-align:middle;\">85,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td style=\"vertical-align:middle;\">8,200/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Serum chemistry</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td style=\"vertical-align:middle;\">138 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td style=\"vertical-align:middle;\">3.6 mEq/L</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td style=\"vertical-align:middle;\">0.8 mg/dL</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\">Urinalysis</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Protein</td><td style=\"vertical-align:middle;\">+2</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Red blood cells</td><td style=\"vertical-align:middle;\">5-10/hpf</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Ketones</td><td style=\"vertical-align:middle;\">negative</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Leukocyte esterase</td><td style=\"vertical-align:middle;\">negative</td></tr><tr><td style=\"vertical-align:middle;\">&nbsp;&nbsp;&nbsp;&nbsp;Nitrites</td><td style=\"vertical-align:middle;\">negative</td></tr><tr><td colspan=\"2\" style=\"vertical-align:middle;\"></td></tr><tr><td style=\"vertical-align:middle;\">TSH</td><td style=\"vertical-align:middle;\">3.4 &micro;U/mL</td></tr></tbody></table><p>Urine and blood toxicology are negative.&nbsp; Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>The <strong>acute onset</strong> of <strong>psychosis</strong> in a child or adolescent is rare, and it is essential to <strong>rule out medical</strong> or <strong>substance-induced</strong> <a href=\"4252\">conditions</a> that are potentially reversible.&nbsp; This patient&#39;s history of arthralgia and psychosis, together with thrombocytopenia, hematuria, and proteinuria, is concerning for <a href=\"1256\">systemic lupus erythematosus (SLE)</a>.&nbsp; The classic malar rash seen in SLE is often absent and should not be relied on for diagnosis.&nbsp; Inflammatory disorders such as SLE can affect the CNS and manifest with both acute and chronic psychiatric symptoms, including psychosis, depression, mania, and anxiety.</p><p>Other neuropsychiatric manifestations seen in SLE include seizures, headaches, peripheral neuropathy, strokes, and chorea.&nbsp; Biological mechanisms of these manifestations are thought to include immune-mediated inflammation and vasculitis.</p><p>The most appropriate next step is to check for <strong>antinuclear antibodies</strong> to aid with the diagnosis of SLE.&nbsp; If these are positive, further testing for more specific antibodies (eg, anti&ndash;double-stranded DNA, anti-Smith, anti&ndash;U1 ribonucleoprotein) should be undertaken.</p><p><strong>(Choice A)</strong>&nbsp; A diagnosis of primary psychiatric illness requires ruling out medical conditions first.&nbsp; This patient&#39;s physical symptoms and abnormal laboratory results suggest a medical cause of her psychosis.</p><p><strong>(Choice B)</strong>&nbsp; Many medications and illicit drugs (eg, amphetamines, corticosteroids, cocaine, hallucinogens, marijuana, bath salts) can cause psychosis via their CNS effects.&nbsp; However, amphetamines rarely cause psychosis when used in therapeutic dosages, and this patient has a normal creatinine level and no recent dosage changes.&nbsp; In addition, her drug screen is negative, indicating that she has not recently taken her amphetamines.&nbsp; Because amphetamine-induced psychotic disorder would not explain this patient&#39;s arthralgias, thrombocytopenia, proteinuria, and hematuria, checking antinuclear antibodies is the most appropriate next step.</p><p><strong>(Choice D)</strong>&nbsp; Thyroiditis can result in anxiety, insomnia, and acute psychosis; however, the patient&#39;s TSH level is normal, making this diagnosis unlikely.</p><p><strong>(Choice E)</strong>&nbsp; A urethral swab could be used to detect gonococcal infection, which commonly presents as a migratory polyarthralgia in young people.&nbsp; Other manifestations include tenosynovitis, genitourinary symptoms, and skin lesions.&nbsp; However, gonococcal infection does not cause acute psychosis.</p><p><strong>Educational objective:</strong><br>The sudden onset of psychosis in a child or adolescent is rare, and it is important to search for potentially reversible conditions such as medical disorders or substance use.&nbsp; Common medical conditions to rule out include systemic lupus erythematosus, thyroiditis, metabolic or electrolyte disorders, CNS infection, and epilepsy.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 24204,
            "topic": "Psychotic disorder due to another medical condition",
            "titleId": 24204,
            "title": "Psychotic disorder due to another medical condition",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Begin low-dose antipsychotic for brief psychotic disorder",
                    "choiceNumber": 1,
                    "correctTaken": 1924,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue amphetamines",
                    "choiceNumber": 2,
                    "correctTaken": 5572,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain antinuclear antibodies",
                    "choiceNumber": 3,
                    "correctTaken": 7615,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain free T4 and T3",
                    "choiceNumber": 4,
                    "correctTaken": 612,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Perform urethral swab culture",
                    "choiceNumber": 5,
                    "correctTaken": 698,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "460,868,true,-1,1*1355,1516,true,-1,1*2150,2432,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29423350",
                    "mediaDataId": 0,
                    "title": "Primary psychiatric disorder masking the diagnosis of neuropsychiatric lupus in a patient with altered mental status: a case report.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29423350",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26664084",
                    "mediaDataId": 0,
                    "title": "New onset psychosis as the first manifestation of neuro-psychiatric lupus. A situation causing diagnostic dilemma.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26664084",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "21051683",
                    "mediaDataId": 0,
                    "title": "Evaluation and treatment of acute psychosis in children with systemic lupus erythematosus (SLE): consultation-liaison service experiences at a tertiary-care pediatric institution.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/21051683",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 122,
            "othersAvgTimeSpent": 95,
            "notes": null,
            "peopleTaken": 16421,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 46,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 1004,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 32,
            "questionId": 18984,
            "questionIndex": 20465,
            "questionText": "<p>An 80-year-old woman is brought to the office by her husband due to behavioral disturbances.&nbsp; The patient has a history of Alzheimer disease.&nbsp; For the past month, she has been wandering the house at night, looking for a pet cat that died 10 years ago.&nbsp; The patient has also been excessively agitated and hits her husband when he tries to assist her.&nbsp; She has had no other symptoms.&nbsp; Environmental and behavioral interventions have been unsuccessful.&nbsp; Medical history also includes hypertension.&nbsp; Medications include amlodipine and donepezil.&nbsp; There have been no recent changes in medications.&nbsp; Vital signs are within normal limits, and physical examination shows no new abnormalities.&nbsp; Blood cell counts, serum electrolytes, and urinalysis are normal.&nbsp; Caregiver education is provided, and nightly risperidone is started after discussing medication options.&nbsp; A week later, the husband reports that the patient is less aggressive, but her restlessness and wandering have worsened.&nbsp; Now, she cannot sit still, even for a few minutes.&nbsp; Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s worsening restlessness, wandering, and inability to sit still that developed a week after starting the antipsychotic medication risperidone is suggestive of <strong>akathisia</strong>, a common <strong>extrapyramidal symptom</strong>.&nbsp; Patients with akathisia experience a sense of inner <strong>restlessness</strong> and an urge to move, which often present as an <strong>inability to sit still </strong>and frequent pacing.&nbsp; This, in turn, may contribute to agitation, especially in patients with dementia, who have limited verbal communication ability.&nbsp; Akathisia is more common with <strong>high-potency antipsychotics</strong> (eg, risperidone, haloperidol), but it can also occur with some lower-potency antipsychotics.</p><p>The first step in management of akathisia would be a <strong>dose-reduction</strong> trial or, if clinical benefit is not significant, <strong>discontinuation of the antipsychotic</strong> entirely.&nbsp; The beta blocker propranolol or a benzodiazepine may be used for symptomatic management of akathisia if antipsychotic discontinuation is not an option.&nbsp; If this patient&#39;s aggressive behavior reoccurs following discontinuation of risperidone, a trial of a different antipsychotic medication (eg, quetiapine) with less potential to cause extrapyramidal symptoms could be considered.</p><p><strong>(Choice A)</strong>&nbsp; Memantine, an NMDA receptor antagonist, is used to treat moderate to severe dementia, but there is no evidence to support use for the treatment of akathisia.</p><p><strong>(Choice B)</strong>&nbsp; It is premature to advise nursing home placement without first addressing a potentially treatable cause of worsening behavioral symptoms and considering alternate medications, particularly given the timeline of symptoms worsening following risperidone initiation.</p><p><strong>(Choice D)</strong>&nbsp; Akathisia is a dose-dependent extrapyramidal symptom.&nbsp; Increasing the dose of risperidone would likely worsen akathisia.</p><p><strong>(Choice E)</strong>&nbsp; Benzodiazepines (eg, lorazepam) generally do not have a role in the treatment of dementia-related neuropsychiatric symptoms due to their significant potential for adverse effects (eg, worsening gait/falls, physical dependence, paradoxical disinhibited agitation).&nbsp; Although benzodiazepines are sometimes used to symptomatically treat symptoms of akathisia, this approach is reserved for cases in which dose reduction or discontinuation has failed.</p><p><strong>Educational objective:</strong><br>Antipsychotics used to treat behavioral disturbances in dementia may cause akathisia, a type of extrapyramidal symptom characterized by an inability to sit still.&nbsp; Initial management consists of a dose-reduction trial or discontinuation of the antipsychotic medication, if feasible.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 15053,
            "topic": "Akathisia",
            "titleId": 15053,
            "title": "Akathisia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Add memantine therapy",
                    "choiceNumber": 1,
                    "correctTaken": 816,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Advise nursing home placement",
                    "choiceNumber": 2,
                    "correctTaken": 169,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone",
                    "choiceNumber": 3,
                    "correctTaken": 3310,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increase the dose of risperidone",
                    "choiceNumber": 4,
                    "correctTaken": 214,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Switch risperidone to lorazepam",
                    "choiceNumber": 5,
                    "correctTaken": 553,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "532,622,true,-1,1*686,1232,true,-1,1*1244,1283,true,-1,1*2088,2271,true,-1,1*2051,2085,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26683525",
                    "mediaDataId": 0,
                    "title": "The clinical challenges of akathisia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26683525",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 118,
            "othersAvgTimeSpent": 83,
            "notes": null,
            "peopleTaken": 5062,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 65,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 437,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 33,
            "questionId": 10770,
            "questionIndex": 11898,
            "questionText": "<p>A 52-year-old man with schizophrenia is brought to the emergency department by his group home staff due to agitation.&nbsp; Staff report that for the past 2 weeks, the patient has been leaving the group home in the mornings and walking all day in the neighborhood.&nbsp; Today, he became very angry and started shouting when asked to remain in the home.&nbsp; A month ago, his antipsychotic was switched from quetiapine to risperidone for increasing auditory hallucinations.&nbsp; Although the intensity of his voices significantly improved after 2 weeks, the patient has since become increasingly agitated, and dosage escalations to target his agitation do not appear to be calming him.&nbsp; On mental status examination, he is cooperative but seems on edge, getting up to pace.&nbsp; No localized abnormal movements are seen.&nbsp; The patient makes limited eye contact and fidgets with his clothes.&nbsp; He is oriented to time, place, person, and circumstance.&nbsp; He does not have auditory hallucinations.&nbsp; Which of the following is the most appropriate next step in pharmacotherapy for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_T39773\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\" style=\"width: 60%;\"><p align=\"center\"><strong>Antipsychotic extrapyramidal effects</strong></p></td><td style=\"width: 40%;\"><p align=\"center\"><strong>Pharmacotherapy<sup>*</sup></strong></p></td></tr><tr><td style=\"width: 20%;\"><p align=\"center\"><strong>Acute<br>dystonia</strong></p></td><td style=\"width: 40%;\"><ul><li>Sudden, sustained contraction of the neck, mouth, tongue &amp; eye muscles</li></ul></td><td style=\"width: 40%;\"><ul><li>Benztropine</li><li>Diphenhydramine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Akathisia</strong></p></td><td style=\"width: 40%;\"><ul><li>Subjective restlessness, inability to sit still</li></ul></td><td style=\"width: 40%;\"><ul><li>Beta blocker (propranolol)</li><li>Benzodiazepine (lorazepam)</li><li>Benztropine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Parkinsonism</strong></p></td><td><ul><li>Gradual-onset tremor, rigidity &amp; bradykinesia</li></ul></td><td><ul><li>Benztropine</li><li>Amantadine</li></ul></td></tr><tr><td><p align=\"center\"><strong>Tardive<br>dyskinesia</strong></p></td><td><ul><li>Gradual onset after prolonged therapy (&gt;6 months): dyskinesia of the mouth, face, trunk &amp; extremities</li></ul></td><td><ul><li>Valbenazine</li><li>Deutetrabenazine</li></ul></td></tr><tr><td colspan=\"3\"><p><sup>*</sup>Management may include reducing the dose or switching to another antipsychotic, depending on the clinical scenario.</p></td></tr></tbody></table></div><p>This patient&#39;s increasing agitation despite improvement in his psychotic symptoms is consistent with <strong>akathisia</strong>, the most common extrapyramidal symptom association with antipsychotic medication.</p><p>Patients with akathisia describe a <strong>subjective</strong> sense of inner <strong>restlessness</strong> that may manifest as pacing or an <strong>inability to sit still</strong> (eg, walking all day in the neighborhood).&nbsp; In severe cases, patients may become extremely distressed, resulting in increased agitation and overall global worsening.&nbsp; Clinicians must differentiate akathisia from worsening psychotic agitation because akathisia is <strong>dose dependent</strong>.&nbsp; An increase in antipsychotic dosage would make akathisia worse, as seen in this patient in whom efforts to target restlessness and agitation by increasing the antipsychotic dose were ineffective <strong>(Choices D and E)</strong>.</p><p>Akathisia is more common with high-potency, first-generation antipsychotics but can also occur with some second-generation antipsychotics, such as risperidone, as in this patient.&nbsp; The first steps in management of akathisia include the following:</p><ul><li><p>Cautiously <strong>reducing the antipsychotic dosage</strong></p></li><li><p><strong>Changing</strong> to an antipsychotic with less potential to cause extrapyramidal symptoms</p></li><li><p>Adding a <strong>beta blocker</strong> (eg, propranolol), an&nbsp;<strong>anticholinergic</strong> (eg, benztropine), or, less commonly, a benzodiazepine (eg, lorazepam)</p></li></ul><p>Propranolol is a common initial choice; it may work by blocking noradrenergic and serotonergic inputs on dopamine pathways.</p><p><strong>(Choice B)</strong>&nbsp; Switching to the first-generation antipsychotic haloperidol would not be indicated because it has a higher risk of causing extrapyramidal symptoms, including akathisia.</p><p><strong>(Choice C)</strong>&nbsp; The patient&#39;s auditory hallucinations have responded well to risperidone.&nbsp; Discontinuing the antipsychotic puts the patient at risk of decompensation.&nbsp; In addition, the use of benzodiazepines, such as lorazepam, in patients with schizophrenia is associated with increased mortality and is not a preferred option for long-term treatment for akathisia unless other measures such as dosage reduction, antipsychotic change, or propranolol have failed.</p><p><strong>Educational objective:</strong><br>Akathisia should be considered if a patient becomes agitated or restless when an antipsychotic is changed or the dosage is increased.&nbsp; Treatment options include reducing the dose, changing to an antipsychotic with less potential to cause extrapyramidal symptoms, and/or starting treatment with propranolol, benztropine, or a benzodiazepine.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "1",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Decrease the antipsychotic dosage and administer propranolol",
                    "choiceNumber": 1,
                    "correctTaken": 6765,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue the antipsychotic and administer haloperidol",
                    "choiceNumber": 2,
                    "correctTaken": 2911,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue the antipsychotic and administer lorazepam",
                    "choiceNumber": 3,
                    "correctTaken": 2865,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increase the antipsychotic dosage and administer benztropine",
                    "choiceNumber": 4,
                    "correctTaken": 1746,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increase the antipsychotic dosage and administer lorazepam",
                    "choiceNumber": 5,
                    "correctTaken": 2703,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2526,2761,true,-1,1*1998,2121,true,-1,1*772,864,true,-1,1*997,1036,true,-1,1*1246,1471,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26683525",
                    "mediaDataId": 0,
                    "title": "The clinical challenges of akathisia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26683525",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 87,
            "othersAvgTimeSpent": 79,
            "notes": null,
            "peopleTaken": 16990,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 40,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 623,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 34,
            "questionId": 4067,
            "questionIndex": 4067,
            "questionText": "<p>A 23-year-old man with schizophrenia is hospitalized in a psychiatric facility after barricading himself in his apartment for &#x22;self-defense.&#x22;&nbsp; The patient hears voices warning about &#x22;secret government agents&#x22; who are hunting him.&nbsp; He is certain that a neighbor has been spying on him and listening through the wall on behalf of the government.&nbsp; The patient&#39;s sister reports that he had his first psychotic episode at age 19 and responded well to olanzapine.&nbsp; At age 21, he stopped taking olanzapine due to weight gain and was hospitalized with a psychotic relapse; he was prescribed risperidone while hospitalized.&nbsp; The patient has been hospitalized 3 more times in the past 2 years.&nbsp; Although he improves rapidly when hospitalized and taking risperidone and is then able to live independently, he typically relapses several months after discharge.&nbsp; On mental status examination, the patient makes poor eye contact and has a flat affect.&nbsp; He says, &#x22;I don&#39;t have a mental illness.&nbsp; Can&#39;t you see the conspiracy is real?&#x22;&nbsp; Which of the following is the most appropriate management for this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s psychotic symptoms rapidly improve with risperidone treatment in the hospital.&nbsp; However, he does not believe he has an illness, and his history of relapsing several months following discharge is suggestive of <strong>medication nonadherence</strong>.&nbsp; Switching to a <strong>long-acting injectable</strong> (LAI) (depot) <strong>antipsychotic</strong> is an effective strategy for breaking the cycle of repetitive hospitalization.</p><p>LAI antipsychotics are administered intramuscularly every few weeks to months, eliminating the need for daily oral medication.&nbsp; Both first-generation (haloperidol, fluphenazine) and second-generation (risperidone, paliperidone, olanzapine, aripiprazole) antipsychotics are available in LAI formulations.&nbsp; Patients with unstable illness who live alone and have poor social support systems, poor insight, and frequent medication nonadherence are good candidates for LAI antipsychotics.&nbsp; These medications can be administered on an outpatient basis with the support of assertive community treatment programs (eg, a clinician can administer the drug in the patient&#39;s home or facilitate adherence to scheduled medication appointments).</p><p><strong>(Choices A, C, and E)</strong>&nbsp; This patient has a history of responding well to risperidone but relapses due to nonadherence.&nbsp; Augmenting risperidone with an antidepressant (eg, sertraline), switching to an alternate antipsychotic such as aripiprazole, or increasing the dosage is not indicated and would be unlikely to improve adherence.</p><p><strong>(Choice B)</strong>&nbsp; Social skills training and family therapy are established psychosocial interventions for schizophrenia.&nbsp; However, introducing such measures is not feasible until the patient&#39;s psychotic symptoms are stabilized and the cycle of frequent relapses and hospitalizations is interrupted.</p><p><strong>(Choice D)</strong>&nbsp; Clozapine is a second-generation antipsychotic with demonstrated superior efficacy in treatment-resistant schizophrenia.&nbsp; It requires routine monitoring of complete blood count due to the risk of agranulocytosis.&nbsp; This patient has a history of responding to first-line antipsychotic medications; therefore, he is not a candidate for clozapine.</p><p><strong>Educational objective:</strong><br>Antipsychotic medication nonadherence is a common cause of relapse and rehospitalization in patients with schizophrenia.&nbsp; Long-acting injectable antipsychotics are useful for patients who have responded to oral antipsychotics but relapse frequently due to medication nonadherence.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "6",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Augment risperidone with sertraline",
                    "choiceNumber": 1,
                    "correctTaken": 89,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Augment risperidone with social skills training and family therapy",
                    "choiceNumber": 2,
                    "correctTaken": 1776,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone and prescribe aripiprazole",
                    "choiceNumber": 3,
                    "correctTaken": 297,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone and prescribe clozapine",
                    "choiceNumber": 4,
                    "correctTaken": 1692,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Increase the dosage of risperidone",
                    "choiceNumber": 5,
                    "correctTaken": 310,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prescribe long-acting injectable risperidone",
                    "choiceNumber": 6,
                    "correctTaken": 12845,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "425,1155,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28580230",
                    "mediaDataId": 0,
                    "title": "The use of long-acting injectable antipsychotics in schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28580230",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28895758",
                    "mediaDataId": 0,
                    "title": "Medication adherence and discontinuation of&#160;long-acting&#160;injectable&#160;versus oral&#160;antipsychotics&#160;in patients with schizophrenia or bipolar disorder.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28895758",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 88,
            "othersAvgTimeSpent": 53,
            "notes": null,
            "peopleTaken": 17014,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 75,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 338,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 35,
            "questionId": 10743,
            "questionIndex": 11876,
            "questionText": "<p>A 38-year-old woman is brought to the emergency department by her husband due to depression and difficulty caring for their 3-week-old son.&nbsp; The husband came home from work and found the patient staring at the television and mumbling to herself while the baby cried in his crib in a soiled diaper.&nbsp; He says that she has already lost all her pregnancy weight and frequently cries for no apparent reason.&nbsp; The patient is exhausted because the baby keeps her up all night.&nbsp; She admits to hearing voices sometimes but insists on going home and says, &#x22;Everything will be okay if I just get some sleep.&#x22;&nbsp; The patient has a history of bipolar disorder; she did not take medication during the pregnancy due to concerns about effects on the fetus.&nbsp; On mental status examination, the patient is alert and speaks slowly and softly.&nbsp; Her mood is depressed and her affect is blunted.&nbsp; At one point, she stares into space and mumbles something before turning to the doctor and saying, &#x22;I am a terrible mother; I should not have brought a baby into this world.&#x22;&nbsp; The patient does not have suicidal ideation or intent.&nbsp; Which of the following is the most appropriate course of action?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t34609\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"4\"><p align=\"center\"><strong>Postpartum blues, depression &amp; psychosis</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>Postpartum<br />blues</strong></p></td><td><p align=\"center\"><strong>Postpartum depression</strong></p></td><td><p align=\"center\"><strong>Postpartum psychosis</strong></p></td></tr><tr><td><p align=\"center\"><strong>Prevalence</strong></p></td><td><p align=\"center\">40%-80%</p></td><td><p align=\"center\">8%-15%</p></td><td><p align=\"center\">0.1%-0.2%</p></td></tr><tr><td><p align=\"center\"><strong>Onset</strong></p></td><td><p align=\"center\">2-3 days (resolves within 14 days)</p></td><td><p align=\"center\">Typically within 4-6 weeks (can be up to 1 year)</p></td><td><p align=\"center\">Variable: days to&nbsp;weeks</p></td></tr><tr><td><p align=\"center\"><strong>Symptoms</strong></p></td><td><p align=\"center\">Mild depression, tearfulness, irritability</p></td><td><p align=\"center\">&ge;2 weeks of moderate to severe depression, sleep or appetite disturbance, low energy, psychomotor changes, guilt, concentration difficulty,<br />suicidal ideation</p></td><td><p align=\"center\">Delusions, hallucinations, thought disorganization,<br />bizarre behavior</p></td></tr><tr><td><p align=\"center\"><strong>Management</strong></p></td><td><p align=\"center\">Reassurance &amp; monitoring</p></td><td><p align=\"center\">Antidepressants, psychotherapy</p></td><td><p align=\"center\">Antipsychotics, antidepressants, mood stabilizers; hospitalization (do not leave mother alone with infant due to risk of infanticide)</p></td></tr></tbody></table></div><p>In addition to depressive symptoms, this patient has auditory hallucinations and bizarre behavior (staring into space and mumbling), raising concern for <strong>postpartum psychosis</strong>.&nbsp; This disorder most commonly occurs within the first weeks after birth and can present with delusions (eg, believing that the baby is evil or does not belong to the mother), hallucinations (eg, command hallucinations to kill the baby or kill herself), thought disorganization, and/or bizarre behavior.&nbsp; Postpartum psychosis is often seen in conjunction with other psychiatric disorders, most commonly bipolar disorder (as in this patient).</p><p>Although it is rare in comparison with postpartum blues and postpartum depression, postpartum psychosis is a <strong>medical emergency</strong>, with an increased <strong>risk</strong> of both <strong>suicide</strong> and <strong>infanticide</strong>.&nbsp; Most patients should be <strong>hospitalized</strong> to ensure safety, as with this patient who is actively hallucinating and expressing remorse for bringing a baby into the world, which places her at high risk of harming herself or the baby.&nbsp; If necessary, involuntary hospitalization should be pursued.&nbsp; <strong>Antipsychotic medication</strong> should be started, with <strong>treatment</strong> of the underlying <strong>mood disorder</strong> (eg, addition of mood stabilizers or antidepressants) if necessary.</p><p><strong>(Choices A, C, D, and E)</strong>&nbsp; Outpatient treatment would be unsafe at this point due to the risks of infanticide and suicide.&nbsp; Treatment with mood stabilizers, antidepressants, and/or antipsychotics would be appropriate on an inpatient basis.&nbsp; Outpatient treatment with an antidepressant and/or psychotherapy would be appropriate for a patient with postpartum depression without psychotic features.</p><p><strong>(Choice F)</strong>&nbsp; Reassurance that symptoms are self-limited would be appropriate only if the patient had postpartum blues, a common mood disturbance characterized by mild depression and mood lability, not psychosis.</p><p><strong>Educational objective:</strong><br>Postpartum psychosis is a medical emergency characterized by delusions, hallucinations, and disorganized thoughts or behavior often accompanied by mood symptoms.&nbsp; Due to the high risk for suicide/infanticide, most patients require hospitalization to ensure safety.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 10428,
            "topic": "Postpartum psychosis",
            "titleId": 10428,
            "title": "Postpartum psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "4",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Arrange for outpatient psychotherapy and childcare support",
                    "choiceNumber": 1,
                    "correctTaken": 393,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hospitalize the patient",
                    "choiceNumber": 2,
                    "correctTaken": 12726,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prescribe a mood stabilizer and schedule outpatient follow-up",
                    "choiceNumber": 3,
                    "correctTaken": 1554,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prescribe an antidepressant and schedule outpatient follow-up",
                    "choiceNumber": 4,
                    "correctTaken": 601,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Prescribe an antipsychotic and schedule outpatient follow-up",
                    "choiceNumber": 5,
                    "correctTaken": 1502,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Reassure that postpartum mood changes often resolve and follow-up in 2 weeks",
                    "choiceNumber": 6,
                    "correctTaken": 142,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "2250,2405,true,-1,1*2417,2616,true,-1,1*1240,1376,true,-1,1*1788,2010,true,-1,1*174,281,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25455249",
                    "mediaDataId": 0,
                    "title": "Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25455249",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27609245",
                    "mediaDataId": 0,
                    "title": "Postpartum&#160;psychosis: madness, mania, and melancholia in motherhood.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27609245",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 114,
            "othersAvgTimeSpent": 53,
            "notes": null,
            "peopleTaken": 16918,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 75,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 538,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 36,
            "questionId": 4897,
            "questionIndex": 4897,
            "questionText": "<p>A 28-year-old woman is brought to the office by her husband, who is concerned about her recent behavior.&nbsp; For the past 6 months, she has refused to eat any food that is not prepackaged out of fear of becoming ill.&nbsp; The patient has also placed a lock on the cabinet where she keeps her food and refuses to eat in restaurants.&nbsp; Before eating, she examines the food on her plate systematically, carefully checking for any possible contaminants.&nbsp; The patient believes that someone has been poisoning her food; as evidence, she points to a rash on her arms and says she is more fatigued than usual.&nbsp; The patient worries that the rash will spread to other areas and fears that she is developing a slowly progressive illness.&nbsp; She has continued to work but seldom interacts with coworkers.&nbsp; The patient has no psychiatric history.&nbsp; Vital signs are stable.&nbsp; Examination shows a 2.27-kg (5-lb) weight loss since a prior visit 9 months ago, and small, dry, scaling, patchy areas in her elbow creases, consistent with eczema.&nbsp; The patient&#39;s mood is anxious and her affect is tense.&nbsp; Which of the following is the most likely diagnosis?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t38406\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Delusional disorder</strong></p></td></tr><tr><td><p style=\"text-align: center;\"><strong>Clinical features</strong></p></td><td><ul><li>&ge;1 delusions for &ge;1 months</li><li>Other psychotic symptoms absent or not prominent</li><li>Behavior not obviously odd/bizarre; ability to function apart from delusion&#39;s impact</li><li>Subtypes: erotomanic, grandiose, jealous, persecutory &amp; somatic</li></ul></td></tr><tr><td><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td><ul><li>Antipsychotics</li><li>Cognitive-behavioral therapy</li></ul></td></tr></tbody></table></div><p>This patient&#39;s history of <strong>persistent delusions</strong> about being poisoned, in the <strong>absence of other prominent psychotic symptoms</strong>, is consistent with delusional disorder.&nbsp; Her behavior unrelated to her delusion does not appear to be bizarre or odd, and she is still able to function at work.&nbsp; <strong>Delusional disorder</strong> may be subtyped based on delusional themes: persecutory (eg, being poisoned, harassed, plotted against), erotomanic (false belief that someone of higher status is in love with them), grandiose (eg, great talent, insights, achievements), jealous (eg, unfaithful partners), and somatic (eg, bodily functions, sensations).</p><p>Delusional disorder must be differentiated from other psychotic disorders.&nbsp; Patients with schizophrenia have additional psychotic symptoms (eg, hallucinations, disorganization, negative symptoms) and greater functional deterioration <strong>(Choice E)</strong>.</p><p><strong>(Choice B)</strong>&nbsp; Patients with illness anxiety disorder experience anxiety with excessive concern and preoccupation about having a serious medical illness, but they do not have delusions.&nbsp; If anxiety about being ill is related to a fixed delusional belief (eg, poisoned food), then delusional disorder is the appropriate diagnosis.</p><p><strong>(Choice C)</strong>&nbsp; This patient lacks the intrusive obsessions and time-consuming compulsive rituals required for diagnosis of obsessive-compulsive disorder.</p><p><strong>(Choices D and F)</strong>&nbsp; Personality disorders are characterized by lifelong patterns of behavior beginning in early adulthood; they do not involve delusional beliefs.&nbsp; Paranoid personality disorder involves pervasive distrust and suspiciousness of others.&nbsp; Patients with schizotypal personality disorder exhibit eccentric behavior, which may include suspiciousness or odd beliefs, but their beliefs are not of delusional intensity.&nbsp; This patient has developed delusions over the past 6 months, which represents a change from her baseline.</p><p><strong>Educational objective:</strong><br>Delusional disorder involves one or more delusions and the absence of other prominent psychotic symptoms.&nbsp; Apart from the impact of delusional beliefs, the individual is still able to function.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 9838,
            "topic": "Psychosis",
            "titleId": 9838,
            "title": "Psychosis",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "1",
            "userAnswer": "1",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 1,
                    "correctTaken": 9814,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Illness anxiety disorder",
                    "choiceNumber": 2,
                    "correctTaken": 1772,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obsessive-compulsive disorder",
                    "choiceNumber": 3,
                    "correctTaken": 995,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Paranoid personality disorder",
                    "choiceNumber": 4,
                    "correctTaken": 2968,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 5,
                    "correctTaken": 1263,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizotypal personality disorder",
                    "choiceNumber": 6,
                    "correctTaken": 217,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1400,1543,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28595494",
                    "mediaDataId": 0,
                    "title": "A psychopathological comparison between delusional disorder and schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28595494",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27468631",
                    "mediaDataId": 0,
                    "title": "Delusional disorder and schizophrenia: a comparative study across multiple domains.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27468631",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 116,
            "othersAvgTimeSpent": 63,
            "notes": null,
            "peopleTaken": 17030,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 58,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 322,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 37,
            "questionId": 14697,
            "questionIndex": 16114,
            "questionText": "<p>A 23-year-old man is brought to the office by his parents due to concerns that he has become increasingly depressed and withdrawn over the past year.&nbsp; The patient dropped out of college in his senior year because of failing grades.&nbsp; Since returning to live with his parents, he broke up with his girlfriend and stopped going out with his friends.&nbsp; His father says, &#x22;It&#39;s frustrating because he refuses to go back to school and just seems to be wasting time.&nbsp; He sits in his room all day.&#x22;&nbsp; His mother reports that for the past few months, he has been watching the same videos over and over, telling her multiple times that he is &#x22;checking for signals and listening for messages from secret channels.&#x22;&nbsp; The patient says, &#x22;I&#39;m fine.&nbsp; I don&#39;t know why everyone&#39;s upset.&#x22;&nbsp; His appetite, sleep, and energy level are normal.&nbsp; He does not use alcohol or illicit drugs.&nbsp; Physical examination and laboratory evaluation are unremarkable.&nbsp; On mental status examination, the patient is cooperative and appears anxious.&nbsp; He avoids eye contact and shows little emotion.&nbsp; His answers are very brief, and he asks if the interview is being secretly recorded.&nbsp; The patient has no suicidal ideation or hallucinations.&nbsp; Which of the following is the most likely diagnosis?</p>",
            "questionHeader": "",
            "explanationText": "<div id=\"div_t41553\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Schizophrenia</strong></p></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Diagnosis</strong></p></td><td style=\"width: 85%;\"><ul><li>&ge;2 of the following (at least 1 symptom from 1-3)<ol><li>Delusions</li><li>Hallucinations</li><li>Disorganized speech</li><li>Disorganized or catatonic behavior</li><li>Negative symptoms (eg, apathy, flat affect)</li></ol></li><li>Continuous impairment &ge;6 months</li><li>Significant functional decline</li></ul></td></tr><tr><td style=\"width: 15%;\"><p style=\"text-align: center;\"><strong>Treatment</strong></p></td><td style=\"width: 85%;\"><ul><li>Antipsychotic medication</li><li>Adjunctive psychosocial interventions (eg, social skills training,<br />cognitive-behavioral therapy, family intervention)</li></ul></td></tr></tbody></table></div><p>This patient&#39;s delusions (receiving special messages from videos, being secretly recorded), negative symptoms, significant functional decline, and continuous impairment lasting &#8805;6 months are consistent with <strong>schizophrenia</strong>.&nbsp; Although common, hallucinations are not required for diagnosis.&nbsp; This patient&#39;s <strong>negative symptoms</strong> include <strong>apathy</strong>, <strong>avolition</strong>, <strong>affective flattening</strong> (lack of facial expression), <strong>alogia</strong> (very brief answers), and <strong>asociality</strong> (social withdrawal and diminished interest in relationships).&nbsp; His course of illness is characterized by a prodromal phase (ie, deterioration in academic functioning and progressive social withdrawal prior to the onset of psychosis) and prominent negative symptoms, which can often be mistaken for depression.</p><p>Families who do not understand that negative symptoms are a core characteristic of schizophrenia may become frustrated with their family members and perceive them as lazy and unmotivated.&nbsp; Family intervention that includes education about the illness can help promote a supportive environment and improve outcomes.</p><p><strong>(Choice A)</strong>&nbsp; Delusional disorder is characterized by &#8805;1 delusion in the absence of other psychotic symptoms.&nbsp; Functioning is normal apart from the direct impact of the delusion.&nbsp; A diagnosis of delusional disorder would not explain this patient&#39;s prominent negative symptoms and significant functional decline.</p><p><strong>(Choice B)</strong>&nbsp; In major depressive disorder with psychotic features, which is a severe subtype of major depressive disorder, the patient develops delusions and/or hallucinations, typically with depressive themes of guilt and worthlessness.&nbsp; This patient&#39;s appetite, sleep, and energy level are normal; he does not have enough depressive symptoms to diagnose a major depressive episode.</p><p><strong>(Choice C)</strong>&nbsp; This patient lacks the obsessions (thoughts, images, urges) and/or compulsions (behaviors and mental acts aimed at relieving distress) necessary to diagnose obsessive compulsive disorder.</p><p><strong>(Choices D, E, and G)</strong>&nbsp; Personality disorders do not include psychotic symptoms and cannot be diagnosed when the pattern of behavior is better explained by another mental disorder (eg, schizophrenia).&nbsp; Patients with paranoid personality disorder are generally suspicious and distrustful and patients with schizoid personality disorder are emotionally detached; neither diagnosis would account for this patient&#39;s delusions.&nbsp; Individuals with schizotypal personality disorder typically exhibit magical beliefs, eccentric behavior, and odd perceptual experiences that are subthreshold for a diagnosis of schizophrenia.</p><p><strong>Educational objective:</strong><br>The diagnosis of schizophrenia requires &#8805;2 of the following: delusions, hallucinations, disorganized speech, disorganized behavior, and negative symptoms; at least 1 of the first 3 findings is required.&nbsp; Negative symptoms are a core domain of schizophrenia and include apathy, avolition, lack of facial expression, alogia, social withdrawal, and diminished interest in relationships.&nbsp; These symptoms may be mistaken for aspects of personality or depressive disorders.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "6",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Delusional disorder",
                    "choiceNumber": 1,
                    "correctTaken": 1889,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Major depressive disorder with psychotic features",
                    "choiceNumber": 2,
                    "correctTaken": 1773,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obsessive compulsive disorder",
                    "choiceNumber": 3,
                    "correctTaken": 32,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Paranoid personality disorder",
                    "choiceNumber": 4,
                    "correctTaken": 1300,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizoid personality disorder",
                    "choiceNumber": 5,
                    "correctTaken": 639,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizophrenia",
                    "choiceNumber": 6,
                    "correctTaken": 10490,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Schizotypal personality disorder",
                    "choiceNumber": 7,
                    "correctTaken": 815,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "1831,2203,true,-1,1*3246,3509,true,-1,1*1688,1820,true,-1,1",
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "29422932",
                    "mediaDataId": 0,
                    "title": "Is the prevalence of the deficit syndrome in schizophrenia higher than estimated?  Results of a meta-analysis.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/29422932",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "28127915",
                    "mediaDataId": 0,
                    "title": "The current conceptualization of negative symptoms in schizophrenia.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/28127915",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 89,
            "othersAvgTimeSpent": 68,
            "notes": null,
            "peopleTaken": 16938,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 62,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 493,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 38,
            "questionId": 11063,
            "questionIndex": 12204,
            "questionText": "<p>A 55-year-old man is brought to the office due to unusual movements of his face and extremities.&nbsp; He lives in a group home and was noted to be sticking out his tongue, smacking his lips, and twisting his body from side to side, actions that were disruptive to the other residents.&nbsp; The patient has a history of schizoaffective disorder that has been treated with risperidone, fluoxetine, and clonazepam for more than 20 years.&nbsp; Examination shows protruding and twisting movements of the tongue, dystonic postures of the neck, and squirming movements of the torso.&nbsp; Which of the following is the most likely underlying cause of this patient&#39;s symptoms?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient exhibits characteristic symptoms of <strong>tardive dyskinesia (TD)</strong>, an involuntary movement disorder associated with <strong>dopamine-blocking agents</strong>.&nbsp; Characteristic movements include orofacial dyskinesias (ie, rhythmic movements of the face, lips, and tongue) and choreoathetoid movements of the trunk and extremities.&nbsp; TD is most commonly associated with prolonged use of antipsychotic medications and is typically seen in patients with chronic psychotic disorders.&nbsp; It is also common for TD to worsen or first appear following antipsychotic dose reduction or discontinuation.&nbsp; Although more common with first-generation antipsychotics that are potent dopamine D2 blockers, TD can also occur with second-generation antipsychotics such as risperidone.</p><p>The pathophysiology of TD is thought to involve <strong>dopamine D2 receptor upregulation and supersensitivity</strong> resulting from chronic blockade of dopamine receptors.&nbsp; Other hypotheses include an imbalance between dopamine D1 receptor and dopamine D2 receptor effects in the basal ganglia as well as excitotoxic destruction of GABA neurons in the striatum.</p><p><strong>(Choices A)</strong>&nbsp; Caudate nucleus atrophy is associated with Huntington disease, an inherited progressive neurodegenerative disorder characterized by choreiform movements, psychiatric symptoms, and dementia.&nbsp; It is not thought to play a role in TD pathogenesis.</p><p><strong>(Choice B)</strong>&nbsp; Chronic use of dopamine receptor-blocking agents such as antipsychotics is associated with upregulation, not downregulation of dopamine receptors.</p><p><strong>(Choices D and E)</strong>&nbsp; GABA receptor upregulation and glutamate receptor supersensitivity are not thought to play a role in TD.</p><p><strong>(Choice F)</strong>&nbsp; Medications that inhibit serotonin reuptake (eg, fluoxetine) cause downregulation of serotonin receptors after several weeks.&nbsp; However, this is not associated with TD.</p><p><strong>(Choice G)</strong>&nbsp; The ventral tegmental area is a region in the midbrain that contains a high density of dopamine-releasing neurons, which project to the nucleus accumbens and modulate reward pathways.&nbsp; Ventral tegmental area atrophy is not thought to play a role in TD pathogenesis.</p><p><strong>Educational objective:</strong><br>Tardive dyskinesia (TD) develops in the setting of prolonged exposure to dopamine-blocking agents, which is thought to result in the upregulation and supersensitivity of dopamine receptors.&nbsp; TD is characterized by abnormal involuntary movements of the mouth, tongue, trunk, and extremities and can first appear during treatment or following antipsychotic dose reduction or discontinuation.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 456,
            "topic": "Tardive dyskinesia",
            "titleId": 456,
            "title": "Tardive dyskinesia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "3",
            "userAnswer": "3",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Caudate nucleus atrophy",
                    "choiceNumber": 1,
                    "correctTaken": 689,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Dopamine receptor downregulation",
                    "choiceNumber": 2,
                    "correctTaken": 6768,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Dopamine receptor supersensitivity",
                    "choiceNumber": 3,
                    "correctTaken": 10188,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "GABA receptor upregulation",
                    "choiceNumber": 4,
                    "correctTaken": 210,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Glutamate receptor supersensitivity",
                    "choiceNumber": 5,
                    "correctTaken": 369,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Serotonin receptor downregulation",
                    "choiceNumber": 6,
                    "correctTaken": 163,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Ventral tegmental area atrophy",
                    "choiceNumber": 7,
                    "correctTaken": 178,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "497,781,true,-1,1*1861,2127,true,-1,1*782,1129,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "26492119",
                    "mediaDataId": 0,
                    "title": "Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/26492119",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25485636",
                    "mediaDataId": 0,
                    "title": "Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics:  a cross-sectional and retrospective study.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25485636",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 81,
            "othersAvgTimeSpent": 42,
            "notes": null,
            "peopleTaken": 18565,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 55,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 529,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 39,
            "questionId": 3794,
            "questionIndex": 3794,
            "questionText": "<p>A 35-year-old man with schizophrenia is brought to the mental health clinic by his parents.&nbsp; They say that his prescription for risperidone ran out, and they are worried because he is not sleeping well, is hardly eating, and has not showered for the past several weeks.&nbsp; The patient reluctantly admits to hearing voices telling him to &#x22;do bad things.&#x22;&nbsp; However, he becomes guarded and refuses to elaborate when asked to describe what the voices say or whether he has followed their directives.&nbsp; The patient has a history of 4 psychiatric hospitalizations and a suicide attempt a year ago.&nbsp; He lives with his elderly parents and is unemployed.&nbsp; On mental status examination, the patient is noted to be unkempt and malodorous.&nbsp; He is highly anxious, makes no eye contact, and paces around the room.&nbsp; At one point, he whispers something while staring out the window.&nbsp; The patient&#39;s speech is tangential and sometimes difficult to follow.&nbsp; When asked about suicidal or homicidal ideation, he shakes his head to indicate &#x22;no.&#x22;&nbsp; Which of the following is the most appropriate next step in management of this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>Although psychiatric treatment should take place in the least restrictive setting, <strong>safety considerations</strong> are paramount and require careful clinical judgment.&nbsp; This acutely psychotic patient is experiencing command auditory hallucinations.&nbsp; His refusal to describe the voices apart from saying that they are telling him to &#x22;do bad things&#x22; is concerning.&nbsp; The patient&#39;s history of multiple inpatient admissions suggests that he has a severe course of illness, and his recent history of a suicide attempt is a risk factor for repeated suicidal behavior.&nbsp; He is not eating well or showering, which indicates an inability to care for himself.&nbsp; This patient appears to be decompensating, making hospitalization the necessary course of action for safety reasons.</p><p>Efforts should be made to hospitalize the patient voluntarily, but <strong>involuntary commitment</strong> should be implemented if he refuses.&nbsp; The legal standards specifying the criteria for civil commitment vary by state, but they generally require the presence of a mental illness, <strong>danger to self or others</strong>, and/or <strong>grave disability</strong> (inability to care for self) <strong>due to mental illness</strong>, as in this patient.</p><p><strong>(Choices A and D)</strong>&nbsp; The patient should be restarted on risperidone as soon as possible, but it would be unsafe to treat him as an outpatient given his current symptoms.&nbsp; Antipsychotics do not work immediately, and there is no way to know if he will take his medication or if his command hallucinations will resolve within the next 24 hours.&nbsp; Clozapine can be considered in the management of treatment-resistant schizophrenia and is a future option for this patient should his psychosis not be responsive to risperidone or another antipsychotic.</p><p><strong>(Choice C)</strong>&nbsp; A urine drug screen (UDS) would be helpful in determining if substances are playing a role in the patient&#39;s decompensation.&nbsp; However, the patient has a long history of psychotic illness and requires hospitalization, whether the UDS is positive or negative.&nbsp; In addition, obtaining a urine sample, especially from someone who is agitated or confused, may take time and should not delay hospitalization.</p><p><strong>(Choice E)</strong>&nbsp; Although converting the patient to a long-acting injectable (depot) antipsychotic would be a reasonable strategy to enhance adherence, it is not an appropriate initial intervention.&nbsp; Conversion to a long-acting injectable formulation could be considered once the patient is stabilized on oral antipsychotics in the hospital.</p><p><strong>Educational objective:</strong><br>Indications for psychiatric hospitalization include being a danger to self or others and/or grave disability.&nbsp; Hospitalization may be implemented on an involuntary basis if necessary.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 4428,
            "topic": "Schizophrenia",
            "titleId": 4428,
            "title": "Schizophrenia",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "2",
            "userAnswer": "2",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Discontinue risperidone and start clozapine",
                    "choiceNumber": 1,
                    "correctTaken": 669,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Hospitalize the patient on an involuntary basis if necessary",
                    "choiceNumber": 2,
                    "correctTaken": 9011,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Obtain a urine drug screen",
                    "choiceNumber": 3,
                    "correctTaken": 1465,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Refill the prescription for risperidone and follow-up within 24 hours",
                    "choiceNumber": 4,
                    "correctTaken": 2231,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Switch the patient to a risperidone long-acting injectable antipsychotic",
                    "choiceNumber": 5,
                    "correctTaken": 3727,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": "913,1176,true,-1,1*2330,2471,true,-1,1",
            "isCorrect": true,
            "isIncorrect": false,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "25595369",
                    "mediaDataId": 0,
                    "title": "Involuntary&#160;admission and treatment of patients with mental disorder.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/25595369",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23375263",
                    "mediaDataId": 0,
                    "title": "Command hallucinations and clinical characteristics of suicidality in patients with psychotic spectrum disorders.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23375263",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 71,
            "othersAvgTimeSpent": 66,
            "notes": null,
            "peopleTaken": 17103,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 53,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 332,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 1,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        },
        {
            "exhibits": null,
            "sequenceId": 40,
            "questionId": 11316,
            "questionIndex": 12468,
            "questionText": "<p>A 38-year-old man with schizoaffective disorder is brought to the emergency department due to a 5-day history of malaise, loss of appetite, nausea, and abdominal pain.&nbsp; The patient was hospitalized 2 months ago for a manic episode with delusions and hallucinations, and his medication regimen was changed.&nbsp; Since discharge, his psychiatric condition has improved.&nbsp; He has no history of medical illness and does not drink alcohol or use illicit drugs.&nbsp; Temperature is 37.8 C (100 F), blood pressure is 100/65 mm Hg, and pulse is 98/min.&nbsp; Abdominal examination reveals right upper quadrant tenderness.&nbsp; Neurologic examination shows a fine bilateral hand tremor.&nbsp; On mental status examination, the patient appears drowsy but responds to questions.&nbsp; He is oriented to person, place, and year but not month or day.&nbsp; He has no suicidal ideation or auditory hallucinations, and no delusions are elicited.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Hematocrit</td><td>42%</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td>180,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td>9,200/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\" height=\"15\"></td></tr><tr><td colspan=\"2\">Serum chemistry</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Blood urea nitrogen</td><td>18 mg/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td>1.0 mg/dL</td></tr><tr><td colspan=\"2\" height=\"15\"></td></tr><tr><td colspan=\"2\">Liver function studies</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Total bilirubin</td><td>2.1 mg/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Alkaline phosphatase</td><td>110 U/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Aspartate aminotransferase</td><td>360 U/L</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Alanine aminotransferase</td><td>520 U/L</td></tr></tbody></table><p>Which of the following medications is most likely responsible for the findings in this patient?</p>",
            "questionHeader": "",
            "explanationText": "<p>This patient&#39;s symptoms of malaise, anorexia, and nausea and findings of right upper quadrant abdominal tenderness and <strong>elevated aminotransferases</strong> are consistent with liver injury.&nbsp; This, in the absence of underlying liver disease, is most likely due to <strong>drug-induced liver injury</strong>.</p><p>Among the psychotropic medications listed, hepatotoxicity is most commonly associated with the anticonvulsant mood stabilizer <strong>valproate</strong>.&nbsp; Serious or fatal hepatotoxicity may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, anorexia, and/or nausea.&nbsp; Most cases occur during the first 6 months of treatment.&nbsp; Patients receiving valproate should have liver tests prior to therapy and regularly thereafter.&nbsp; In addition to hepatotoxicity, valproate is also associated with tremor, thrombocytopenia, and alopecia.</p><p><strong>(Choice A)</strong>&nbsp; The antidepressant bupropion is associated with increased risk of seizures.</p><p><strong>(Choice B)</strong>&nbsp; Clozapine, used in treatment-resistant schizophrenia/schizoaffective disorder, is associated with the risk of severe neutropenia.</p><p><strong>(Choice C)</strong>&nbsp; Haloperidol is less likely to cause liver injury.&nbsp; The low-potency antipsychotic chlorpromazine has been associated with cholestatic jaundice.</p><p><strong>(Choice D)</strong>&nbsp; Lamotrigine can cause serious rashes, including Stevens-Johnson syndrome.</p><p><strong>(Choice E)</strong>&nbsp; Lithium is not metabolized and is excreted almost exclusively through the kidneys.&nbsp; It is associated with effects on renal and thyroid function.</p><p><strong>(Choice F)</strong>&nbsp; Trazodone has been associated with the rare adverse effect of priapism.</p><p><strong>Educational objective:</strong><br>The anticonvulsant mood stabilizer valproate can cause elevated aminotransferases and in rare cases hepatic failure, most commonly in the first 6 months of treatment.</p>",
            "abstractId": 0,
            "qbankId": 2,
            "sectionId": 1010,
            "section": "Step 2 Review",
            "subjectId": 105,
            "subject": "Psychiatry",
            "secondarySubjectId": 0,
            "secondarySubject": null,
            "systemId": 218,
            "system": "Psychiatric/Behavioral & Substance Use Disorder",
            "topicId": 23660,
            "topic": "Drug induced liver injury",
            "titleId": 23660,
            "title": "Drug induced liver injury",
            "topicAttributeId": 330661,
            "topicAttribute": "Psychotic disorders",
            "correctAnswer": "7",
            "userAnswer": "5",
            "parentQuestionId": 0,
            "subParentQuestionId": 0,
            "questionSetSequenceId": 0,
            "questionSetCount": 0,
            "questionToAnswerBeforeThis": 0,
            "answerChoiceList": [
                {
                    "questionId": 0,
                    "choice": "Bupropion",
                    "choiceNumber": 1,
                    "correctTaken": 86,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Clozapine",
                    "choiceNumber": 2,
                    "correctTaken": 1299,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Haloperidol",
                    "choiceNumber": 3,
                    "correctTaken": 1617,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lamotrigine",
                    "choiceNumber": 4,
                    "correctTaken": 986,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Lithium",
                    "choiceNumber": 5,
                    "correctTaken": 3365,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Trazodone",
                    "choiceNumber": 6,
                    "correctTaken": 153,
                    "questionIndex": 0
                },
                {
                    "questionId": 0,
                    "choice": "Valproate",
                    "choiceNumber": 7,
                    "correctTaken": 9679,
                    "questionIndex": 0
                }
            ],
            "formatTypeId": 1,
            "questionTypeId": 1,
            "highlights": null,
            "isCorrect": false,
            "isIncorrect": true,
            "isMarked": false,
            "isOmitted": false,
            "isQuestionDirty": false,
            "isAnswerChoiceDisabled": false,
            "isQuestionDisabled": false,
            "questionMappingReferencesList": [
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "22915484",
                    "mediaDataId": 0,
                    "title": "Non-fatal and fatal liver failure associated with valproic acid.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/22915484",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "27842773",
                    "mediaDataId": 0,
                    "title": "Drug-induced liver disease:  clinical course.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/27842773",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                },
                {
                    "questionIndex": 0,
                    "contentId": 0,
                    "contentTypeId": 0,
                    "referenceId": "23873292",
                    "mediaDataId": 0,
                    "title": "The prevalence and management of side effects of lithium and anticonvulsants as mood stabilizers in bipolar disorder from a clinical perspective:  a review.",
                    "referenceTypeId": 1,
                    "referenceLink": "http://www.ncbi.nlm.nih.gov/pubmed/23873292",
                    "superDivisionId": 0,
                    "subDivisionId": 0,
                    "level3DivisionId": 0,
                    "level4DivisionId": 0
                }
            ],
            "questionMedia": null,
            "timeSpent": 95,
            "othersAvgTimeSpent": 81,
            "notes": null,
            "peopleTaken": 17185,
            "hotspotImageUrl": null,
            "lastUpdatedDate": "01/01/2025",
            "correctPercentile": 56,
            "isSubmitted": false,
            "isActive": true,
            "activeStatusId": 1,
            "hint": null,
            "allowCalculator": false,
            "difficultyLevelId": null,
            "additionalText": null,
            "mobileExcerpt": null,
            "passageExcerpt": null,
            "confSurveyValue": 0,
            "timePerQuestionInMilliSec": 90000,
            "answerHeader": null,
            "standards": null,
            "totalTimeSpentReview": 0,
            "dailyTimeSpentReview": 0,
            "dailyTimeSpent": 0,
            "isHintUsed": null,
            "examYear": 2024,
            "newExamYearQuestionIndex": 0,
            "vocabularyList": null,
            "copyrightId": null,
            "copyrightText": null,
            "frequentHighlights": null,
            "totalWeight": 0,
            "weightScored": null,
            "maxAnswerSelection": 0,
            "scoreTypeId": null,
            "passingScore": 0,
            "questionSourceId": 1,
            "customSequenceId": null,
            "annotations": null,
            "competencyId": null,
            "scoringGuide": null,
            "skillId": null,
            "passageTypeId": null,
            "passageType": null,
            "skill": null,
            "gradeDetails": null
        }
    ],
    "abstractList": null,
    "deckList": [
        {
            "deckId": 9788456,
            "deckName": "Notes",
            "deckColor": "#36c8a3",
            "isDefault": true,
            "dateCreated": "01/01/0001 12:00:00 AM",
            "noOfFlashCards": 4,
            "groupId": null,
            "studySettingsId": null,
            "lastStudyDate": null,
            "isCustomStudyDeck": false,
            "parentDeckId": null,
            "customStudySettings": null,
            "subscriptionId": 0
        }
    ],
    "newExamYearQuestionList": null,
    "flashCardList": null,
    "questionModes": [
        {
            "id": 1,
            "name": "UNUSED"
        }
    ],
    "subscriptionElapsedTime": 0.0,
    "isFacultyControlled": null,
    "endCATTest": null,
    "questionSourceIds": null
}